Cas protein, corresponding gene editing system and application thereof
Patent Information
- Application Number
- CN202480002205.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-10
- Filing Date
- 2024-05-11
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-05-11
AI Technical Summary
The existing CRISPR/Cas system has differences in target recognition and cleavage efficiency, which is difficult to meet the diverse application needs, and the size and PAM structure of different Cas proteins are different, which limits its wide application.
A new Cas protein and its variant polypeptides, including the CasY7 protein, has high cleavage activity and can surpass its cleavage activity in the target sequence compared with LbCpf1 and can enhance the target in double-stranded DNA by amino acid mutations. Cutting activity and combining guide RNA to form complexes to achieve specific cleavage of target DNA.
It achieves efficient cleavage activity for exogenous or endogenous genes in vitro and cellular levels, improves the specific cleavage efficiency of target DNA, enhances the gene editing ability of Cas protein, and is suitable for diverse application needs.
Smart Images

Figure 00000123_0000 
Figure 00000123_0001 
Figure 00000124_0000
Abstract
Description
A Cas protein, its corresponding gene editing system and application Technical Field
[0001] The present disclosure relates to the field of gene editing, and in particular, to a Cas protein and its variant polypeptides, and their corresponding gene editing systems and applications. Background Art
[0002] The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system was developed by bacteria and archaea to defend against invading phage DNA. The most common of these is the CRISPR / Cas9 system, in which the Cas9 protein, with the assistance of a trans-encoded small RNA (tracrRNA), processes pre-crRNA into mature crRNA that binds to tracrRNA. Subsequently, it was discovered that by artificially constructing a single-stranded chimeric guide RNA (gRNA) that mimics the crRNA-tracrRNA complex, the Cas9 protein can effectively mediate target recognition and cleavage. The three bases immediately adjacent to the 3′ end of the target must be in the form of 5′-NGG-3′, thus forming the PAM (protospacer adjacent motif) structure required for the Cas / crRNA complex to recognize the target.
[0003] However, the different CRISPR / Cas systems currently in existence have different advantages and disadvantages. For example, different Cas protein sizes, guide RNAs, and PAMs all differ.
[0004] Therefore, there is still a need to develop new Cas proteins and CRISPR-Cas systems to meet diverse application needs.
[0005] Summary of the Invention
[0006] The main purpose of the present invention is to provide a new Cas protein and its variant polypeptide, and a CRISPR-Cas system comprising the same, to meet the above-mentioned application requirements.
[0007] In one aspect, the present disclosure provides a Cas protein selected from the group consisting of:
[0008] (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1;
[0009] (b) a polypeptide having at least about 60% (e.g., 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%) identity to the amino acid sequence of SEQ ID NO: 1;
[0010] (c) The amino acid sequence shown in SEQ ID NO: 1 is formed by substitution, deletion or addition of one or more amino acid residues.
[0011] In another aspect, the present disclosure provides a fusion protein comprising the Cas protein of the present disclosure; and one or more functional domains.
[0012] In yet another aspect, the present disclosure provides an isolated polynucleotide encoding the Cas protein of the present disclosure or the fusion protein of the present disclosure;
[0013] Preferably, the polynucleotide has been codon-optimized for expression in eukaryotic cells;
[0014] Preferably, the polynucleotide comprises a nucleotide sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%) sequence identity to the nucleotide sequence shown in any one of SEQ ID NO. 2, 37, 83, 85, 87.
[0015] Preferably, the polynucleotide has a nucleotide sequence as shown in any one of SEQ ID NO. 2, 37, 83, 85, and 87.
[0016] In another aspect, the present disclosure provides a guide RNA (gRNA), wherein the guide RNA comprises
[0017] (1) a direct repeat (DR) sequence capable of forming a complex with the Cas protein described in the first aspect or the fusion protein described in the second aspect;
[0018] (2) A spacer sequence that is capable of hybridizing with a target sequence of a target DNA, thereby guiding the complex to the target DNA.
[0019] 65, 66, 67, 68, 69, or 70 nt in length.
[0020] Optionally, the spacer sequence is 15-50 nt in length.
[0021] Optionally, the spacer sequence is 18-41 nt in length.
[0022] Optionally, the spacer sequence is 18-27 nt in length.
[0023] Optionally, the spacer sequence is 18-24 nt in length.
[0024] Optionally, the spacer sequence is 18-22 nt in length.
[0025] Optionally, the 5' end of the direct repeat sequence is connected to the spacer sequence.
[0026] Optionally, the spacer sequence comprises at least 15 consecutive nucleotides in the nucleotide sequence of any one of SEQ ID NO. 6, 11, 53, 55, 57, 59, and 61.
[0027] In yet another aspect, the present disclosure provides an isolated nucleic acid molecule comprising or consisting of a sequence selected from the group consisting of:
[0028] (i) the sequence shown in SEQ ID NO: 5 or 71;
[0029] (ii) a sequence having one or more base substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 base substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 5 or 71;
[0030] (iii) a sequence having at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the sequence set forth in SEQ ID NO: 5 or 71;
[0031] (iv) a sequence that hybridizes under stringent conditions to the sequence described in any one of (i) to (iii); or (v) a complementary sequence to the sequence described in any one of (i) to (iii);
[0032] Furthermore, the sequence of any one of (ii) to (v) substantially retains the biological function of the sequence from which it is derived;
[0033] For example, the isolated nucleic acid molecule is RNA;
[0034] For example, the isolated nucleic acid molecule comprises a direct repeat (DR) sequence in the CRISPR / Cas system.
[0035] In yet another aspect, the present disclosure provides a delivery composition comprising a delivery vehicle and one or more selected from the following: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure.
[0036] In yet another aspect, the present disclosure provides a composite comprising:
[0037] (i) a protein component selected from the group consisting of a Cas protein of the present disclosure, a fusion protein of the present disclosure, or a combination thereof; and
[0038] (ii) a guide RNA of the present disclosure;
[0039] Wherein, the protein component and the nucleic acid component combine with each other to form a complex.
[0040] In yet another aspect, the present disclosure provides a CRISPR-Cas system comprising:
[0041] (i) a Cas protein or a fusion protein of the present disclosure, or a nucleotide encoding the Cas protein or the fusion protein; and
[0042] (ii) a guide RNA, or a nucleotide encoding the guide RNA;
[0043] The guide RNA comprises:
[0044] (a) a direct repeat (DR) sequence that is capable of forming a complex with the Cas protein or fusion protein, and
[0045] (b) a spacer sequence capable of hybridizing to a target sequence of a target DNA, thereby guiding the complex to the target DNA.
[0046] In yet another aspect, the present disclosure provides a CRISPR-Cas composition comprising:
[0047] (i) a first component selected from the group consisting of a Cas protein of the present disclosure, a fusion protein of the present disclosure, a nucleotide sequence encoding a Cas protein of the present disclosure or a fusion protein of the present disclosure, and any combination thereof; and
[0048] (ii) a second component, which comprises one or more guide RNAs disclosed herein, or a nucleotide sequence encoding the one or more guide RNAs disclosed herein;
[0049] The guide RNA is capable of forming a complex with the protein or fusion protein described in (i).
[0050] In yet another aspect, the present disclosure provides a CRISPR-Cas system comprising one or more vectors, wherein the one or more vectors comprise:
[0051] (i) a first nucleic acid, which is a nucleotide sequence encoding the Cas protein of the present disclosure or the fusion protein of the present disclosure; optionally, the first nucleic acid is operably linked to a first regulatory element; and
[0052] (ii) a second nucleic acid encoding a nucleotide sequence comprising a guide RNA of the present disclosure; optionally, the second nucleic acid is operably linked to a second regulatory element;
[0053] in:
[0054] The first nucleic acid and the second nucleic acid are present on the same or different vectors;
[0055] The guide RNA is capable of forming a complex with the protein or fusion protein described in (i).
[0056] The present disclosure provides a kit comprising one or more components selected from the following: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure.
[0057] In certain embodiments, the kit further comprises a label or instructions.
[0058] In certain embodiments, the kit is used for one or more of gene or genome editing, disease treatment, targeting a target gene, and cleaving a target gene or a non-target gene.
[0059] In yet another aspect, the present disclosure provides a delivery composition comprising a delivery vehicle and one or more selected from the following: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure.
[0060] In yet another aspect, the present disclosure provides a host cell comprising the Cas protein of the present disclosure, the fusion protein of the present disclosure, the polynucleotide of the present disclosure, the complex of the present disclosure, the vector of the present disclosure, the composition of the present disclosure, the system of the present disclosure, or the delivery composition of the present disclosure.
[0061] In yet another aspect, the present disclosure provides an enzyme preparation comprising the Cas protein of the present disclosure, the fusion protein of the present disclosure, the complex of the present disclosure, the CRISPR-Cas composition of the present disclosure, or the system of the present disclosure, or the delivery composition of the present disclosure.
[0062] In certain embodiments, the enzyme preparation includes an injection and / or a lyophilized preparation.
[0063] In yet another aspect, the present disclosure provides a kit comprising:
[0064] A first container, and the complex of the present disclosure, the composition of the present disclosure, or the system of the present disclosure, or a drug containing the complex of the present disclosure, the composition of the present disclosure, or the system of the present disclosure located in the first container.
[0065] In yet another aspect, the present disclosure provides a kit comprising:
[0066] (a1) a first container, and a Cas protein of the present disclosure, or a fusion protein of the present disclosure, or a gene encoding the Cas protein of the present disclosure, or an expression vector thereof, or a drug containing the Cas protein of the present disclosure, or a fusion protein of the present disclosure, or a gene encoding the Cas protein of the present disclosure, or an expression vector thereof, located in the first container;
[0067] (b1) an optional second container, and the guide RNA of the present disclosure or its expression vector, or a drug containing the guide RNA of the present disclosure or its expression vector, located in the second container.
[0068] In another aspect, the present disclosure provides a method for targeting and editing a target gene or cutting a target gene, comprising: contacting the Cas protein of the present disclosure, or the fusion protein of the present disclosure, or the complex of the present disclosure, or the composition of the present disclosure, or the system of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the drug kit of the present disclosure with the target gene, or delivering it to a cell comprising the target gene, wherein the target sequence is present in the target gene.
[0069] In another aspect, the present disclosure provides a method of inducing a change in a cell state, the method comprising contacting the Cas protein of the present disclosure, or the fusion protein of the present disclosure, or the complex of the present disclosure, or the composition of the present disclosure, or the system of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the drug kit of the present disclosure with a target gene in a cell.
[0070] In another aspect, the present disclosure provides a method for altering the expression of a gene product, comprising: contacting the Cas protein of the present disclosure, or the fusion protein of the present disclosure, or the complex of the present disclosure, or the composition of the present disclosure, or the system of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the drug kit of the present disclosure with a nucleic acid molecule encoding the gene product, or delivering it to a cell comprising the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.
[0071] In yet another aspect the present disclosure provides a cell or progeny thereof obtained by a method of the present disclosure, wherein the cell comprises a modification not present in its wild-type form.
[0072] In yet another aspect, the present disclosure provides a cell product of a cell of the present disclosure or a progeny thereof.
[0073] In yet another aspect, the present disclosure provides an in vitro, ex vivo or in vivo cell or cell line or progeny thereof, comprising: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, a system of the present disclosure or a delivery composition of the present disclosure.
[0074] In yet another aspect, the present disclosure provides a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure, or a kit of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, or a use of the present disclosure or a drug kit of the present disclosure for the preparation of a medicament or a formulation for nucleic acid editing (e.g., gene or genome editing).
[0075] In another aspect, the present disclosure provides a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure, or a kit of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, or a drug kit of the present disclosure for the preparation of a medicament or formulation for one or more selected from the group consisting of:
[0076] (i) ex vivo gene or genome editing;
[0077] (ii) detection of single-stranded DNA in vitro;
[0078] (iii) editing a target sequence in a target locus to modify an organism or non-human organism;
[0079] (iv) treating a disorder caused by a defect in the target sequence in the target locus;
[0080] (v) treating a condition or disease in a subject in need thereof.
[0081] In another aspect, the present disclosure provides a method for detecting the presence of a target nucleic acid molecule in a sample, the method comprising contacting the sample with the Cas protein, fusion protein, or complex, CRISPR-Cas composition, or system, kit, or delivery composition, or enzyme preparation, and a non-target sequence, and detecting a detectable signal generated by cleavage of the non-target sequence, thereby detecting the target nucleic acid molecule, wherein the non-target sequence does not hybridize with the guide RNA.
[0082] In certain embodiments, the non-target sequence is cleaved by a protein in the complex or CRISPR-Cas composition or system or delivery composition, indicating the presence of a target nucleic acid molecule in the sample; and the non-target sequence is not cleaved by a protein in the complex or CRISPR-Cas composition or system or delivery composition, indicating the absence of a target nucleic acid molecule in the sample.
[0083] In yet another aspect, the present disclosure provides a method for diagnosing, preventing or treating a disease in a subject in need thereof, the method comprising administering to the subject a vector of the present disclosure, a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure, or a kit of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, or a drug kit of the present disclosure, wherein the disease is associated with a target DNA, wherein a spacer sequence is capable of hybridizing with a target sequence of the target DNA, and the target DNA is modified, thereby diagnosing, preventing or treating the disease.
[0084] In yet another aspect, the present disclosure provides a pharmaceutical composition comprising a vector of the present disclosure, a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure, or a kit of the present disclosure, or a delivery composition of the present disclosure, or a host cell of the present disclosure, or an enzyme preparation of the present disclosure, and a pharmaceutically acceptable carrier or excipient.
[0085] According to WIPO Standard ST.26, the symbol "t" is used to represent T in DNA and U in RNA. Therefore, in this sequence listing prepared according to ST.26, when the sequence is RNA, T in the sequence should be regarded as U.
[0086] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0087] An understanding of certain features and advantages of the present disclosure will be gained by referring to the following detailed description, which sets forth illustrative embodiments in which the principles of the present disclosure may be utilized, and to the accompanying drawings, in which:
[0088] FIG1 shows the maps of the CasY7 recombinant expression plasmid ( FIG1A ) and the LbCpf1 recombinant expression plasmid ( FIG1B ).
[0089] FIG2 shows a schematic diagram of the predicted secondary structure of the RNA transcript of the direct repeat (DR) sequence corresponding to CasY7.
[0090] FIG3 shows the Target plasmid map used to evaluate the cleavage activity of CasY7 in E. coli.
[0091] FIG4 shows a comparison of the editing efficiency of CasY7 and LbCpf1 in E. coli.
[0092] FIG5 shows a plasmid map of PHK09T used to express gRNA.
[0093] FIG6 shows a comparison of the editing efficiency of CasY7 and LbCpf1 in HEK293T cells.
[0094] FIG7 shows four mutants of CasY7 with different point mutations that abolished the catalytic activity (cleavage activity) compared to the WT CasY7 protein.
[0095] Figure 8 shows the activity test of the base editor containing dCasY7 in base editing (A>G), wherein Figure 8A shows the single base editing (A>G) efficiency at the TTR gene target sequence A2, A4, A13, A15-A17 sites; Figure 8B shows the single base editing (A>G) efficiency at another target sequence A7, A13, A20 sites of the TTR gene.
[0096] FIG9 shows a comparison of the cleavage activities of different CasY7 mutants at the TTR gene target sequence.
[0097] Figure 10 shows a comparison of the cleavage activity of different CasY7 mutants in the PD-1 gene target sequence, where WT represents the cleavage activity of wild-type CasY7.
[0098] FIG11 shows a comparison of the cleavage activities of different CasY7 mutants at the TRAC gene Trac-1 target sequence.
[0099] FIG12 shows a comparison of the cleavage activities of different CasY7 mutants on the target sequence of the TRAC gene Trac-2.
[0100] FIG13 shows a comparison of the cleavage activities of different CasY7 mutants on the target sequence of the TRAC gene Trac-3.
[0101] FIG14 shows a comparison of the cleavage activities of different CasY7 mutants on the target sequence of the TRAC gene Trac-4.
[0102] FIG15 shows a schematic diagram of the predicted secondary structure of the RNA transcript of the DR sequence variant DR-1.
[0103] Figure 16 shows the comparison of the cleavage activity of CasY7 targeting the TTR gene target sequence under the mediation of gRNA containing different DR sequences.
[0104] FIG17 shows a dual fluorescence reporter system, wherein FIG17A shows the structure of the LU×UC sequence, and FIG17B shows a map of the dual luciferase reporter plasmid.
[0105] Figure 18 shows the editing activity of the fusion protein of CasY7 variant C05440 and T5 in the hHAO1 gene target sequence. The results show that the editing activity of C05440-T5 is the best, which is much higher than that of T5-C05440 and C05440.
[0106] FIG19 shows the on-target cleavage activity of the Trac gene target mediated by CasY7, as well as the off-target cleavage of 28 OT (off-target) targets. DETAILED DESCRIPTION
[0107] The following examples are only used to illustrate the present invention, rather than to limit the present invention. Unless otherwise specified, the experiments and methods described in the examples were basically carried out according to conventional methods well known in the art and described in various references.
[0108] In addition, if specific conditions are not specified in the examples, the experiments were performed under conventional conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be obtained commercially. It is understood that the examples describe the present invention by way of example and are not intended to limit the scope of the present invention. All publications and other references mentioned herein are incorporated herein by reference in their entirety.
[0109] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.
[0110] the term
[0111] Unless otherwise described, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art. For the purpose of interpreting this specification, the following terminology will be used, and where appropriate, terms used in the singular will also include the plural, and vice versa. The disclosures of all patents and other publications cited herein are incorporated herein by reference in their entirety. In the event that any description or interpretation of a term herein conflicts with any document incorporated herein by reference, the description and interpretation of the following terminology shall prevail.
[0112] As used herein, the singular forms "a," "an," and "the" include both singular and plural referents unless the context clearly dictates otherwise.
[0113] As used herein, the term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0114] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."
[0115] As used herein, the term "optionally" means that the subsequently described event, circumstance or substituent may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0116] As used herein, the terms "substantially" and "essentially" refer to a degree, quantity, level, value, amount, frequency, percentage, dimension, size, amount, weight, or length that is about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more compared to a degree, reference quantity, level, value, quantity, frequency, percentage, dimension, size, amount, weight, or length. For example, as used herein, a "substantially identical sequence" can refer to a sequence, polynucleotide, or polypeptide that has a certain degree of identity to a reference sequence.
[0117] As used herein, the term "and / or" means either or both of the alternatives.
[0118] As used herein, the terms "nucleic acid," "nucleic acid molecule," and "polynucleotide" are used interchangeably to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or their analogs, in single-stranded, double-stranded, or multi-stranded form. A polynucleotide can be exogenous or endogenous to a cell. A polynucleotide can be present in a cell-free environment. A polynucleotide can be a gene or a fragment thereof. A polynucleotide can be DNA or RNA. A polynucleotide can include one or more analogs (e.g., altered backbones, sugars, or nucleobases). If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acids, heterologous nucleic acids, morpholinos, locked nucleic acids, glycerol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to a sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, quercetin, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of genes or gene fragments, multiple loci (one locus) defined according to linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated DNA of any sequence, cell-free polynucleotides comprising cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes and primers. Nucleotide sequences may be interspersed with non-nucleotide components. Polynucleotides may include mixtures of nucleotides found in nature and nucleotide analogs (e.g., synthetic nucleotide analogs).
[0119] As used herein, the terms "peptide," "polypeptide," and "protein" are used interchangeably herein and generally refer to a polymer of at least two amino acid residues linked by a peptide bond. This term does not indicate the specific length of the polymer, nor is it intended to imply or distinguish whether the peptide is produced using recombinant technology, chemical or enzymatic synthesis, or is naturally occurring. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers that include at least one modified amino acid. In some cases, the polymer may be interspersed with non-amino acids. The term encompasses amino acid chains of any length, including full-length proteins, and proteins with or without secondary and / or tertiary structure (e.g., domains). The term also encompasses amino acid polymers that have been modified; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulation, such as conjugation with a labeling component.
[0120] As used herein, the term "identity" refers to the overall correlation between polymer molecules, for example, between nucleic acid molecules (for example, DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Sequence identity (or homology) is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein), and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. Taking a polypeptide sequence as an example, if the mutation type is one or more of the following: substitution / replacement of one or more amino acids / nucleotides, insertion within the sequence, and deletion within the sequence, the total number of residues is calculated as the larger of the molecules being compared. If the mutation type also includes insertions (extensions) at either or both ends of the sequence or deletions (truncations) at either or both ends of the sequence, the number of amino acids inserted or deleted at either or both ends (for example, the number of insertions or deletions at both ends is less than 20) is not included in the total number of residues. When calculating percent identity, the sequences being compared are aligned in a manner that produces the largest match between the sequences, and gaps in the alignment (if any) are resolved by a specific algorithm. Nucleotide identity is calculated similarly.
[0121] As used herein, the terms "amino acid" and "amino acids" generally refer to natural and non-natural amino acids, including but not limited to modified amino acids and amino acid analogs. Modified amino acids can include natural and non-natural amino acids that have been chemically modified to include groups or chemical moieties that are not naturally present on the amino acid. Amino acid analogs can refer to amino acid derivatives. The term "amino acid" includes D-amino acids and L-amino acids.
[0122] As used herein, the term "nuclease" refers to a polypeptide that is capable of cleaving phosphodiester bonds between nucleotide subunits of a nucleic acid; the term "endonuclease" refers to a polypeptide that is capable of catalyzing (e.g., cleaving) phosphodiester bonds within a polynucleotide (e.g., DNA or RNA) chain.
[0123] As used herein, the term "exonuclease" refers to a protein or polypeptide that is capable of digesting nucleic acid (eg, RNA or DNA) from a free end.
[0124] As used herein, the term "non-natural" generally refers to a nucleic acid or polypeptide sequence not found in natural nucleic acids or proteins. Non-natural can refer to affinity tags. Non-natural can refer to fusions. Non-natural can refer to naturally occurring nucleic acids or polypeptide sequences comprising mutations, insertions and / or deletions. Non-natural sequences can exhibit and / or encode an activity (e.g., enzymatic activity, methyltransferase activity, acetyltransferase activity, kinase activity, ubiquitination activity, etc.) that can also be exhibited by nucleic acids and / or polypeptide sequences fused with non-natural sequences. Non-natural nucleic acids or polypeptide sequences can be connected to produce chimeric nucleic acids and / or polypeptide sequences encoding chimeric nucleic acids and / or polypeptides by genetic engineering. As used herein, the term "fusion protein" refers to a hybrid polypeptide comprising protein domains from at least two different proteins. A protein can be positioned at the amino terminal (N-terminal) portion of the fusion protein or at the carboxyl terminal (C-terminal) protein, thereby forming amino terminal fusion protein or carboxyl terminal fusion protein, respectively. The protein may comprise different domains, for example, a nucleic acid binding domain (e.g., a gRNA binding domain of a Cas protein that guides the binding of the protein to the target site) and a nucleic acid cleavage domain, or a catalytic domain of a nucleic acid editing protein. In some embodiments, a linker may be present between proteins. In some embodiments, a protein comprises a protein portion (e.g., an amino acid sequence that constructs a nucleic acid binding domain) and an organic compound (e.g., a compound that can act as a nucleic acid cleavage agent). In some embodiments, a protein is complexed or associated with a nucleic acid (e.g., RNA or DNA).
[0125] As used herein, the term "joint" refers to any means, entity or part for joining two or more entities. In some embodiments, the joint is a covalent joint. In some embodiments, the joint is a non-covalent joint. Examples of covalent joints include covalent bonds or joint parts that are covalently attached to one or more proteins or domains to be connected. In some embodiments, the joint is a non-covalent bond, for example, an organometallic bond through a metal center (such as a platinum atom). The joint can be permanent or reversible. For covalent attachment, various functional groups can be used, such as amide groups, including carbonic acid derivatives, ethers, esters (including organic esters and inorganic esters), amino groups, carbamates, ureas, etc. In order to provide a connection, the domain can be modified by oxidation, hydroxylation, substitution, reduction, etc. to provide a coupling site. Conjugation methods are well known to those skilled in the art and are encompassed in the present invention for use. The joint part includes but is not limited to a chemical joint part, or for example a peptide joint part (joint sequence). The length and type of the joint can be designed as needed. In some embodiments, the joint can be an artificially synthesized amino acid sequence or a naturally occurring polypeptide sequence. It will be appreciated that modifications that do not significantly reduce the function of the RNA binding domain and the effector domain are preferred.
[0126] As used herein, the term "complementary" refers to the ability of a first polynucleotide sequence's nucleobases (e.g., a guide sequence) to base pair with a second polynucleotide sequence's nucleobases (such as a target sequence) by traditional Watson-Crick base pairing. In some embodiments, a first polynucleotide can be substantially complementary to a second polynucleotide, i.e., have at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% complementarity to the second polynucleotide. In some embodiments, a first polynucleotide is fully complementary to a second polynucleotide, i.e., has 100% complementarity to the second polynucleotide. "Substantially complementary" refers to a degree of complementarity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions. The term "stringent conditions," in relation to hybridization, refers to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes to the target sequence and does not substantially hybridize to non-target sequences. Stringent conditions are generally sequence-dependent and depend on a number of factors. Generally, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized by hydrogen bonding between the bases of the nucleotide residues. The complex may comprise two strands forming a duplex, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute one step in a broader process, such as the initiation of PCR or the cleavage of a polynucleotide by an enzyme. A sequence capable of hybridizing to a given sequence is referred to as the "complement" of that given sequence.
[0127] As used herein, the term "regulatory element" refers to a DNA sequence that controls or influences one or more aspects of transcription and / or expression and is intended to include promoters, enhancers, silencers, transcription termination signals, internal ribosome entry sites (IRES), protein degradation signals, and other expression control elements (e.g., such as polyadenylation signals and poly-U sequences, such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, CA (1990)). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cells, as well as those that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Regulatory elements can also direct expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue- or cell-type specific.
[0128] As used herein, the term "domain" or "protein domain" refers to a portion of a protein sequence that can exist and function independently of the rest of the protein chain.
[0129] As used herein, the term "operably linked" refers to a functional connection between a regulatory sequence and a nucleic acid sequence of interest, resulting in expression of the latter (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
[0130] As used herein, the term "wild type" is a term understood by technicians and means the typical form of an organism, strain, gene or feature because it exists in nature, as opposed to a mutant or variant form. Therefore, as used herein, when an amino acid or nucleotide sequence refers to a wild-type sequence, a variant refers to a variant of the sequence, for example, comprising a substitution, deletion, or insertion. For example, the "wild-type Cas protein" of the present disclosure refers to a naturally occurring, unmodified Cas protein, the nucleotides of which can be obtained by genetic engineering techniques, such as genome sequencing, polymerase chain reaction (PCR), etc., and the amino acid sequence can be derived from the nucleotide sequence.
[0131] As used herein, the terms "parent," "parent polypeptide," and "parent sequence" refer to the original polypeptide (eg, a reference polypeptide or starting polypeptide) to which changes are made to produce a variant polypeptide of the present invention.
[0132] As used herein, the term "variant polypeptide" refers to a polypeptide comprising a change (such as, but not limited to, substitution, insertion, deletion, addition and / or fusion) at one or more residue positions compared to a parent polypeptide. In some embodiments, a variant polypeptide is different from its reference entity. For example, a variant polypeptide may be different from a reference polypeptide due to one or more differences in amino acid sequence and / or one or more differences in a chemical moiety (such as, carbohydrate, lipid, etc.) covalently attached to a polypeptide backbone. In some embodiments, a variant polypeptide shows an overall sequence identity to a reference polypeptide (such as, a Cas protein of the present disclosure), and the sequence identity is at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Alternatively or in addition, in some embodiments, a variant polypeptide does not share at least one characteristic sequence element with a reference polypeptide. In some embodiments, a reference polypeptide has one or more biological activities. In some embodiments, variant polypeptides share one or more biological activities of a reference polypeptide, such as nuclease activity. In some embodiments, variant polypeptides lack one or more biological activities of a reference polypeptide. In some embodiments, compared to a reference polypeptide, variant polypeptides show one or more biological activities (such as nuclease activity, such as off-target nuclease activity) of reduced levels. In some embodiments, if the polypeptide of interest has the same amino acid sequence as the parent, but has a small amount of sequence changes at a specific position, the polypeptide of interest is considered to be a "variant" of the parent or reference polypeptide. Typically, compared to a parent or reference polypeptide, less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the residues in the variant are substituted. In some embodiments, variants have 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 substituted residues compared to a parent or reference polypeptide. Variants often have a very small amount of (e.g., less than 5, 4, 3, 2 or 1) substituted functional residues (i.e., residues involved in a specific biological activity). In some embodiments, the variant has no more than 5, 4, 3, 2 or 1 additions or deletions, and often no additions or deletions, compared to the parent or reference polypeptide. In addition, any additions or deletions are typically less than about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6 residues, and usually less than about 5, about 4, about 3 or about 2 residues. In some embodiments, the parent or reference polypeptide is wild type. A variant of a polynucleotide or polypeptide can be naturally occurring, such as an allelic variant, or it can be a variant known not to be naturally occurring.Non-naturally occurring variants of polynucleotides and polypeptides can be prepared by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to those skilled in the art.
[0133] As used herein, the term "conservative amino acid substitution" refers to a substitution with a chemically or functionally similar amino acid that does not affect the normal function of the protein, such as the interchangeability in proteins of amino acid residues with similar side chains: a group of amino acids with aliphatic side chains consists of glycine, alanine, valine, leucine, and isoleucine; a group of amino acids with aliphatic-hydroxy side chains consists of serine and threonine; a group of amino acids with amide-containing side chains consists of asparagine and glutamine; a group of amino acids with aromatic side chains consists of phenylalanine, tyrosine, and tryptophan; a group of amino acids with basic side chains consists of lysine, arginine, and histidine; a group of amino acids with sulfur-containing side chains consists of cysteine and methionine. In some embodiments, conservative amino acid substitutions include: aspartic acid-glutamic acid, lysine-arginine-histidine, serine-threonine-asparagine-glutamine, glycine-alanine-valine-leucine-isoleucine, cysteine-methionine-proline, and phenylalanine-tyrosine-tryptophan. In some embodiments, conservative amino acid substitutions include: valine-leucine-methionine-isoleucine, alanine-serine-threonine.
[0134] As used herein, the terms "clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) (CRISPR-Cas) system" or "CRISPR system" are used interchangeably and have the meaning commonly understood by those skilled in the art, which generally includes transcripts or other elements associated with the expression of CRISPR-associated ("Cas") genes, or transcripts or other elements capable of directing the activity of the Cas genes.
[0135] As used herein, the term "Cas protein" is used interchangeably with Cas polypeptide in the present disclosure and is used in its broadest sense to include a parent or reference Cas protein (e.g., comprising a Cas12i protein set forth in SEQ ID NO: 1), derivatives or variants thereof, and functional fragments, such as nucleic acid-binding fragments thereof, including endonuclease-deficient (inactive) Cas polypeptides (dCas).
[0136] As used herein, the term "complex" refers to a combination of two or more molecules. In some embodiments, the complex includes polypeptides and nucleic acid molecules that interact with each other (e.g., bind, contact, adhere). For example, the term "complex" can refer to a combination of a guide RNA and a polypeptide (e.g., a Cas protein). Alternatively, the term "complex" can refer to a combination of a guide RNA, a Cas protein, and a complementary region of a target nucleic acid.
[0137] As used herein, the term "cleavage" refers to the breaking of the covalent backbone of a DNA molecule. Cutting can be performed by a variety of methods, including but not limited to enzymatic or chemical hydrolysis of phosphodiester bonds. Both single-stranded and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two different single-stranded cleavage events. DNA cleavage can result in the production of blunt ends or sticky ends.
[0138] The term "cleave" or "cleavage" refers to the hydrolysis of at least one phosphodiester bond within the backbone of a target nucleotide sequence, which can result in single-strand or double-strand breaks within the target sequence. For example, the Cas protein or variant polypeptide thereof disclosed herein can act as an endonuclease, or can be an exonuclease (removing consecutive nucleotides from the ends (5' and / or 3' ends) of a polynucleotide) to cleave nucleotides within a polynucleotide. In some embodiments, cleavage of a target polynucleotide by a Cas protein or variant polypeptide thereof disclosed herein can result in staggered breaks or blunt ends.
[0139] As used herein, the term "protospacer adjacent motif" or "PAM" refers to a short sequence (or motif) adjacent to the protospacer sequence on the non-target strand of a target nucleic acid that is recognized by a CRISPR complex. The target nucleic acid is double-stranded DNA (dsDNA), one strand contains the target sequence adjacent to the PAM and is referred to as the "PAM strand" (e.g., the non-target strand or the non-spacer complementary strand), while the other complementary strand is referred to as the "non-PAM strand" (e.g., the target strand or the spacer complementary strand). As used herein, the term "adjacent" includes situations where the RNA guide of the complex specifically binds, interacts, or associates with the target sequence immediately adjacent to the PAM. In such cases, there are no nucleotides between the target sequence and the PAM. The term "adjacent" also includes situations where there are a small number (e.g., 1, 2, 3, 4, or 5) of nucleotides between the target sequence bound to the targeting moiety and the PAM.
[0140] As used herein, the terms "guide nucleic acid," "RNA guide," "RNA guide sequence," "guide RNA (gRNA)," and "single guide RNA (sgRNA)" are used interchangeably to refer to nucleic acid-based molecules capable of forming a complex with a CRISPR-Cas protein (e.g., a Cas protein of the present disclosure), and comprising a sequence (e.g., a guide sequence) that is sufficiently complementary to a target nucleic acid to hybridize with the target nucleic acid and guide the complex to the target nucleic acid, including but not limited to RNA-based molecules such as guide RNA. A guide nucleic acid may comprise a segment that may be referred to as a "nucleic acid targeting segment" or a "nucleic acid targeting sequence," which may comprise a subsegment that may be referred to as a "protein binding segment" or a "protein binding sequence" or a "Cas protein binding segment." A guide nucleic acid may be a DNA molecule, an RNA molecule, or a DNA / RNA mixture molecule. A "DNA / RNA mixture molecule" refers to a nucleic acid comprising one or more modified or unmodified ribonucleotides and one or more modified or unmodified deoxyribonucleotides, whether consecutive or not. However, a "DNA molecule" or "RNA molecule" may also refer to a DNA molecule containing one or more modified or unmodified ribonucleotides, whether consecutive or not, or an RNA molecule containing one or more modified or unmodified deoxyribonucleotides, whether consecutive or not.
[0141] As used herein, the term "activity" refers to biological activity. In some embodiments, nuclease activity includes enzymatic activity of a nuclease, such as catalytic activity. For example, nuclease activity can include nuclease activity. In some embodiments, nuclease activity includes binding activity, such as binding activity of a nuclease to an RNA guide and / or target nucleic acid.
[0142] As used herein, the terms "upstream" and "downstream" refer to relative positions within a single nucleic acid (e.g., DNA) sequence in a nucleic acid molecule. "Upstream" and "downstream" refer to the 5' to 3' direction in which RNA transcription occurs, respectively. When the 3' end of a first sequence appears before the 5' end of a second sequence, the first sequence is upstream of the second sequence. When the 5' end of a first sequence appears after the 3' end of a second sequence, the first sequence is downstream of the second sequence.
[0143] As used herein, "regulatory elements" include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals, poly-U sequences), which are described in detail in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif (1990). In some cases, regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can primarily direct expression in the desired tissue of interest, such as muscle, neurons, bone, skin, blood, specific organs (e.g., liver, pancreas), or special cell types (e.g., lymphocytes). In other cases, regulatory elements can also direct expression in a temporally dependent manner (e.g., in a cell cycle-dependent or developmental stage-dependent manner), which may or may not be tissue- or cell-type specific. As used herein, the term "promoter" refers to a non-coding nucleotide sequence that is located upstream of a gene and that can initiate downstream gene expression. A constitutive promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or limiting a gene product, results in the production of a gene product in the cell under most or all physiological conditions of the cell. An inducible promoter refers to a promoter that selectively expresses a coding sequence or functional RNA in response to the presence of endogenous or exogenous stimuli, such as by responding to chemical compounds (chemical inducers), or to environmental, hormone, chemical, and / or developmental signals. Inducible or regulated promoters include promoters that are induced or regulated, for example, by light, heat, stress, flooding or drought, salt stress, osmotic stress, plant hormones, wounds, or chemicals (such as ethanol, abscisic acid (ABA), jasmonate, salicylic acid, or safeners).
[0144] As used herein, the term "on-target" refers to a predetermined or intended region of DNA that is bound, cut, and / or edited by a Cas protein or variant polypeptide thereof of the present disclosure.
[0145] As used herein, the term "off-target" refers to an unintended or unexpected region of DNA that is, for example, bound, cut, and / or edited by a Cas protein or its variant polypeptide disclosed herein. In some embodiments, a DNA region is an off-target region when it is different from a region of DNA that is predetermined or expected to be bound, cut, and / or edited by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides. In some embodiments, targeted sequencing of off-target sites predicted by computer simulations or other methods known in the art are used to detect such sites.
[0146] As used herein, the term "in vivo" refers to events that occur within a multicellular organism, such as a human or non-human animal. In the context of cell-based systems, it can be used to refer to events that occur within living cells (as opposed to, for example, in vitro systems).
[0147] As used herein, the term "ex vivo" refers to events that occur in cells or tissues that are grown outside of a multicellular organism rather than within the body of the multicellular organism.
[0148] As used herein, the term "cell" should be understood to refer not only to a particular individual cell, but also to the progeny or potential progeny of a cell. Because certain modifications may occur in subsequent generations due to mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell but are still included within the scope of the term.
[0149] As used herein, the terms "subject," "individual," and "patient" are used interchangeably herein.
[0150] "Individuals" refers to vertebrates, preferably mammals, more preferably humans. Mammals include, but are not limited to, rodents, monkeys, humans, farm animals, sports animals, and pets. Also encompassed are tissues, cells, and progeny of biological entities obtained in vivo or cultured in vitro.
[0151] As used herein, the term "disease" refers to any condition or disorder that damages or interferes with the normal function of cells, tissues, or organs, including but not limited to those specific diseases that have been medically or clinically defined.
[0152] As used herein, the term "treating" refers to the administration of a therapeutic molecule (e.g., a CRISPR-Cas system as described herein) that partially or completely alleviates, ameliorates, alleviates, inhibits, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms or features of a disease, disorder, and / or condition. Such treatment can be for subjects who do not develop symptoms of the relevant disease, disorder, and / or condition and / or for subjects who only develop early signs of a disease, disorder, and / or condition. Alternatively, or in addition, such treatment can be for subjects who develop one or more established symptoms of the relevant disease, disorder, and / or condition.
[0153] As used herein, "biological sample" can contain whole cells and / or living cells and / or cell fragments. A biological sample can include (or be derived from) a "body fluid". In some embodiments, a body fluid can be selected from amniotic fluid, aqueous humor, vitreous humor, bile, serum, milk, cerebrospinal fluid, cerumen (ear wax), chyle, chyme, endolymph, perilymph, exudate, feces, female ejaculation, gastric acid, gastric juice, lymph, mucus (including nasal drainage and phlegm), pericardial fluid, peritoneal fluid, pleural fluid, pus, thin mucus, saliva, sebum (skin oil), semen, sputum, synovial fluid, sweat, tears, urine, vaginal secretions, vomitus, and a mixture of one or more thereof. A biological sample includes cell culture, body fluid, and a cell culture from a body fluid. Body fluid can be obtained from a mammal, for example, by puncture or other collection or sampling procedures.
[0154] As used herein, the term "activity" refers to biological activity. In some embodiments, nuclease activity includes enzymatic activity of a nuclease, such as catalytic activity. For example, nuclease activity may include nuclease activity. In some embodiments, nuclease activity includes binding activity, such as binding activity of a nuclease to an RNA guide and / or target nucleic acid.
[0155] As used herein, "expression of a genomic locus" or "gene expression" is the process by which information from a gene is used to synthesize a functional gene product. The product of gene expression is typically a protein, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is a functional RNA. All known organisms - eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea), and viruses use gene expression processes to produce functional products in order to survive. As used herein, "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acids in cloning systems and in any other context. As used herein, "expression" also refers to the process by which a polynucleotide is transcribed from a DNA template (such as into mRNA or other RNA transcripts) and / or the process by which the transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides can be collectively referred to as "gene products." If a polynucleotide is derived from genomic DNA, expression can include splicing of mRNA in a eukaryotic cell.
[0156] Any protein provided herein can be produced by any method known in the art. For example, the protein provided herein can be produced via recombinant protein expression and purification, which is particularly suitable for fusion proteins comprising peptide linkers. Methods for recombinant protein expression and purification are well known and include those described in "Molecular Cloning: A Laboratory Manual" (Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)), the entire contents of which are incorporated herein by reference.
[0157] Various embodiments are described below. It should be noted that the specific embodiments are not intended to be exhaustive descriptions or as limitations on the broader aspects discussed herein. An aspect described in conjunction with a specific embodiment is not necessarily limited to the embodiment and can be practiced together with any other embodiment. Throughout the specification, references to "one embodiment," "embodiments," "some embodiments," "embodiments," and "example embodiments" refer to specific features, structures, or characteristics described in conjunction with the embodiment that are included in at least one embodiment of the present invention. Therefore, the phrases "in one embodiment," "in an embodiment," or "an example embodiment" that appear throughout the specification do not necessarily all refer to the same embodiment, but may. In addition, in one or more embodiments, specific features, structures, or characteristics can be combined in any suitable manner, which will be apparent to those skilled in the art based on this disclosure. In addition, although some embodiments described herein include some but not other features included in other embodiments, the combination of features of different embodiments is intended to be within the scope of the present invention. For example, in the appended claims, any claimed embodiment can be used in any combination.
[0158] Novel Cas proteins
[0159] The present disclosure has discovered a new Cas protein, which is named CasY7 in the present disclosure. It has single-stranded or double-stranded DNA cleavage activity. The sequence identity of the protein is extremely low with other known Cas proteins. The protein molecule is smaller and can be better delivered.
[0160] The CasY7 protein disclosed herein has excellent cleavage activity against exogenous genes or endogenous genes in vitro or at the cellular level, and its cleavage activity is comparable to or even better than that of LbCpf1. The cleavage activity of specific target sequences of exogenous genes or endogenous genes at the cellular level can reach greater than about 8%, 9%, 10%, 15%, 20%, 30%, 40%, 50%, or higher. In general, its cleavage activity against specific target sequences of exogenous genes or endogenous genes at the cellular level is higher than that of LbCpf1. The above novel Cas proteins may also contain amino acid mutations that have no substantial effect on catalytic activity (endonuclease cleavage activity) or nucleic acid binding function.
[0161] Parent or reference Cas protein
[0162] In some aspects, the parent or reference Cas protein is selected from:
[0163] (1) the Cas protein (CasY7) represented by the amino acid sequence represented by SEQ ID NO: 1 of the present disclosure;
[0164] (2) an ortholog, homolog, variant or functional fragment of the Cas protein shown in (1);
[0165] (3) A polypeptide having about 60% identity with any one of (1) or (2). Optionally, the parent or reference Cas protein can be wild type or not wild type.
[0166] In a preferred example of the present invention, the wild-type Cas protein is CasY7, and the sequence is shown in SEQ ID NO.1.
[0167] It should be understood that the amino acid numbering in the mutant proteins disclosed herein is based on the parent or reference Cas protein. When the sequence homology of a specific mutant protein to the parent or reference Cas protein reaches 80% or more, the amino acid numbering of the mutant protein may be misplaced relative to the amino acid numbering of the parent or reference Cas protein, such as misplacement of 1-100 positions to the N-terminus or C-terminus of the amino acid. Using conventional sequence alignment techniques in the art, those skilled in the art can generally understand that such misplacement is within a reasonable range, and that mutant proteins with a homology of 80% (such as 90%, 95%, 98%) and the same or similar gene editing activity (such as cleavage activity) relative to the wild-type Cas protein (SEQ ID NO.1) should not be excluded from the scope of the mutant proteins disclosed herein due to the misplacement of amino acid numbering. Characterization of representative variant polypeptides (or mutant proteins) and variant polypeptides
[0168] In one aspect of the present disclosure, the variant polypeptides of the present disclosure have or retain or have improved endonuclease activity (on-target) against target DNA for specific cleavage of target DNA. In some embodiments, the variant polypeptides have on-target cleavage activity against double-stranded DNA. In some embodiments, the variant polypeptides substantially retain the on-target cleavage activity against double-stranded DNA of SEQ ID NO: 1.
[0169] In another aspect of the present disclosure, the variant polypeptide of the Cas protein of the present disclosure may substantially lack endonuclease activity (on target), but retains its ability to be complexed with the guide RNA and to be guided to the target DNA and thereby achieve the ability of the functional domain associated with the Cas protein variant polypeptide to be guided to the target DNA and function. The characterization of the Cas protein variant polypeptide of the present disclosure is not limited to the ability of the target DNA to be cut therein.
[0170] Increased on-target cleavage activity
[0171] In some aspects, the present disclosure provides variant polypeptides of Cas proteins that are engineered based on a parent or reference Cas protein. Exemplarily, the variant polypeptides are mutated at multiple amino acid positions of the polypeptide shown in SEQ ID NO. 1. And compared with the parent or reference Cas protein, it has higher double-stranded DNA target cleavage activity, for example, compared with the parent or reference Cas protein (using the same guide RNA mediated), its double-stranded DNA target cleavage activity is increased by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300% or more.
[0172] In some embodiments, the variant polypeptide is a polypeptide having at least about 60%, such as 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% identity to the amino acid sequence shown in SEQ ID NO.1.
[0173] In some embodiments, the variant polypeptides of the present disclosure have amino acid substitutions relative to a parent or reference Cas protein. In some embodiments, the substitutions are conservative amino acid substitutions.
[0174] In one aspect, the present disclosure provides a variant polypeptide comprising any amino acid substitution at one or more of the following positions relative to SEQ ID NO. 1:
[0175] V7, R8, T11, S12, S110, I149, N150, H151, N152, L153, Q160, E161, Y162, N163, C164, Y165, S1 66. S167, F168, K195, S196, K197, S198, A199, C215, T216, A217, K219, S225, L227, L229, M23 1. D234, S240, S241, Q242, E243, I244, S250, F251, E252, K253, V254, K260, T261, E263, N276 , Y282, D283, A285, N292, S303, I304, L307, Y308, S309, R315, E316, T317, I318, I319, V348, I349, E350, P351, L354, S355, N356, L357, K358, I373, G416, I417, E418, F419, D420, I455, R 456, V458, H486, N487, S488, L501, R509, P510, V511, L512, G513, N514, R515, V516, L525, I5 26. N527, K528, K529, C633, T634, T635, K636, N637, D638, R639, G640, E641, F642, E648, L65 0. A651, Y652, A661, T681, N682, E683, S684, G727, K728, N729, E730, S743, E748, G749, S751, K752, K781, L782, G783, E784, C785, S787, K865, P866, Y867, N868, I872, D896, N936, M957, F958, Q960, W961, P1018, S1019, R1020, N1021, S1022.
[0176] In some embodiments, the variant polypeptide has about 1-50, about 1-40, about 1-30, about 2 to 25, preferably 2-20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acid mutations relative to SEQ ID NO.1.
[0177] In some embodiments, the variant polypeptide comprises the following mutations relative to SEQ ID NO. 1:
[0178] (a)M231+D234;
[0179] Preferably, selected from M231K+D234V;
[0180] (b) S240+S241+Q242+E243;
[0181] Preferably, selected from S240A+S241R+Q242P+E243L,
[0182] S240L+S241A+Q242S+E243H+I244L+L307R+Y308F+S309A;
[0183] (c)L227+L229;
[0184] Preferably, selected from L227I+L229R, S225P+L227A+L229R;
[0185] (d) L307+Y308+S309;
[0186] Preferably, selected from S240L+S241A+Q242S+E243H+I244L+L307R+Y308F+S309A, D283S+A285P+L307R+Y308F+S309A,
[0187] L307R+Y308F+S309A+E648R+L650I+A651P+Y652F、
[0188] D283S+A285P+L307R+Y308F+S309A+I373V+E748G+S751G+K752R+S787F,
[0189] S303T+I304M+L307R+Y308A+S309I、
[0190] S196N+K197F+S198N+A199T+I304A+L307R+Y308A+S309A,
[0191] L307R+Y308F+S309A;
[0192] (e)S250+F251+E252+K253+V254;
[0193] Preferably, selected from S250W+F251A+E252A+K253R+V254R;
[0194] (f)K260+T261+E263;
[0195] Preferably, selected from K260R+T261P+E263H;
[0196] (g)R315+E316+T317+I318+I319;
[0197] Preferably, selected from R315L+E316R+T317R+I318V+I319A,
[0198] Y282F+D283Q+A285T+R315A+E316Q+T317R+I318L+I319Q、
[0199] Y282F+D283Q+A285T+R315S+E316R+T317K+I318K+I319W+E648S+A651L;
[0200] (h)L354+S355+N356+L357+K358;
[0201] Preferably, selected from L354F+S355G+N356D+L357I+K358R;
[0202] (i) E648+A651;
[0203] Preferably, selected from E648S+A651L, E648S+A651T+Y652W,
[0204] Y282F+D283Q+A285T+E648T+A651S+Y652F、
[0205] Y282F+D283Q+A285T+E648L+A651G, N276S+D283N+E648S+A651L,
[0206] Y282F+D283Q+A285T+R315S+E316R+T317K+I318K+I319W+E648S+A651L;
[0207] (j)T681+N682+E683;
[0208] Preferably, selected from T681V+N682G+E683R+S684G, T681P+N682T+E683G+S684R,
[0209] T681S+N682P+E683R+S684G, T681A+N682H+E683Y+S684R,
[0210] Y282F+D283Q+A285T+T681P+N682P+E683Q+S684C,
[0211] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+T681N+N682P+E683G+S684A,
[0212] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+T681D+N682A+E683R+S684D,
[0213] Y165W+S166R+S198N+G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R、
[0214] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509N+P510G+V511G+L512S+T681S+N682R+E683R,
[0215] G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R+G727V+K728C+N729G+E730G,
[0216] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509V+P510R+V511L+L512A+T681S+N682R+E683R,
[0217] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509Q+P510A+V511A+L512R+T681S+N682R+E683R+A661V,
[0218] S110G+Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509A+P510A+V511R+L512Q+T681S+N682R+E683R,
[0219] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509L+P510V+V511S+L512F+T681S+N682R+E683R,
[0220] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509G+P510K+L512C+T681S+N682R+E683R,
[0221] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+T634V+T635Y+K636S+N637R+T681S+N682R+E683R;
[0222] (k)Y165+S166;
[0223] Preferably, selected from Y165W+S166R, Y165W+S166V+S167I+F168I,
[0224] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T、
[0225] Y165W+S166R+G416R+I417E+E418Q+F419V+D420A,
[0226] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+T681D+N682A+E683R+S684D,
[0227] Y165W+S166R+S198N+G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R、
[0228] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+N682G+E683A+D896N、
[0229] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509N+P510G+V511G+L512S+T681S+N682R+E683R、
[0230] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513L+N514A+R515V+V516M+N682G+E683A+S684R+D896N、
[0231] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+N682G+E683A+S684R+D896N、
[0232] Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+N487N+S488W+N682G+E683A+S684R+D896N、
[0233] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509Q+P510A+V511A+L512R+T681S+N682R+E683R+A661V、
[0234] S110G+Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509A+P510A+V511R+L512Q+T681S+N682R+E683R、
[0235] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509L+P510V+V511S+L512F+T681S+N682R+E683R、
[0236] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+T635S+K636G+N637L+N682G+E683A+S684R+D896N、
[0237] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+T634V+T635Y+K636S+N637R+T681S+N682R+E683R,
[0238] Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+K781T+G783S+E784F+C785L+D896N,
[0239] Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+D638F+R639P+G640N+E641Y+F642L,
[0240] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+N682G+E683A+S684R+P1018L+S1019R+R1020P+N1021R+S1022V;
[0241] (l)Q160+E161+Y162+N163+C164;
[0242] Preferably, selected from Q160V+E161I+Y162T+N163S+C164V,
[0243] Q160S+E161S+Y162L+N163C+C164V、
[0244] Q160P+E161V+Y162H+N163S+C164T、
[0245] Q160L+E161S+Y162F+N163S+C164A;
[0246] (m)V7+T11+S12;
[0247] Preferably, selected from V7H+T11R+S12M, V7F+R8L+T11R+S12V,
[0248] V7I+T11V+S12M+Y282F+D283Q+A285T;
[0249] (n)I149+N150+H151+N152+L153;
[0250] Preferably, selected from I149M+N150S+H151C+N152T+L153Y;
[0251] (o)K195+K197+S198+A199;
[0252] Preferably, selected from K195R+K197A+S198A+A199G;
[0253] (p)T216+A217+K219;
[0254] Preferably, selected from T216L+A217T+K219R, C215V+T216S+A217S+K219R;
[0255] (q)D283+A285;
[0256] Preferably, selected from Y282F+D283Q+A285T, D283I+A285R+N292L,
[0257] Y282F+D283Q+A285T+K865S+P866S+Y867H+N868F+I872L、
[0258] Y282F+D283Q+A285T+M957V+F958L+Q960V+W961V,
[0259] Y282F+D283Q+A285T+V348I+I349V+E350L+P351T、
[0260] Y282F+D283Q+A285T+T681P+N682P+E683Q+S684C,
[0261] Y282F+D283Q+A285T+E748A+G749S+S751G、
[0262] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V、
[0263] Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A,
[0264] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q、
[0265] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+N936S、
[0266] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+T681N+N682P+E683G+S684A、
[0267] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q、
[0268] Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A+I455G+R456E+V458E、
[0269] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+ L512F+L525R+I526V+N527D+K528P+K529G+N682G+E683A+S684R+D896N、
[0270] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509V+P510R+V511L+L512A+T681S+N682R+E683R、
[0271] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V、
[0272] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509G+P510K+L512C+T681S+N682R+E683R、
[0273] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+G727E+K728H+N729Q+E730R、
[0274] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+S743T、
[0275] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+K781H+L782I+G783F+E784R+C785S、
[0276] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+D638P+E641M+F642V、
[0277] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+P1018S+S1019R+R1020V+N1021M+S1022P、
[0278] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633N+T634E+T635E+K636G+N637L+N682G+E683A+S684R+S743T、
[0279] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633F+T634P+T635F+K636P+N637C+N682G+E683A+S684R+S743T、
[0280] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633S+T634C+T635G+K636H+N637F+N682G+E683A+S684R+S743T、
[0281] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+ L512F+C633R+T634Y+T635L+K636V+N637D+N682G+E683A+S684R+S743T;
[0282] (r)G416+I417+E418+F419+D420;
[0283] Preferably, selected from G416R+I417W+E418T+F419R+D420V,
[0284] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V、
[0285] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T、
[0286] Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A,
[0287] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q、
[0288] Y165W+S166R+G416R+I417E+E418Q+F419V+D420A,
[0289] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+N936S,
[0290] Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+T681N+N682P+E683G+S684A,
[0291] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+T681D+N682A+E683R+S684D,
[0292] Y165W+S166R+S198N+G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R、
[0293] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+N682G+E683A+D896N、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q、
[0294] R509C+P510S+L512F+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+ N682G+E683A+S684R+D896N、
[0295] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509N+P510G+V511G+L512S+T681S+N682R+E683R、
[0296] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513L+N514A+R515V+V516M+N682G+E683A+S684R+D896N、
[0297] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+N682G+E683A+S684R+D896N、
[0298] G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R+G727V+K728C+N729G+E730G、
[0299] Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A+I455G+R456E+V458E、
[0300] Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+N487N+S488W+N682G+E683A+S684R+D896N、
[0301] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+L525R+I526V+N527D+K528P+K529G+N682G+E683A+S684R+D896N、
[0302] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509V+P510R+V511L+L512A+T681S+N682R+E683R、
[0303] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509Q+P510A+V511A+L512R+T681S+N682R+E683R+A661V、
[0304] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V、
[0305] S110G+Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509A+P510A+V511R+L512Q+T681S+N682R+E683R、
[0306] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509L+P510V+V511S+L512F+T681S+N682R+E683R、
[0307] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509G+P510K+L512C+T681S+N682R+E683R、
[0308] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+G727E+K728H+N729Q+E730R、
[0309] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+T635S+K636G+N637L+N682G+E683A+S684R+D896N、
[0310] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+T634V+T635Y+K636S+N637R+T681S+N682R+E683R、
[0311] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+S743T、
[0312] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+K781H+L782I+G783F+E784R+C785S、
[0313] Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+K781T+G783S+E784F+C785L+D896N、
[0314] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+D638P+E641M+F642V、
[0315] Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+D638F+R639P+G640N+E641Y+F642L、
[0316] Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+N682G +E683A+S684R+P1018L+S1019R+R1020P+N1021R+S1022V、
[0317] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+P1018S+S1019R+R1020V+N1021M+S1022P、
[0318] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+ L512F+C633N+T634E+T635E+K636G+N637L+N682G+E683A+S684R+S743T、
[0319] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+ L512F+C633F+T634P+T635F+K636P+N637C+N682G+E683A+S684R+S743T,
[0320] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+ L512F+C633S+T634C+T635G+K636H+N637F+N682G+E683A+S684R+S743T,
[0321] Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+ L512F+C633R+T634Y+T635L+K636V+N637D+N682G+E683A+S684R+S743T.
[0322] Endonuclease-deficient variant polypeptide (dCas)
[0323] In some aspects, the present disclosure provides a nuclease-deficient variant polypeptide, exemplified by retaining only a portion (e.g., less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% or less) of the spacer-specific nuclease cleavage activity against a target sequence of a target DNA complementary to a guide RNA relative to a parent or reference Cas protein.
[0324] In some embodiments, the variant polypeptide substantially lacks spacer sequence-specific (on-target) double-stranded DNA cleavage activity.
[0325] In some embodiments, the variant polypeptide substantially lacks the spacer sequence-specific (on-target) double-stranded DNA cleavage activity of SEQ ID NO:1.
[0326] In some embodiments, when used in combination with the same guide RNA, the variant polypeptide has reduced spacer sequence-specific (on-target) double-stranded DNA cleavage activity compared to SEQ ID NO: 1, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% reduced spacer sequence-specific (on-target) double-stranded DNA cleavage activity.
[0327] In some embodiments, the variant polypeptide comprises one or more amino acid substitutions at the following positions relative to SEQ ID NO: 1: D592, D643, E820, and D992.
[0328] In some embodiments, the variant polypeptide comprises one or more amino acid substitutions at the following positions relative to the amino acid sequence shown in SEQ ID NO: 1: D592A, D643A, E820A, and D992A.
[0329] In some embodiments, the variant polypeptide has an amino acid substitution selected from one of D592A, D643A, E820A and D992A relative to the amino acid sequence shown in SEQ ID NO: 1.
[0330] In some embodiments, the variant polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs:47-50, or an amino acid sequence that has at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%) sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:47-50.
[0331] Fusion protein
[0332] In one aspect, the present disclosure provides a fusion protein comprising a Cas protein or variant polypeptide of the present disclosure, and one or more functional domains associated with the Cas protein or variant polypeptide. In one embodiment, the functional domain is a heterologous functional domain.
[0333] As used herein, the term "functional domain" is taken in its broadest sense, including proteins such as enzymes or factors themselves or fragments / domains thereof having specific functions. When a fusion protein includes more than one functional domain, the functional domains may be the same or different.
[0334] In one embodiment, the functional domain is selected from a nuclear localization signal (NLS), a nuclear export signal (NES), a reporter protein (e.g., a fluorescent protein), a Cas protein targeting portion, a DNA binding domain (e.g., Lex A DBD, Gal4DBD, Sp1 DBD), an epitope tag (e.g., His, myc, V5, FLAG, HA, VSV-G, etc.), a transcriptional activation domain (e.g., VP64, VPR, p65, Rta), a transcriptional repression domain (e.g., a KRAB domain, a SID domain, a NuE domain, an NcoR domain, or a SID4X domain), a nuclease, a deaminase (e.g., adenosine deaminase or cytidine deaminase), a methylase (e.g., a DNA methylase DNMT), a demethylase, a transcription release factor, an HDAC, a cleavage-active polypeptide, a ligase, an integrase, a transposase, a recombinase, a polymerase, an exonuclease (e.g., T5E), and a base excision repair inhibitor (e.g., a uracil-DNA glycosylase inhibitor (UGI)).
[0335] In some embodiments, the functional domain comprises one or more of the following enzymatic activities on a target sequence: methylase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity, glycosylation activity (e.g., from O-GlcNAc transferase), and deglycosylation activity.
[0336] In some embodiments, the functional domain is selected from a deaminase.
[0337] As used herein, "adenosine deaminase" or "adenosine deaminase protein" refers to a protein, polypeptide, or one or more functional domains of a protein or polypeptide that can catalyze the hydrolytic deamination reaction of converting adenine (or the adenine portion of a molecule) to hypoxanthine (or the hypoxanthine portion of a molecule). In some embodiments, the functional domain is selected from adenosine deaminase. In some embodiments, the adenosine deaminase comprises a protein that can deaminate adenine (A) to hypoxanthine (I). In some embodiments, the deamination of adenine to hypoxanthine converts adenosine (A) or deoxyadenosine (dA) containing adenine to guanosine (G) or deoxyguanosine (dG). In some embodiments, the adenosine deaminase is, but is not limited to, a member of the enzyme family known as adenosine deaminases acting on RNA (ADAR), a member of the enzyme family known as adenosine deaminases acting on tRNA (ADAT), and other family members containing adenosine deaminase domains (ADAD). In some embodiments, the adenosine deaminase is capable of targeting adenine in RNA / DNA and RNA duplexes. In some embodiments, the adenosine deaminase has been modified to increase its ability to edit DNA in RNA / DNA heteroduplexes of RNA duplexes.
[0338] In some embodiments, the adenosine deaminase is derived from one or more metazoan species, including but not limited to mammals, birds, frogs, squid, fish, flies, and worms. In some embodiments, the adenosine deaminase is human, squid, or Drosophila adenosine deaminase.
[0339] In some embodiments, the adenosine deaminase is a human ADAR, including hADAR1, hADAR2, and hADAR3. In some embodiments, the adenosine deaminase is a Caenorhabditis elegans ADAR protein, including ADR-1 and ADR-2. In some embodiments, the adenosine deaminase is a Drosophila ADAR protein, including dAdar. In some embodiments, the adenosine deaminase is a squid (Loligo pealeii) ADAR protein, including sqADAR2a and sqADAR2b. In some embodiments, the adenosine deaminase is a human ADAT protein. In some embodiments, the adenosine deaminase is a Drosophila ADAT protein. In some embodiments, the adenosine deaminase is a human ADAD protein, including TENR (hADAD1) and TENRL (hADAD2).
[0340] In some embodiments, the adenosine deaminase is a TadA protein, such as Escherichia coli TadA. See Kim et al., Biochemistry 45:6407-6416 (2006); Wolf et al., EMBO J. 21:3841-3851 (2002). In some embodiments, the adenosine deaminase is mouse ADA. See Grunebaum et al., Curr. Opin. Allergy Clin. Immunol. 13:630-638 (2013). In some embodiments, the adenosine deaminase is human ADAT2. See Fukui et al., J. Nucleic Acids 2010:260512 (2010). In some embodiments, the deaminase (e.g., an adenosine or cytidine deaminase) is one or more of those described in Cox et al., Science. 2017 Nov 24;358(6366):1019-1027; Komore et al., Nature. 2016 May 19;533(7603):420-4; and Gaudelli et al., Nature. 2017 Nov 23;551(7681):464-471.
[0341] In some embodiments, the adenosine deaminase protein recognizes one or more target adenosine residues in a double-stranded nucleic acid substrate and converts them into inosine residues. In some embodiments, the double-stranded nucleic acid substrate is an RNA-DNA hybrid duplex. In some embodiments, the adenosine deaminase protein recognizes a binding window on the double-stranded substrate. In some embodiments, the binding window comprises at least one target adenosine residue. In some embodiments, the binding window is in the range of about 3 bp to about 100 bp. In some embodiments, the binding window is in the range of about 5 bp to about 50 bp. In some embodiments, the binding window is in the range of about 10 bp to about 30 bp. In some embodiments, the binding window is about 1 bp, 2 bp, 3 bp, 5 bp, 7 bp, 10 bp, 15 bp, 20 bp, 25 bp, 30 bp, 40 bp, 45 bp, 50 bp, 55 bp, 60 bp, 65 bp, 70 bp, 75 bp, 80 bp, 85 bp, 90 bp, 95 bp, or 100 bp.
[0342] In some embodiments, the adenosine deaminase protein comprises one or more deaminase domains. Without wishing to be bound by a particular theory, it is expected that the deaminase domain is used to identify one or more target adenosine (A) residues contained in a double-stranded nucleic acid substrate and convert them into inosine (I) residues. In some embodiments, the deaminase domain comprises an active center. In some embodiments, the active center comprises a zinc ion. In some embodiments, during the AI editing process, the base pairing at the target adenosine residue is destroyed, and the target adenosine residue is "flipped" out of the double helix to become accessible to the adenosine deaminase. In some embodiments, the amino acid residue in or near the active center interacts with one or more nucleotides at the 5' end of the target adenosine residue. In some embodiments, the amino acid residue in or near the active center interacts with one or more nucleotides at the 3' end of the target adenosine residue. In some embodiments, the amino acid residue in or near the active center further interacts with nucleotides complementary to the target adenosine residue on the opposite chain. In some embodiments, the amino acid residue forms a hydrogen bond with the 2' hydroxyl group of the nucleotide.
[0343] In some embodiments, the adenosine deaminase comprises a human ADAR2 holoprotein (hADAR2) or a deaminase domain thereof (hADAR2-D). In some embodiments, the adenosine deaminase is an ADAR family member homologous to hADAR2 or hADAR2-D.
[0344] In some embodiments, the adenosine deaminase comprises the wild-type amino acid sequence of hADAR2-D. In some embodiments, the adenosine deaminase comprises one or more mutations in the hADAR2-D sequence such that the editing efficiency and / or substrate editing preference of hADAR2-D are altered according to specific needs.
[0345] In some embodiments, the adenosine deaminase is a tRNA adenosine deaminase (TadA) or a deaminase domain thereof or a functional variant or fragment thereof. Exemplarily, the adenosine deaminase is selected from TadA8e (SEQ ID NO: 79), TadA8.17, TadA8.20, TadA9, TadA8EV106W, TadA8EV106W+D108Q, TadA-CDa, TadA-CDb, TadA-CDc, TadA-CDd, TadA-CDe, TadA-dual, TADAC-1.2, TADAC-1.14, TADAC-1.17, TADAC-1.19, TADAC-2.5, TADAC-2.6, TADAC-2.9, TADAC-2.19, TADAC-2.23, TadA8e-N46L, and TadA8e-N46P.
[0346] In some embodiments, the adenosine deaminase comprises an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 31 (selected from the 005V1 deaminase in CN114634923A, in which the amino acid sequence is SEQ ID NO: 2) or SEQ ID NO: 70 (selected from the 004V1 deaminase in CN114634923A, in which the amino acid sequence is SEQ ID NO: 1), and it retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 31.
[0347] In some embodiments, the amino acid sequence of the adenosine deaminase comprises amino acid additions, insertions, deletions, and substitutions relative to the amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, the catalytic domain of the adenosine deaminase comprises a mutant of the amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, the adenosine deaminase comprises the amino acid sequence set forth in SEQ ID NO: 32.
[0348] In some embodiments, the adenosine deaminase comprises an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:32, and it retains the deamination activity of the amino acid sequence shown in SEQ ID NO:32.
[0349] In some embodiments, the amino acid sequence of the adenosine deaminase comprises amino acid additions, insertions, deletions, and substitutions relative to the amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the catalytic domain of the adenosine deaminase comprises a mutant of the amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the adenosine deaminase comprises the amino acid sequence set forth in SEQ ID NO. 32.
[0350] In some embodiments, the amino acid sequence of the adenosine deaminase comprises an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 70 (selected from 004V1 deaminase in CN114634923A, in which the amino acid sequence is SEQ ID NO: 1), and it retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 70.
[0351] In some embodiments, the functional domain is selected from cytidine deaminase.
[0352] As used herein, the term "cytidine deaminase" or "cytidine deaminase protein" refers to a protein, polypeptide, or one or more functional domains of a protein or polypeptide that can catalyze the hydrolytic deamination reaction that converts cytosine (or the cytosine portion of a molecule) into uracil (or the uracil portion of a molecule). In some embodiments, the cytosine-containing molecule is cytidine (C), and the uracil-containing molecule is uridine (U). The cytosine-containing molecule can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
[0353] In some embodiments, the cytidine deaminase is selected from APOBEC (eg, APOBEC3, eg, APOBEC3A, APOBEC3B, APOBEC3C).
[0354] In some embodiments, the cytidine deaminase is selected from hAPOBEC3-W104A (SEQ ID NO: 95). In some embodiments, the cytidine deaminase comprises the wild-type amino acid sequence of cytosine deaminase. In some embodiments, the cytidine deaminase comprises one or more mutations in the cytosine deaminase sequence such that the editing efficiency and / or substrate editing preference of the cytosine deaminase is altered according to specific needs.
[0355] In some embodiments, the functional domain is a base excision repair inhibitor. Exemplarily, the base excision repair inhibitor is a uracil-DNA glycosylase inhibitor (UGI).
[0356] In some embodiments, the uracil-DNA glycosylase inhibitor (UGI) is derived from a human UGI domain (exemplarily, the UGI domain is shown in SEQ ID NO. 96).
[0357] In one embodiment, the functional domain is a methylase, such as HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3, ZMET2, CMT1, CMT2, etc.
[0358] In one embodiment, the functional domain is a demethylase, for example, TET1 (ten-eleven translocation 1), ten-eleven translocation (TET) dioxygenase 1 (TET1CD), DME, DML1, DML2, ROS1, etc.
[0359] In one embodiment, the functional domain is a transcriptional release factor, such as eukaryotic release factor 1 (ERF1) activity, eukaryotic release factor 3 (ERF3).
[0360] In one embodiment, the nuclear export signal comprises human protein tyrosine kinase 2.
[0361] In one embodiment, the reporter protein comprises one or more of glutathione-S-transferase, horseradish peroxidase, chloramphenicol acetyltransferase, β-galactosidase, β-glucuronidase, or an autofluorescent protein.
[0362] In one embodiment, the autofluorescent protein includes one or more of green fluorescent protein, HcRed, DsRed, cyan fluorescent protein, yellow fluorescent protein or blue fluorescent protein.
[0363] In one embodiment, the DNA binding domain comprises one or more of methylation binding protein, LexADBD, Sp1DBD, or Gal4DBD.
[0364] In one embodiment, the epitope tag comprises one or more of a His (histidine tag), a V5 tag, a FLAG tag, an influenza virus hemagglutinin tag, a Myc tag, a VSV-G tag, or a thioredoxin tag.
[0365] In one embodiment, the transcriptional activation domain comprises one or more of VP64, p65, Rta, and VPR.
[0366] In one embodiment, the transcriptional repression domain comprises KRAB and / or SID.
[0367] In one embodiment, the nuclease comprises FokI.
[0368] In one embodiment, the cleavage-active polypeptide includes a polypeptide having single-stranded RNA cleavage activity, a polypeptide having double-stranded RNA cleavage activity, a polypeptide having single-stranded DNA cleavage activity, or a polypeptide having double-stranded DNA cleavage activity.
[0369] In one embodiment, the ligase comprises DNA ligase and / or RNA ligase.
[0370] In some embodiments, the functional domain is an exonuclease. According to the disclosure herein, there are a variety of eligible exonucleases or programmable exonucleases. Examples of exonucleases suitable for use as part of the fusion proteins in this application include MRE11, EXO1, EXO III, EXO VII, EXOT, DNA2, CtIP, TREX1, TREX2, Apollo, RecE, Red, T5, Lexo, RecBCD, and mung bean exonucleases. Other suitable exonucleases are also contemplated.
[0371] In some embodiments, the exonuclease is selected from T5 exonuclease or T7 exonuclease.
[0372] In some embodiments, the T5 exonuclease comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence of any one of SEQ ID NO:81.
[0373] In some embodiments, the functional domain is a nuclear localization signal. As used herein, "NLS," "nuclear localization sequence," or "nuclear localization signal" are used interchangeably herein and refer to an amino acid sequence that promotes protein entry into the cell nucleus. Nuclear localization sequences are known in the art (e.g., Plank et al., International PCT Application PCT / EP2000 / 011690, filed November 23, 2000, and described in WO / 2001 / 038547, published on May 31, 2001), which is incorporated herein by reference for its disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS, such as, for example, that described in Koblan et al., Nature Biotech. 2018 doi: 10.1038 / nbt.4172. In some embodiments, the NLS comprises the following amino acid sequence: KRTADGSEFESPKKKRKV (SEQ ID NO.38), AVKRPAATKKAGQAKKKKLD (SEQ ID NO.39), KRPAATKKAGQAKKKK (SEQ ID NO.40), KKTELQTTNAENKTKKL (SEQ ID NO.41), KRGINDRNFWRGENGRKTR (SEQ ID NO.42), RKSGKIAAIVVKRPRK (SEQ ID NO.43), PKKKRKV (SEQ ID NO.44), or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO.45).
[0374] polynucleotides
[0375] In one aspect, the present disclosure provides a polynucleotide, which is a polynucleotide sequence encoding the Cas protein or variant polypeptide thereof of the present disclosure, or a polynucleotide sequence encoding the fusion protein of the present disclosure.
[0376] In one embodiment, the polynucleotide is a DNA molecule that is codon-optimized according to the codon preference of the host cell;
[0377] Optimization of the present disclosure may require mutation of the nucleotide sequence of the coded protein (e.g., Cas protein of the present disclosure or its variant polypeptide) to simulate the codon preference of the expected host organism or cell when encoding the same protein at the same time. Therefore, the codons can be changed, but the encoded protein remains unchanged. For example, if the expected target cell is a human cell, a nucleotide sequence of the coded protein optimized by human codons can be used. As another non-limiting embodiment, if the expected host cell is an animal cell (e.g., mouse cell, insect cell), the nucleotide sequence of the coded protein optimized by the animal codon can be generated. As another non-limiting embodiment, if the expected host cell is a plant cell, the nucleotide sequence of the coded protein optimized by plant codons can be generated.
[0378] A selection list of codons is readily available, for example, the "Codon Usage Database" available at www.kazusa.or.jp / codon. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant polypeptide, or its fusion protein, which is codon-optimized for expression in eukaryotic cells. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant polypeptide, or its fusion protein, which is codon-optimized for expression in animal cells. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant polypeptide, or its fusion protein, which is codon-optimized for expression in fungal cells. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant polypeptide, or its fusion protein, which is codon-optimized for expression in plant cells.
[0379] In some embodiments, the nucleic acid molecules of the present disclosure comprise a nucleotide sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%) sequence identity to the nucleotide sequence set forth in any one of SEQ ID NO. 2, 37, 83, 85, 87.
[0380] In some embodiments, the polynucleotide has a nucleotide sequence as shown in any one of SEQ ID NO. 2, 37, 83, 85, and 87.
[0381] In one embodiment, the host cell comprises a prokaryotic cell or a eukaryotic cell;
[0382] In some embodiments, the present disclosure provides a polynucleotide encoding a guide RNA. In some embodiments, the polynucleotide encoding a guide RNA comprises DNA, RNA, or a DNA / RNA mixture.
[0383] "DNA / RNA mixture" refers to a nucleic acid comprising one or more modified or unmodified ribonucleotides and one or more modified or unmodified deoxyribonucleotides, whether or not consecutive. However, "DNA" or "RNA" may also refer to DNA containing one or more modified or unmodified ribonucleotides, whether or not consecutive, or RNA containing one or more modified or unmodified deoxyribonucleotides, whether or not consecutive. In some embodiments, the polynucleotide encoding the guide RNA is operably linked to a promoter or under the regulation of a promoter.
[0384] In some embodiments, the polynucleotide encoding the Cas protein is DNA, RNA, or a DNA / RNA mixture. "DNA / RNA mixture" refers to a nucleic acid comprising one or more modified or unmodified ribonucleotides and one or more modified or unmodified deoxyribonucleotides, whether or not continuous. However, "DNA" or "RNA" may also refer to a DNA containing one or more modified or unmodified ribonucleotides, whether or not continuous, or an RNA containing one or more modified or unmodified deoxyribonucleotides, whether or not continuous.
[0385] In some embodiments, the polynucleotide encoding the Cas protein is operably linked to a promoter or is under the regulation of a promoter. In some embodiments, the promoter is a broad-spectrum promoter, a tissue-specific promoter, a cell type-specific promoter, a constitutive promoter, or an inducible promoter.
[0386] In some embodiments, the polynucleotide encoding the guide RNA and / or Cas protein is functionally or operably connected to a regulatory element and thus regulated. Alternatively, the promoter may be selected from the group consisting of: pol I promoter, pol II promoter, pol III promoter, T7 promoter, U6 promoter, H1 promoter, retroviral Rous sarcoma virus (RSV) LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter, and EF1α promoter. In some embodiments, the promoter is a U6 promoter.
[0387] CRISPR system
[0388] The Cas proteins and variant polypeptides disclosed herein can be used in combination with guide RNA and guided to target DNA by the guide RNA to exert an effect on the target DNA.
[0389] In one aspect, the present disclosure provides a CRISPR-Cas system comprising:
[0390] (i) a first component selected from the group consisting of a Cas protein or variant polypeptide of the present disclosure, a fusion protein of the present disclosure, a nucleotide sequence encoding a Cas protein or variant polypeptide of the present disclosure, or a fusion protein of the present disclosure, and any combination thereof; and
[0391] (ii) a second component, which comprises one or more guide RNAs disclosed herein, or a nucleotide sequence encoding one or more guide RNAs disclosed herein.
[0392] In some embodiments, the guide RNA comprises:
[0393] (i) a direct repeat (DR) sequence capable of forming a complex with the Cas protein or fusion protein; and
[0394] (ii) a spacer sequence capable of hybridizing to a target sequence of a target DNA, thereby guiding the complex to the target DNA.
[0395] In some embodiments, the CRISPR-Cas system is non-naturally occurring or engineered.
[0396] In some embodiments, the system is a complex comprising a Cas protein complexed with a guide RNA.
[0397] In some embodiments, the complex further comprises a target DNA hybridized to the target sequence.
[0398] In one aspect, the present disclosure provides a composite comprising:
[0399] (i) a protein component selected from the group consisting of a Cas protein of the present disclosure, a fusion protein of the present disclosure, or a combination thereof; and
[0400] (ii) the guide RNA of the present disclosure.
[0401] In one aspect, the present invention further provides a CRISPR-Cas composition comprising:
[0402] (1) Protein component: the Cas protein or fusion protein disclosed herein; or a nucleic acid molecule encoding the Cas protein or the fusion protein disclosed herein;
[0403] (2) RNA component: the guide RNA disclosed herein, or one or more nucleic acids encoding the guide RNA, or a precursor RNA of the guide RNA, or a nucleic acid encoding a precursor RNA of the guide RNA; the protein component and the nucleic acid component bind to each other to form a complex.
[0404] In one embodiment, the composition is an activated CRISPR complex, further comprising: a target sequence of a target nucleic acid bound to the guide RNA.
[0405] guide RNA
[0406] In another aspect, the present disclosure provides a guide RNA (gRNA), comprising:
[0407] (1) a direct repeat (DR) sequence capable of forming a complex with the Cas protein of the present disclosure, and
[0408] (2) A spacer sequence capable of hybridizing with a target sequence of a target DNA, thereby guiding the complex to the target DNA.
[0409] In some embodiments, the guide RNA does not comprise tracrRNA.
[0410] In some embodiments, the direct repeat (DR) sequence is at the 5' end of the spacer sequence, which is capable of forming a complex with the Cas protein or variant polypeptide thereof of the present disclosure, or the fusion protein of the present disclosure.
[0411] In some embodiments, the guide RNA comprises, consists essentially of, or consists of a direct repeat sequence (DR) and a spacer sequence. In some embodiments, the guide RNA is a single molecule nucleic acid, and the direct repeat (DR) sequence is linked to the spacer sequence.
[0412] In some embodiments, the guide RNA comprises multiple spacer sequences arranged in tandem, optionally separated by nucleotide sequences such as direct repeat (DR) sequences as defined herein. The position of different spacer sequences is tandem without affecting activity.
[0413] In some embodiments, the spacer sequence comprises a series of 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 25, 25, 30 or more sequences, each of which is capable of specifically hybridizing with a target sequence in a target genomic locus in a cell. In some embodiments, a functional CRISPR-Cas system or complex can edit multiple target sequences, for example, the target sequence can include a genomic locus, and in some embodiments, there can be changes in gene expression. In some embodiments, a functional CRISPR-Cas system or complex can include other functional domains. In some embodiments, the disclosure provides methods for changing or modifying the expression of multiple gene products. The method may include introducing a cell containing the target nucleic acid, such as a DNA molecule, or containing and expressing a target nucleic acid, such as a DNA molecule; for example, the target nucleic acid can encode a gene product or provide expression of a gene product (such as a regulatory sequence). In some embodiments, the guide RNA comprises a direct repeat (DR) sequence, a spacer sequence, and a direct repeat (DR) sequence (DR-spacer-DR). This is a typical configuration of pre-crRNA. In some embodiments, the guide RNA comprises a DR-spacer-DR-spacer structure. In some embodiments, the guide RNA comprises two or more DRs and two or more spacer sequences. In some embodiments, the crRNA comprises a truncated direct repeat (DR) sequence and a spacer sequence. This is a typical processed or mature guide RNA. In some embodiments, the Cas protein or its variant polypeptide of the present disclosure forms a complex with the guide RNA, and the spacer sequence guides the complex to a target nucleic acid complementary to the spacer sequence to achieve sequence-specific binding.
[0414] Multiple guide RNAs
[0415] In one aspect, the CRISPR-Cas system of the present disclosure comprises a plurality (exemplarily, 2, 3, 4, 5, or more) of guide RNAs, for example, each of the plurality of guide RNAs specifically targets a DNA molecule encoding a gene product in a cell, such that each of the plurality of guide RNAs targets its specific DNA molecule encoding a gene product, and the Cas protein cuts the target DNA molecule encoding the gene product, thereby changing the expression of the gene product; and wherein the CRISPR protein and the guide RNA do not naturally exist together.
[0416] In some embodiments, multiple guide nucleic acids are operably linked to or under the regulation of the same regulatory element (e.g., promoter) or separate regulatory elements (e.g., promoters).
[0417] In some embodiments, the guide RNA comprises non-naturally occurring nucleic acids and / or non-naturally occurring nucleotides and / or nucleotide analogs and / or chemical modifications. Preferably, these non-naturally occurring nucleic acids and non-naturally occurring nucleotides are located outside the guide RNA. Non-naturally occurring nucleic acids can include, for example, a mixture of natural and non-naturally occurring nucleotides. Non-naturally occurring nucleotides and / or nucleotide analogs can be modified in the ribose, phosphate and / or base moieties. In one embodiment, the guide RNA comprises ribonucleotides and non-ribonucleotides.
[0418] In one embodiment, the guide RNA comprises one or more non-naturally occurring nucleotides or nucleotide analogs, such as nucleotides with phosphorothioate linkages, locked nucleic acids (LNA) or bridged nucleic acids (BNA) comprising a methylene bridge between the 2' and 4' carbon atoms of the ribose ring. Other examples of modified nucleotides include 2'-O-methyl analogs, 2'-deoxy analogs, or 2'-fluoro analogs. Other examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine. Examples of guide RNA chemical modifications include, but are not limited to, incorporation of 2'-O-methyl (M), 2'-O-methyl 3' phosphorothioate (MS), S-constrained ethyl (cEt), or 2'-O-methyl 3' thio PACE (MSP) at one or more terminal nucleotides.
[0419] In one embodiment, the 5' and / or 3' ends of the guide RNA are modified with a variety of functional moieties including fluorescent dyes, polyethylene glycol, cholesterol, proteins, or detection tags (see Kelly et al., 2016, J. Biotech. 233: 74-83). In one embodiment, the guide RNA comprises ribonucleotides in the region bound to the target sequence and one or more deoxyribonucleotides and / or nucleotide analogs in the region bound to the nucleic acid-guided nuclease. In one embodiment, the 3-5 nucleotides at the 3' or 5' end of the guide RNA are chemically modified. In one embodiment, only smaller modifications, such as 2'-F modifications, are introduced into the seed region. In one embodiment, the guide RNA is modified to include a chemical moiety at its 3' and / or 5' end. Such moieties include, but are not limited to, amines, azides, alkynes, thiols, dibenzocyclooctyne (DBCO), or rhodamine. In some embodiments, the chemical moiety is conjugated to the guide RNA via a linker such as an alkyl chain. In one embodiment, the chemical moiety of the modified guide RNA can be used to attach the guide RNA to another molecule, such as DNA, RNA, protein, or nanoparticles. Such chemically modified guide RNAs can be used to identify or enrich cells that are typically edited by nucleic acid-guided nucleases and related systems (see Lee et al., eLife, 2017, 6:e25312, DOI: 10.7554).
[0420] Direct repeat (DR) sequences
[0421] The present disclosure provides DR sequences corresponding to Cas proteins and variant polypeptides thereof, which can bind to Cas proteins or variant polypeptides thereof to form a complex. In some embodiments, DR comprises a sequence as shown in SEQ ID NO.5 or SEQ ID NO.71, or a nucleotide sequence having at least about 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with the nucleotide sequence shown in any one of SEQ ID NO.5 or 71. In some embodiments, DR is a "functional variant" (e.g., a "functional truncated version," "functionally extended version," or "functionally replaced version") of the RNA sequence shown in SEQ ID NO.5 or 71, but still has DR function and retains at least part (e.g., at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more) of the function of the reference DR (parent DR).
[0422] In some embodiments, the DR sequence comprises a stem-loop structure near the 3' end (immediately adjacent to the spacer sequence).
[0423] "Stem-loop structure" refers to a nucleic acid with a secondary structure, comprising a region of nucleotides known or predicted to form a double-stranded (stem) portion, connected at one end by a basic single-stranded nucleotide linking region (loop). The term "hairpin" structure is also used herein to refer to a stem-loop structure. These structures are well known in the art, and these terms are used according to the meaning generally known in the art. Stem-loop structures do not require precise base pairing. Therefore, the stem may contain one or more base mispairings. Alternatively, the base pairing may be precise, i.e., not including any mispairings.
[0424] In one embodiment, the guide RNA of the present disclosure comprises a DR comprising a stem-loop structure near the 3' end of the DR sequence. In some embodiments, the stem contained in the DR consists of 5 pairs of complementary bases that hybridize with each other, and the length of the loop is 6, 7, 8 or 9 nucleotides. In some embodiments, the length of the loop is 7 nucleotides. In some embodiments, the stem can comprise at least 2, at least 3, at least 4 or at least 5 base pairs. In some embodiments, the DR comprises two complementary nucleotide segments of approximately 5 nucleotides in length, separated by approximately 7 nucleotides. In some embodiments, the stem-loop structure comprises a first stem nucleotide chain of 5 nucleotides in length; a second stem nucleotide chain of 5 nucleotides in length, wherein the first and second stem nucleotide chains can hybridize with each other; and a cyclic nucleotide chain arranged between the first and second stem nucleotide chains, wherein the cyclic nucleotide chain comprises 6, 7 or 8 nucleotides.
[0425] As used herein, the secondary structures of two or more guide RNAs being substantially identical or having no substantial differences means that the stems and / or loops comprised by these crRNAs differ by no more than 1, 2, or 3 nucleotides in length, and differ by no more than 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides in nucleotide type (A, U, G, or C) when the nucleotide sequences of these guide RNAs are compared by sequence alignment. In some embodiments, the secondary structures of two or more guide RNAs being substantially identical or having no substantial differences means that the crRNAs comprise stems that differ by at most a pair of complementary bases, and / or loops that differ by at most a single nucleotide in length, and / or comprise stems of the same length but with mismatched bases.
[0426] In some embodiments, the stem-loop structure comprises 5'-X1X2X3X4X5NNNNNNNX6X7X8X9X 10 -3';X1,X2,X3,X4,X5,X6,X7,X8,X9,X 10 is any base including A, T, C or G, N is any base including A, T, C or G; wherein X1, X2, X3, X4, X5 and X6, X7, X8, X9, X 10 can hybridize to each other to form a stem and make NNNNNNN form a loop; more preferably, wherein the DR sequence comprises any one of the following stem-loop structures near the 3' end of the DR sequence:
[0427] 5'-CCGTCNNNNNNNGACGG-3' (SEQ ID NO. 80); wherein N is any base including A, T, C or G.
[0428] In some embodiments, the DR sequence that can guide any Cas protein or variant polypeptide of the present disclosure to the target site comprises one or more nucleotide changes selected from nucleotide additions, insertions, deletions and substitutions, which do not result in substantial differences in secondary structure compared to the DR sequence listed in SEQ ID NO5, 70 or a functional truncated version thereof.
[0429] spacer sequence
[0430] In certain embodiments, the length of the spacer sequence is at least about 15 nucleotides, preferably about 15 to about 100 nucleotides, more preferably about 15 to about 50 nucleotides (e.g., any one of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides). In certain embodiments, the spacer sequence is about 16 to about 27 nucleotides, e.g., about 17 to about 24 nucleotides, about 18 to about 24 nucleotides, or about 18 to about 22 nucleotides.
[0431] In some embodiments, the spacer sequence has at least about 70% complementarity to the target sequence (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%). In some embodiments, there are at least about 15 (e.g., at least about 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more) nucleotide matches between the spacer sequence and the target sequence of the target nucleic acid (e.g., DNA). Perfect complementarity is not required for the spacer sequence, as long as there is sufficient complementarity for the guide RNA to function (i.e., to guide the Cas protein to the target site). In some embodiments, the efficiency of cleavage mediated by the Cas protein can be adjusted by introducing one or more mismatches between the spacer sequence and the target sequence (e.g., 1 or 2 mismatches between the spacer sequence and the target sequence, including mismatch positions along the spacer / target sequence). When the mismatch is located at a more central position of the spacer sequence (i.e., not at the 3' or 5' end of the spacer sequence), the effect of the mismatch (such as a double mismatch) on the cleavage efficiency is greater. Therefore, by selecting the position of the mismatch along the spacer sequence, the cleavage efficiency of the Cas protein can be adjusted. For example, if it is desired that the cleavage rate of the target sequence is less than 100% (e.g., in a cell population), 1 or 2 mismatches between the spacer sequence and the target sequence can be introduced into the spacer sequence.
[0432] In some embodiments, the spacer sequence comprises at least 15 consecutive nucleotides in the nucleotide sequence of any one of SEQ ID NO. 6, 11, 53, 55, 57, 59, 61, and 101.
[0433] In some embodiments, the spacer sequence comprises a nucleotide sequence described in any one of SEQ ID NOs. 6, 11, 53, 55, 57, 59, 61, and 101.
[0434] PAM; target sequence
[0435] PAM identification experiments can be performed according to any of the examples in Karvelis et al. Methods. 2017 May 15; 121-122: 3-8 (the entire contents of which are incorporated herein by reference) to identify PAM sequence specificity to allow optimal synthetic sequence targeting. In one embodiment, cells carrying plasmids encoding any enzyme described herein and a protospacer sequence targeting guide RNA are co-transformed with a plasmid library containing an antibiotic resistance gene and a protospacer sequence flanked by randomized PAM sequences. Plasmids containing functional PAMs are cleaved by the enzyme, resulting in cell death. Deep sequencing of a pool of enzyme-resistant plasmids isolated from surviving cells reveals depleted plasmids containing functional PAMs that allow cleavage, thereby identifying the PAM preference of the Cas protein.
[0436] In certain embodiments, the Cas protein of the present disclosure can recognize a PAM (protospacer adjacent motif) to act on the target DNA. In certain embodiments, the PAM comprises or consists of 5'-TTN-3' (wherein N is A, T, G, or C). In certain embodiments, the PAM comprises or consists of 5'-TTC-3', 5'-TTA-3', 5'-TTT-3', or 5'-TTG-3'.
[0437] As used herein, the term "target nucleic acid" is used interchangeably with "target sequence" or "target nucleic acid sequence" or "target nucleic acid molecule" to refer to a specific nucleic acid comprising a nucleic acid sequence that is fully or partially complementary to a spacer sequence in a guide RNA, and is a polynucleotide targeted by a spacer sequence in a guide RNA, such as a sequence complementary to the spacer sequence, wherein the hybridization between the target sequence and the spacer sequence will promote the formation of a CRISPR-Cas complex (including Cas protein and guide RNA) so that the target DNA is specifically modified by the Cas protein. Complete complementarity is not required, as long as there is sufficient complementarity to cause hybridization and promote the formation of a CRISPR-Cas complex. In some embodiments, the target sequence comprises a non-coding region (e.g., a promoter or terminator). In some embodiments, the target nucleic acid is single-stranded or double-stranded. The target sequence can comprise any polynucleotide, such as DNA. In some cases, the target sequence is located inside or outside the cell. In some cases, the target sequence is located in the nucleus, cytoplasm, or organelle (e.g., mitochondria or chloroplasts) of the cell. The target nucleic acid can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA). In some cases, the target sequence should be associated with a protospacer adjacent motif (PAM).
[0438] In some embodiments, the protospacer sequence is about or at least about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,
[0439] In some embodiments, the protospacer sequence is a stretch of about 20 consecutive nucleotides of the target DNA.
[0440] In some embodiments, the protospacer comprises about or at least about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 or more consecutive nucleotides of the target DNA, or a range of consecutive nucleotides between any two of the aforementioned values, such as about 15 to about 50 or about 16 to about 23 consecutive nucleotides of the target DNA. In some embodiments, the protospacer comprises about 20 consecutive nucleotides of the target DNA.
[0441] In some embodiments, the target sequence is a stretch of contiguous nucleotides identified from a target strand of a target DNA.The target sequence is the reverse complement of the protospacer sequence. 65, 66, 67, 68, 69, 70, or more contiguous nucleotides on the target strand of the target DNA, or a range of contiguous nucleotides between any two of the foregoing values, such as from about 15 to about 50 or from about 16 to about 22 contiguous nucleotides on the target strand of the target DNA. In some embodiments, the target sequence is a stretch of about 20 contiguous nucleotides on the target strand of the target DNA.
[0442] 65, 66, 67, 68, 69, 70, or more consecutive nucleotides of the target DNA, or a range of values between any two of the foregoing values, such as from about 16 to about 50 or about 17 to about 22 consecutive nucleotides of the target DNA. In some embodiments, the target sequence comprises about 20 contiguous nucleotides of the target DNA.
[0443] In some embodiments, the target sequence comprises about or at least about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or more consecutive nucleotides on the target strand of the target DNA, or a range of consecutive nucleotides between any two of the foregoing values, such as about 15 to about 50 or about 17 to about 23 consecutive nucleotides on the target strand of the target DNA. In some embodiments, the target sequence comprises about 20 contiguous nucleotides on the target strand of the target DNA.
[0444] In some embodiments, the reverse complement of the target sequence is immediately 3' to the protospacer adjacent motif (PAM).
[0445] In some embodiments, the non-target strand is the sense strand of the target DNA. In some embodiments, the non-target strand is the antisense strand of the target DNA. In some embodiments, the target strand is the sense strand of the target DNA. In some embodiments, the target strand is the antisense strand of the target DNA.
[0446] In some embodiments, the protospacer or target sequence is located within an exon of the target DNA. In some embodiments, the protospacer or target sequence is located within an intron of the target DNA. In some embodiments, the target DNA comprises DNA derived from a eukaryote or DNA derived from a prokaryote. In some embodiments, the target DNA is eukaryotic DNA. In some embodiments, the target nucleic acid comprises non-human mammalian DNA, human DNA, insect DNA, bird DNA, reptile DNA, amphibian DNA, rodent DNA, fish DNA, worm DNA, nematode DNA, or yeast DNA;
[0447] In one embodiment, the non-human mammalian DNA comprises non-human primate DNA.In some embodiments, the target DNA is associated with a disease mutation.
[0448] 65, 66, 67, 68, 69, 70, or more nucleotides in length, or a range of length between any two of the foregoing values, such as about 15 to about 50 nucleotides, about 17 to about 22 nucleotides, or about 18 to about 20 nucleotides in length. In some embodiments, the spacer sequence is about 20 nucleotides in length.
[0449] In some embodiments, (1) the spacer sequence is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% (perfect), optionally about 100% (perfect), reverse complementary to the target sequence; (2) the spacer sequence contains no more than 5, 4, 3, 2 or 1 mismatches to the target sequence or no mismatches; or (3) the spacer sequence is located 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 70, 71, 72, 73, 74, 75 69, 70, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 nucleotides of the spacer sequence.
[0450] In some embodiments, a variety of strategies and methods can be used to use the system of the present disclosure to modify the target DNA in the cell. "Modification" as used herein includes but is not limited to cutting, incision, editing, deletion, knockout, knockdown, mutation, correction, exon skipping, etc. In some embodiments, the modification results in correction or compensation of mutations in the cell, thereby producing edited cells so that the expression of the target DNA is changed, such as the transcript (mRNA) level of the target DNA is reduced or increased, and the level of the target DNA expression product (such as protein) is reduced or increased. In some embodiments, the modification includes suppressing or eliminating the expression of a gene product by knocking down or knocking out a gene (e.g., at least reducing about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, or more). In some embodiments, the modification increases the level of an expression product (e.g., protein) of the target DNA (e.g., by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, or more). In some embodiments, the modification decreases the level of an expression product (e.g., protein) of the target DNA (e.g., by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, or more).
[0451] Reagent test kit
[0452] In one aspect, the present disclosure provides a kit comprising one or more components selected from the following: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a complex of the present disclosure, a vector of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure.
[0453] In some embodiments, the kit further comprises one or more labels or instructions, and / or instructions for combining with additional one or more components that may be obtained or required elsewhere. In some embodiments, the kit further comprises instructions for using the kit, e.g., instructions in more than one language.
[0454] In one aspect, the present invention also provides a container comprising the aforementioned kit.
[0455] In one embodiment, the container comprises a sterile container.
[0456] In one embodiment, the container comprises a syringe.
[0457] In some embodiments, the kit further includes one or more buffers that can be used to dissolve any one of the one or more components contained therein, and / or provide suitable reaction conditions for one or more of the one or more components. Such buffers can include one or more of the following: PBS, HEPES, Tris, MOPS, Na2CO3, NaHCO3, NaB or a combination thereof. In some embodiments, the reaction conditions include a suitable pH, such as an alkaline pH. In some embodiments, the pH is between 7-10. In some embodiments, any one or more of the kit components can be stored in a suitable container or stored at a suitable temperature, for example, at 4 degrees Celsius. In certain embodiments, the kit is used for gene or genome editing, disease treatment, targeting a target gene, cutting a target gene or non-target gene.
[0458] deliver
[0459] The components of the CRISPR-Cas systems / compositions of the present disclosure can be delivered in various forms, for example, the Cas protein can be delivered as a polynucleotide encoding DNA or a polynucleotide encoding RNA, or as a protein.
[0460] The guides can be delivered as DNA encoding polynucleotides or RNA. All possible combinations are contemplated, including mixed delivery formats.
[0461] In one aspect, the present disclosure provides a delivery composition comprising a delivery vehicle and one or more selected from the following: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a vector of the present disclosure, a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure.
[0462] As used herein, methods for introducing nucleic acids into host cells are known in the art, and any convenient method can be used to introduce polynucleotides (e.g., expression constructs / vectors of Cas proteins) into target cells (e.g., prokaryotic cells, eukaryotic cells, plant cells, animal cells, mammalian cells, human cells, etc.). Suitable methods include, for example, viral infection, transfection, conjugation, protoplast fusion, liposome transfection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery (see, for example, Panyam et al. Adv Drug Deliv Rev. 2012 Sep 13. pii: S0169-409X(12)00283-9. doi: 10.1016 / j.addr.2012.09.023), etc.
[0463] In some embodiments, the Cas protein of the present disclosure can be provided as a polynucleotide encoding the Cas protein (e.g., mRNA, DNA, plasmid, expression vector, viral vector, etc.). In some embodiments, the Cas protein of the present disclosure is provided directly as a protein (e.g., not with an associated guide RNA or with an associated guide RNA, i.e., as a ribonucleoprotein complex (RNP)). The Cas protein of the present disclosure can be introduced into a cell (provided to a cell) by any convenient method; such methods are known to those of ordinary skill in the art. Exemplarily, for example, the Cas protein of the present disclosure or a fusion protein comprising the same can be injected directly into a cell (e.g., with or without a Cas protein guide RNA or a nucleic acid encoding a Cas protein guide RNA, and with or without a donor polynucleotide). As another example, a preformed complex (RNP) of a Cas protein of the present disclosure and a Cas protein-guide RNA can be introduced into a cell (e.g., a eukaryotic cell) (e.g., by injection, by nucleofection; via a protein transduction domain (PTD) conjugated to one or more components, e.g., conjugated to a Cas protein, conjugated to a guide RNA, conjugated to a Cas protein of the present disclosure and a guide RNA, etc.).
[0464] In some embodiments, a fusion protein comprising a Cas protein (e.g., dCas fused to a functional domain, etc.) is provided as a nucleic acid encoding the fusion protein (e.g., mRNA, DNA, plasmid, expression vector, viral vector, etc.). In some embodiments, the fusion protein of the present invention is provided directly as a protein (e.g., not with an associated guide RNA or with an associated guide RNA, i.e., as a ribonucleoprotein complex (RNP)). The fusion protein of the Cas protein of the present invention can be introduced into the cell by any convenient method; such methods are known to those of ordinary skill in the art. As an illustrative example, the fusion protein of the present invention can be directly injected into the cell (e.g., with or without a nucleic acid encoding a guide RNA, and with or without a donor polynucleotide). As another example, a preformed complex of a fusion protein of the present invention and a Cas protein guide RNA (RNP) can be introduced into the cell (e.g., by injection; by nuclear transfection; by a protein transduction domain (PTD) conjugated to one or more components, e.g., conjugated to a fusion protein, conjugated to a guide RNA, conjugated to a fusion protein of the present invention and a guide RNA, etc.).
[0465] In some embodiments, a polynucleotide (e.g., a Cas protein guide RNA; a polynucleotide comprising a nucleotide sequence encoding a Cas protein of the present disclosure, etc.) is delivered to a cell (e.g., a target host cell) and / or a protein (e.g., a Cas protein; a fusion protein comprising a Cas protein) in or associated with a particle.
[0466] In some embodiments, the CRISPR-Cas system of the present invention is delivered to cells in or associated with particles. The terms "particle" and "nanoparticle" can be used interchangeably as appropriate. Recombinant expression vectors comprising nucleotide sequences encoding Cas proteins of the present invention and / or Cas protein guide RNAs, mRNAs comprising nucleotide sequences encoding Cas proteins of the present invention, and guide RNAs can be delivered simultaneously using particles or lipid envelopes; for example, Cas proteins and guide RNAs, for example as complexes (e.g., ribonucleoprotein (RNP) complexes) can be delivered by particles, for example, by delivery particles comprising lipids or lipidoids and hydrophilic polymers (e.g., cationic lipids and hydrophilic polymers).
[0467] The Cas protein of the present disclosure (or mRNA comprising a nucleotide sequence encoding the Cas protein of the present disclosure; or a recombinant expression vector comprising a nucleotide sequence encoding the Cas protein of the present disclosure) and / or Cas protein guide RNA (or nucleic acid, such as one or more expression vectors encoding Cas protein guide RNA) can be delivered simultaneously using particles or lipid envelopes. For example, nanoparticles having a biodegradable core-shell structure having a poly(β-amino ester) (PBAE) core encapsulated by a phospholipid bilayer shell can be used. In some embodiments, poly(β-amino alcohol) (PBAA) can be used to deliver the Cas protein of the present disclosure, the fusion protein of the present disclosure, the ribonucleoprotein (RNP) complex of the present disclosure, the polynucleotide of the present disclosure, or the CRISPR-Cas system of the present disclosure to target cells. U.S. Patent Publication No. 20130302401 relates to a class of poly(β-amino alcohols) (PBAA) prepared using combinatorial polymerization.
[0468] In some embodiments, lipid nanoparticles (LNPs) are used to deliver Cas proteins of the present disclosure, fusion polypeptides of the present disclosure, RNPs of the present disclosure, polynucleotides of the present disclosure, or CRISPR-Cas systems of the present disclosure to target cells. Negatively charged polymers (such as RNA) can be loaded into LNPs at low pH values (e.g., pH 4), where ionizable lipids display positive charges. However, at physiological pH values, LNPs exhibit low surface charges compatible with longer circulation times.
[0469] In some embodiments, LNP can be used to deliver DNA molecules (e.g., comprising coding sequences of CasY7 protein and / or guide RNA) and / or RNA molecules (e.g., CasY7 protein, guide RNA). In some embodiments, LNP can be used to deliver RNP complexes of CasY7 / guide RNA. Cationic lipids form complexes with mRNA to form lipid complexes, which are then endocytosed by cells. In an exemplary embodiment, LNP comprises cationic lipids, auxiliary lipids, cholesterol, and polyethylene glycol (PEG). In some embodiments, nanoparticles can be developed according to selective organ targeting (SORT), wherein various categories of lipid nanoparticles are systematically engineered to specifically edit extrahepatic tissues via the addition of supplementary SORT molecules. In one embodiment, the lipid nanoparticles comprise cationic lipids, neutral lipids, cholesterol, PEG lipids, or a combination thereof, wherein a plurality of lipid nanoparticles optionally have an average particle size between 80 nm and 160 nm; and wherein the lipid nanoparticles comprise one or more polynucleotides encoding at least one polypeptide of the present disclosure (e.g., CasY7 polypeptide).
[0470] As used herein, "nanoparticle" refers to any particle having a diameter of less than 1000 nm. In some embodiments, the nanoparticles suitable for delivering the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotides of the present disclosure or the CRISPR-Cas system of the present disclosure to the target cell have a diameter of 500 nm or less, for example, 25 nm to 35 nm, 35 nm to 50 nm, 50 nm to 75 nm, 75 nm to 100 nm, 100 nm to 150 nm, 150 nm to 200 nm, 200 nm to 300 nm, 300 nm to 400 nm or 400 nm to 500 nm. In some embodiments, the nanoparticles suitable for delivering the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotides of the present disclosure or the CRISPR-Cas system of the present disclosure to the target cell have a diameter of 25 nm to 200 nm. In some embodiments, the nanoparticles suitable for delivering the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotides of the present disclosure or the CRISPR-Cas system of the present disclosure to the target cell have a diameter of 100 nm or less. In some cases, the nanoparticles suitable for delivering the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotides of the present disclosure or the CRISPR-Cas system of the present disclosure to the target cell have a diameter of 35 nm to 60 nm.
[0471] Nanoparticles suitable for delivering the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotide of the present disclosure or the CRISPR-Cas system of the present disclosure to target cells can be provided in different forms, for example, as solid nanoparticles (e.g., metals (such as silver, gold, iron, titanium), non-metals, lipid-based solids, polymers), suspensions of nanoparticles, or combinations thereof. Metallic, dielectric and semiconductor nanoparticles can be prepared, as well as hybrid structures (e.g., core-shell nanoparticles). If the nanoparticles made of semiconductor materials are small enough (typically less than 10 nm) so that quantization of the electron energy levels occurs, they can also be labeled with quantum dots. Such nanoscale particles are used as drug carriers or imaging agents in biomedical applications and can be used for similar purposes in the present disclosure.
[0472] In some embodiments, semisolid and soft nanoparticles are also suitable for delivering the Cas proteins of the present disclosure, the fusion proteins of the present disclosure, the RNPs of the present disclosure, the polynucleotides of the present disclosure, or the CRISPR-Cas systems of the present disclosure to target cells. A prototype nanoparticle with semisolid properties is a liposome.
[0473] In some embodiments, exosomes can be used to deliver the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the nucleic acid of the present disclosure, or the CRISPR-Cas system of the present disclosure to target cells. Exosomes are endogenous nanovesicles that transport RNA and proteins and can deliver RNA to the brain and other target organs.
[0474] In some embodiments, liposomes can be used to deliver the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotide of the present disclosure or the CRISPR-Cas system of the present disclosure to target cells. Liposomes are spherical vesicle structures, which are composed of a single or multilayer lipid bilayer surrounding an internal aqueous compartment and a relatively impermeable external lipophilic phospholipid bilayer. Liposomes can be made of several different types of lipids; however, phospholipids are most commonly used to generate liposomes. Although liposome formation is spontaneous when the lipid membrane is mixed with an aqueous solution, the formation of liposomes can also be accelerated by applying force in the form of shaking using a homogenizer, an ultrasonic crusher or an extrusion device. Several other additives can be added to liposomes in order to change their structure and properties. For example, cholesterol or sphingomyelin can be added to the liposome mixture to help stabilize the liposome structure and prevent leakage of the liposome contents (inner cargo). Liposomal formulations may be composed primarily of natural phospholipids and lipids such as 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), sphingomyelin, egg phosphatidylcholine, and monosialogangliosides.
[0475] In some embodiments, lipids can be formulated with the CRISPR-Cas system of the present disclosure, or one or more components thereof, or nucleic acids encoding the same, to form lipid nanoparticles (LNPs).
[0476] In some embodiments, the CRISPR-Cas system of the present disclosure, or components thereof, may be delivered encapsulated in PLGA microspheres, such as those further described in U.S. Published Applications 20130252281, 20130245107, and 20130244279.
[0477] In some embodiments, the booster protein can be used to deliver the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotide of the present disclosure or the CRISPR-Cas system of the present disclosure to the target cell. Supercharged proteins are a class of engineered or naturally occurring proteins that have an abnormally high positive or negative net theoretical charge. Both supernegatively charged proteins and superpositively charged proteins show the ability to withstand thermal or chemically induced aggregation. Superpositively charged proteins are also able to penetrate mammalian cells. The association of cargo with these proteins (such as plasmid DNA, RNA or other proteins) can achieve the functional delivery of these macromolecules to mammalian cells in vitro and in vivo.
[0478] In some embodiments, when the delivery target is a plant cell, cell penetrating peptides (CPPs) can be used to deliver the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotide of the present disclosure or the CRISPR-Cas system of the present disclosure to the target cell. CPPs generally have the following amino acid composition, which contains a high relative abundance of positively charged amino acids (such as lysine or arginine), or a sequence containing an alternating pattern of polar / charged amino acids and non-polar hydrophobic amino acids.
[0479] In some embodiments, an implantable device can be used to deliver the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the nucleic acid of the present disclosure (e.g., Cas protein guide RNA, nucleic acid encoding Cas protein guide RNA, polynucleotide encoding Cas protein, donor template, etc.) or the CRISPR-Cas system of the present disclosure to a target cell (e.g., a target cell in vivo, wherein the target cell is a target cell in circulation, a target cell in a tissue, a target cell in an organ, etc.). An implantable device suitable for delivering the Cas protein of the present disclosure, the fusion protein of the present disclosure, the RNP of the present disclosure, the polynucleotide of the present disclosure or the CRISPR-Cas system of the present disclosure to a target cell (e.g., a target cell in vivo, wherein the target cell is a target cell in circulation, a target cell in a tissue, a target cell in an organ, etc.) can include a container (e.g., a reservoir, a matrix, etc.) comprising the Cas protein, fusion protein, RNP or CRISPR-Cas system (or a component thereof, such as a nucleic acid of the present disclosure).
[0480] In some cases, suitable implantable drug delivery device comprises a polymer substrate (such as matrix) for example as device body, and comprises other support material (such as metal or other polymer), and enhances visibility and imaging material. Implantable delivery device can advantageously provide local and long-time release, wherein polypeptide to be delivered and / or nucleic acid are directly discharged into target site, such as extracellular matrix (ECM), vascular system around tumor, diseased tissue etc. Suitable implantable delivery device comprises the device being applicable to be delivered to such as peritoneal cavity and / or wherein drug delivery system is not anchored or adheres to any other type of administration, comprises biostable and / or degradable and / or bioabsorbable polymer matrix, it can such as optionally be matrix. In some cases, suitable implantable drug delivery device comprises degradable polymer, and wherein main release mechanism is overall erosion (bulk erosion). In some cases, suitable implantable drug delivery device comprises nondegradable or slowly degraded polymer, wherein main release mechanism is diffusion rather than overall erosion, makes outer part as film and its inner part as drug reservoir, in fact, described drug reservoir is not subject to the impact of surrounding environment in (such as approximately one week to approximately several months) for a long time. Combinations of different polymers with different release mechanisms may also be optionally used. Over the effective period of the total release period, the concentration gradient may remain effectively constant, and thus the diffusion rate is effectively constant (referred to as "zero mode" diffusion). As used herein, the term "constant" means that the diffusion rate remains above a lower threshold for therapeutic effectiveness, but it is still optionally characterized by an initial burst and / or may fluctuate, for example, increase and decrease to a certain extent. The diffusion rate may be maintained for a long time, and the diffusion rate may be considered constant to a certain level to optimize the effective period of treatment, for example, an effective silent period.
[0481] In some embodiments, the implantable delivery system is designed to protect the nucleotide-based therapeutic agent from degradation, whether chemical or degradation caused by attack by enzymes and other factors in the subject. The implantation site or target site of the device can be selected to obtain maximum therapeutic efficacy. For example, the delivery device can be implanted in or near the tumor environment, or in or near the blood supply associated with the tumor. The insertion method (such as implantation) may optionally have been used for other types of tissue implantation and / or for insertion and / or for tissue sampling, optionally without modification, or alternatively only with non-major modifications in such methods. Such methods optionally include, but are not limited to, brachytherapy, biopsy, endoscopy with and / or without ultrasound (such as stereotactic methods for entering brain tissue), laparoscopy (including laparoscope implantation in joints, abdominal organs, bladder wall, and body cavities). In some embodiments, the delivery device can be selected from a gene gun, a prefilled syringe, an automatic injector, an aerosol spray, a spray can, or a patch injector.
[0482] In some embodiments, the delivery vehicle is a nanoparticle, a liposome, an exosome, a microvesicle, or a gene gun.
[0483] carrier
[0484] As used herein, a vector is a nucleic acid molecule that is capable of transporting another nucleic acid molecule to which it is connected. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules comprising one or more free ends, no free ends (e.g., circular); nucleic acid molecules comprising DNA, RNA, or both; and other various polynucleotides known in the art. The vector can be introduced into a host cell by transformation, transduction, or transfection so that the genetic material elements it carries are expressed in the host cell. A vector can be introduced into a host cell to produce transcripts, proteins, or peptides, including protein variants, fusion proteins, isolated nucleic acid molecules, etc. as described herein (e.g., CRISPR transcripts, such as nucleic acid transcripts, proteins, or enzymes). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. The vector may also contain a replication initiation site.
[0485] The term "vector" refers to a plasmid or viral vector, wherein the plasmid is a circular double-stranded DNA loop that can be inserted into another DNA fragment by, for example, standard molecular cloning techniques. Viral vectors include virally derived DNA or RNA sequences that are present in vectors for packaging viruses, and viruses include, for example, retroviruses, replication-defective retroviruses, adenoviruses, replication-defective adenoviruses, and adeno-associated viruses. Viral vectors also include polynucleotides carried by viruses for transfection into a host cell. Some vectors (for example, bacterial vectors and episomal mammalian vectors with bacterial origins of replication) can replicate autonomously in the host cells into which they are introduced.
[0486] Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell and are replicated together with the host genome. Furthermore, some vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to as "expression vectors."
[0487] In some embodiments, the vector (e.g., a viral vector or a non-viral vector, such as a lentiviral vector or a plasmid) can be delivered to the target tissue by, for example, intramuscular injection, intravenous administration, transdermal administration, intranasal administration, oral administration, or mucosal administration. The above-mentioned delivery can be carried out via a single dose or multiple doses. It will be understood by those skilled in the art that the actual dose to be delivered herein can vary to a large extent according to a variety of factors, including but not limited to vector selection, target cells, organisms, tissues, the general condition of the subject to be treated, the degree of transformation / modification sought, the route of administration, the mode of administration, and the type of transformation / modification sought.
[0488] In some aspects, the present disclosure provides a vector comprising a polynucleotide of the present disclosure, or a nucleotide encoding a guide RNA of the present disclosure.
[0489] In some embodiments, the vector comprises a plasmid or a viral vector;
[0490] In some embodiments, the viral vector is selected from the group consisting of adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, herpes virus, SV40, poxvirus, or a combination thereof;
[0491] In some embodiments, the vector includes a cloning vector, a transformation vector, an expression vector, a shuttle vector, an integration vector, and a multifunctional vector;
[0492] In some embodiments, the vector comprises:
[0493] (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the Cas protein of the present disclosure or a nucleotide sequence encoding the fusion protein of the present disclosure; and
[0494] (2) a second regulatory element, the second regulatory element being operably linked to a nucleotide sequence encoding a guide RNA, the guide RNA comprising:
[0495] (a) a direct repeat (DR) sequence capable of forming a complex with the Cas protein or fusion protein of the present disclosure, and
[0496] (b) a spacer sequence capable of hybridizing to a target sequence of a target DNA, thereby guiding the complex to the target DNA.
[0497] In some embodiments, the first regulatory element and the second regulatory element are located on the same or different vectors.
[0498] In some embodiments, the first regulatory element and / or the second regulatory element is a promoter, such as an inducible promoter.
[0499] In some embodiments, the vector comprises one or more promoters operably linked to the nucleic acid sequence, enhancer, transcription termination signal, polyadenylation sequence, origin of replication, selectable marker, nucleic acid restriction site, and / or homologous recombination site.
[0500] In one aspect, the present disclosure provides a CRISPR-Cas system comprising one or more vectors, the one or more vectors comprising:
[0501] (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the Cas protein or a variant thereof or a nucleotide sequence encoding the fusion protein; and
[0502] (2) a second regulatory element, the second regulatory element being operably linked to a nucleotide sequence encoding the guide RNA, the guide RNA comprising:
[0503] (a) a spacer sequence capable of hybridizing to a target sequence of a target nucleic acid, and
[0504] (b) a direct repeat (DR) sequence connected to the spacer sequence and capable of guiding the Cas protein or its variant to bind to the guide RNA to form a CRISPR-Cas complex targeting the target sequence.
[0505] The first regulatory element and the second regulatory element are located on the same or different vectors of the CRISPR-Cas vector system.
[0506] In one embodiment, the first regulatory element or the second regulatory element comprises a promoter, and the promoter comprises one or more of an inducible promoter, a constitutive promoter, or a tissue-specific promoter.
[0507] In one embodiment, the promoter comprises one or more of T7, SP6, T3, CMV, EF1a, SV40, PGK1, human β-actin, CAG, U6, H1, T7, T7lac, araBAD, trp, lac, or Ptac.
[0508] In one embodiment, the first regulatory element and the second regulatory element are located on the same or different vectors.
[0509] In one embodiment, the vector comprises a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes simplex vector or a phagemid vector. In one embodiment, the vector comprises a plasmid vector.
[0510] In some aspects, the present disclosure provides a delivery composition comprising a delivery vehicle and one or more selected from the following: a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a vector of the present disclosure, a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure.
[0511] host cells
[0512] The system of the present disclosure can be introduced into a host cell and cause the host cell to change the production of one or more cell products (such as antibodies, starch, ethanol or any other desired product). Such host cells and their progeny are within the scope of the present disclosure. "Host cell" herein refers to a eukaryotic cell (e.g., an animal cell, a plant cell, a fungal cell, etc.), a prokaryotic cell (e.g., some microbial cells, Escherichia coli, Bacillus subtilis, etc.), or a cell from a multicellular organism (e.g., a cell line) cultured as a unicellular entity, which serves as a receptor (e.g., an expression vector) for nucleic acids, and includes progeny of the original cell that has been genetically modified by nucleic acids.
[0513] It is understood that the progeny of a single cell may not necessarily have exactly the same morphology or genome, etc., as the original parent cell due to natural, accidental, or deliberate mutations. A "recombinant host cell" (also known as a "genetically modified host cell") is a host cell into which a heterologous nucleic acid, such as an expression vector, has been introduced. Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the desired expression level, etc.
[0514] In one aspect, the present disclosure provides a host cell or its progeny, which host cell comprises the Cas protein of the present disclosure, or the fusion protein of the present disclosure, or the polynucleotide of the present disclosure, or the vector system of the present disclosure, or the CRISPR-Cas system of the present disclosure, or the composition of the present disclosure.
[0515] In some embodiments, the cell is a stem cell. In some embodiments, the cell is not a human embryonic stem cell. In some embodiments, the cell is not a human germ cell.
[0516] In some embodiments, the cell is a prokaryotic cell.
[0517] In some embodiments, the cell is a eukaryotic cell (e.g., an animal cell, a vertebrate cell, a mammalian cell, a non-human mammalian cell, a non-human primate cell, a rodent (e.g., mouse or rat) cell, a human cell, a plant cell, or a yeast cell) or a prokaryotic cell (e.g., a bacterial cell).
[0518] In some embodiments, the cells are from a plant or animal.
[0519] In some embodiments, the plant is a dicot. In some embodiments, the dicot is selected from soybean, cabbage (e.g., Chinese cabbage), rapeseed, Brassica, watermelon, melon, potato, tomato, tobacco, eggplant, pepper, cucumber, cotton, alfalfa, eggplant, grape. In some embodiments, the plant is a monocot. In some embodiments, the monocot is selected from rice, corn, wheat, barley, oats, sorghum, millet, grasses, Poaceae, Zizania, Avena, Coix, Hordeum, Oryza, Panicum (e.g., Panicum miliaceum), Secale, Setaria (e.g., Setaria italica), Sorghum, Triticum, Zea, Cymbopogon, Saccharum (e.g., Saccharum officinarum), Phyllostachys, Dendrocalamus, Bambusa, Yushania.
[0520] In some embodiments, the animal is selected from the group consisting of pig, cow, sheep, goat, mouse, rat, alpaca, monkey, rabbit, chicken, duck, goose, fish (eg, zebrafish).
[0521] In some embodiments, the cell is a eukaryotic cell injected into a mammalian cell, including a human cell (primary human cell or established human cell line). In some embodiments, the cell is a non-human mammalian cell, such as a cell from a non-human primate (e.g., monkey), cow / bull / cow, sheep, goat, pig, horse, dog, cat, rodent (e.g., rabbit, mouse, rat, hamster, etc.). In some embodiments, the cell is from fish (e.g., salmon), bird (e.g., fowl, including chicken, duck, goose), reptile, shellfish (e.g., oyster, clam, lobster, prawn), insect, worm, yeast, etc. In some embodiments, the cell is from a plant, such as a monocot or dicot. In certain embodiments, the plant is a food crop, such as barley, cassava, cotton, groundnut or peanut, maize, millet, oil palm fruit, potato, dry bean, rapeseed or canola (canola), rice, rye, sorghum, soybean, sugarcane, sugar beet, sunflower and wheat. In some embodiments, the plant is a cereal (barley, maize, millet, rice, rye, sorghum, and wheat). In some embodiments, the plant is a tuber (cassava and potato). In some embodiments, the plant is a sugar crop (sugar beet and sugar cane). In some embodiments, the plant is an oil crop (soybean, groundnut or peanut, rapeseed or canola, sunflower, and oil palm fruit). In some embodiments, the plant is a fiber crop (cotton). In some embodiments, the plant is a tree (such as a peach or nectarine tree, an apple or pear tree, a nut tree (such as an almond or walnut tree or pistachio tree), or a citrus tree (e.g., an orange tree, a grapefruit tree, or a lemon tree)), a grass, a vegetable, a fruit, or an algae. In certain embodiments, the plant is a nightshade plant; a Brassica plant; a Lactuca plant; a Spinacia plant; a Capsicum plant; cotton, tobacco, asparagus, carrot, cabbage, broccoli, cauliflower, tomato, eggplant, pepper, lettuce, spinach, strawberries, blueberries, raspberries, blackberries, grapes, coffee, cocoa, etc.
[0522] In one embodiment, the host cell comprises a non-human mammal, human, insect, bird, reptile, amphibian, rodent, fish, worm, nematode, or yeast cell.
[0523] In yet another aspect, the present invention also provides a multicellular organism comprising the aforementioned cell or its progeny.
[0524] In one embodiment, the multicellular organism is an animal model or a plant model for a relevant disease.
[0525] In yet another aspect, the present disclosure provides a cell modified by a system of the present disclosure or a method of the present disclosure. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is modified in vitro, in vivo, or ex vivo.
[0526] enzyme preparations
[0527] In one aspect, the present disclosure provides an enzyme preparation comprising a Cas protein of the present disclosure, a fusion protein of the present disclosure, a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure or a delivery composition of the present disclosure.
[0528] In some embodiments, the enzyme preparation includes an injectable and / or lyophilized preparation.
[0529] Modification method
[0530] The CRISPR-Cas system of the present disclosure comprises the Cas protein or fusion protein of the present disclosure, and has various uses, including modifying (e.g., cutting, deleting, inserting, translocating, inactivating or activating) target DNA in various cell types. The method and / or system of the present disclosure can be used to modify the target DNA, for example, to modify the translation and / or transcription of one or more genes of the cell. For example, the modification can result in an increase in the transcription / translation / expression of the gene. In other embodiments, the modification can result in a decrease in the transcription / translation / expression of the gene.
[0531] As used herein, cutting refers to the DNA breakage in the target nucleic acid produced by the Cas protein of the present disclosure, and in some embodiments, cutting is a double-stranded DNA break. In some embodiments, cutting is a single-stranded DNA break. In some embodiments, cutting is a non-spacer complementary strand of a double-stranded target nucleic acid and causes it to produce a nick. In some embodiments, cutting is that two chains of a double-stranded nucleic acid are cut at different sites, resulting in staggered cutting.
[0532] In one aspect, the present disclosure provides a method for targeting and editing a target gene or cleaving a target gene, comprising: contacting the Cas protein of the present disclosure, or the fusion protein of the present disclosure, or the complex of the present disclosure, or the CRISPR-Cas system of the present disclosure, or the composition of the present disclosure, or the system of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the drug kit of the present disclosure with the target DNA, or delivering it to a cell containing the target DNA, wherein the target sequence is present in the target DNA.
[0533] In yet another aspect, the present disclosure further provides a method of inducing a change in cell state, comprising contacting a Cas protein of the present disclosure, or a fusion protein of the present disclosure, or a complex of the present disclosure, or a CRISPR-Cas system of the present disclosure, or a composition of the present disclosure, or a system of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, or a drug kit of the present disclosure with a target gene in a cell. In some embodiments, the cell state comprises apoptosis or dormancy.
[0534] In yet another aspect, the present disclosure also provides a method for altering the expression of a gene product, comprising: contacting the Cas protein of the present disclosure, or the fusion protein of the present disclosure, or the complex of the present disclosure, or the CRISPR-Cas system of the present disclosure, or the composition of the present disclosure, or the system of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the drug kit of the present disclosure with a nucleic acid molecule encoding the gene product, or delivering it to a cell comprising the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.
[0535] In yet another aspect, the present disclosure provides a method for modifying a target DNA, comprising contacting the target DNA with a Cas protein of the present disclosure, or a fusion protein of the present disclosure, or a complex of the present disclosure, or a CRISPR-Cas system of the present disclosure, a composition of the present disclosure, or a system of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, or a medicine box of the present disclosure. In some embodiments, the target DNA is intracellular. In some embodiments, the modification comprises one or more of cutting, base editing, repairing, and insertion or integration of an exogenous sequence of the target DNA.
[0536] In some embodiments, the method for modifying the target DNA of the present disclosure includes contacting the target DNA with the following substances: the Cas protein of the present disclosure, the guide RNA of the present disclosure; a donor nucleic acid, for example, a donor template. In some embodiments, the donor template is a double-stranded nucleic acid or a single-stranded nucleic acid. In some embodiments, the donor template nucleic acid is linear or circular (for example, a plasmid). In some examples, the donor template is an exogenous nucleic acid molecule. In some embodiments, the donor template is an endogenous nucleic acid molecule (for example, a chromosome). In some embodiments, genetic recombination can be achieved using a donor template, and the recombination is homologous recombination.
[0537] Pharmaceutical composition
[0538] In one aspect, the present disclosure provides a pharmaceutical composition comprising a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a composition of the present disclosure, a system of the present disclosure, a delivery composition of the present disclosure, or a host cell of the present disclosure, and a pharmaceutically acceptable excipient.
[0539] The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient. The pharmaceutical composition of the present invention is administered to a subject or a patient.
[0540] Some non-limiting examples of substances that can be used as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricants such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols such as propylene glycol. ; (11) polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol (PEG); (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; (22) fillers such as polypeptides and amino acids; (23) serum alcohols such as ethanol; and (24) other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives, and antioxidants may also be present in the formulation.
[0541] The pharmaceutical composition can include one or more pH buffer compounds to maintain the pH of the preparation at a predetermined level reflecting physiological pH, such as in the range of approximately 5.0 to approximately 8.0. The pH buffer compound used for aqueous liquid preparations can be an amino acid or an amino acid mixture, such as histidine or an amino acid (such as histidine and glycine) mixture. Alternatively, the pH buffer compound is preferably maintained at a predetermined level (such as in the range of approximately 5.0 to approximately 8.0) for the pH of the preparation, and does not chelate the calcium ion. The illustrative examples of this pH buffer compound include but are not limited to imidazoles and acetate ions. The pH buffer compound can exist with any amount suitable for maintaining the pH of the preparation at a predetermined level.
[0542] The pharmaceutical composition may also contain one or more osmotic regulators, which adjust the osmotic properties (e.g., tension, osmotic pressure, and / or osmotic pressure) of the preparation to a level acceptable to the blood flow and blood cells of the recipient individual. An osmotic regulator may be an agent that does not chelate calcium ions. An osmotic regulator may be any compound known or available to those skilled in the art that regulates the osmotic properties of the preparation. Those skilled in the art can empirically determine the suitability of a given osmotic regulator in the preparations of the present invention. Illustrative examples of suitable osmotic regulator types include, but are not limited to, salts such as sodium chloride and sodium acetate; sugars such as sucrose, dextrose, and mannitol; amino acids such as glycine; and mixtures of one or more of these agents and / or dosage forms. One or more osmotic regulators may be present in any concentration sufficient to regulate the osmotic properties of the preparation.
[0543] Treatment
[0544] In one aspect, the present disclosure provides a method for diagnosing, preventing or treating a disease in a subject in need thereof, the method comprising administering (e.g., a therapeutically effective dose) to the subject a Cas protein of the present disclosure, a fusion protein of the present disclosure, a polynucleotide of the present disclosure, a vector of the present disclosure, a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure, a kit of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, or a kit of the present disclosure, or a pharmaceutical composition of the present disclosure, wherein the disease is associated with a target DNA, wherein the spacer sequence is capable of hybridizing to a target sequence of the target DNA, wherein the target DNA is modified by the complex, and wherein the modification of the target DNA diagnoses, prevents or treats the disease.
[0545] As used herein, the term "treat" refers to treating or curing a condition in a subject, delaying the onset of symptoms of a condition, and / or delaying the severity of a condition.
[0546] In some embodiments, suitable routes of administration include, but are not limited to, topical, subcutaneous, transdermal, intradermal, intralesional, intraarticular, intraperitoneal, intravesical, transmucosal, gingival, intradental, intracochlear, transtympanic, intraorgan, epidural, intrathecal, intramuscular, intravenous, intravascular, intraosseous, periocular, intratumoral, intracerebral, and intraventricular administration. In some embodiments, administration to a subject is by injection, by catheter, by suppository, or by implant, which is a porous, non-porous, or gel-like material, including membranes, such as salivary membranes or fibers.
[0547] In some embodiments, the target DNA encodes mRNA, tRNA, ribosomal RNA, microRNA (miRNA), noncoding RNA, long noncoding (lnc) RNA, nuclear RNA, interfering RNA, small interfering RNA (siRNA), ribozyme, riboswitch, satellite RNA, microswitch, yeast (microzyme) or viral RNA.
[0548] In some embodiments, the target DNA is eukaryotic DNA. In some embodiments, the eukaryotic DNA is mammalian DNA (such as non-human mammalian DNA), non-human primate DNA, human DNA, plant DNA, insect DNA, bird DNA, reptile DNA, rodent (e.g., mouse, rat) DNA, fish DNA, nematode DNA, or yeast DNA.
[0549] In some embodiments, the target DNA is within a eukaryotic cell (eg, a human cell, a non-human primate cell, or a mouse cell).
[0550] In some embodiments, administration comprises topical administration or systemic administration. In some embodiments, administration is injection or infusion. In some embodiments, the subject is a human, a non-human primate, or a mouse.
[0551] In some embodiments, the level of a transcript (e.g., mRNA) of a target DNA is decreased or increased in a subject by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or more compared to the level of the transcript (e.g., mRNA) of the target DNA in the subject before administration.
[0552] In some embodiments, the level of the expression product (e.g., protein) of the target DNA in the subject is reduced or increased by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85% or more compared to the level of the expression product (e.g., protein) of the target DNA in the subject before administration. In some embodiments, the expression product is a functional mutant of the expression product of the target DNA.
[0553] In some embodiments, the disease is selected from the group consisting of treating a non-dividing cell disease, and in one embodiment, the gene or transcript to be corrected is located in a non-dividing cell. Exemplary non-dividing cells are muscle cells or neurons.
[0554] In some embodiments, the disease is selected from diseases affecting the eye, such as glaucoma, retinal degenerative diseases. In one embodiment, for administration to the eye, a lentiviral vector is selected.
[0555] In some embodiments, the disease is selected from a muscle disease and a cardiovascular disease. In some embodiments, the disease comprises Duchenne muscular dystrophy (DMD).
[0556] In some embodiments, the disease is selected from liver and kidney diseases. In some embodiments, the disease can also be selected from epithelial diseases and lung diseases, skin diseases, cancer.
[0557] In some embodiments, the disease is selected from familial hypercholesterolemia (FH), atherosclerosis (ASCVD), transthyretin amyloidosis (ATTR), alpha-1-antitrypsin deficiency (AATD), primary hyperoxaluria (PH1), hereditary angioedema (HAE), Angelman syndrome (AS), Alzheimer's disease (AD), transthyretin amyloid cardiomyopathy (ATTR-CM), cystic fibrosis (CF), diabetes mellitus, Duchenne muscular dystrophy, Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, benign prostatic hyperplasia (BMD), spinal muscular atrophy (SMA), Pompe disease, myotonic dystrophy, Huntington disease (HTT), fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, hereditary chronic kidney disease, hyperlipidemia, Leber congenital amaurosis (LCA), sickle cell disease, thalassemia (e.g., beta thalassemia), Parkinson's disease (PD), myelodysplastic syndrome (MDS), retinitis pigmentosa (RP), age-related macular degeneration (AMD), hepatitis B, non-alcoholic fatty liver disease (NAFLD), acquired immunodeficiency syndrome, corneal dystrophy (CD), hypercholesterolemia, heart disease (e.g., hypertrophic cardiomyopathy (HCM)) and cancer.
[0558] In some embodiments, the median survival of subjects who have the disease but receive the administration is 5 days, 10 days, 20 days, 30 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1.5 years, 2 years, 2.5 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years or more longer than the median survival of a subject or population of subjects who have the disease and do not receive the administration.
[0559] The therapeutically effective dose can be via a single dose or multiple doses. It will be understood by those skilled in the art that the actual dose can vary greatly depending on a variety of factors, such as vector selection, target cells, organisms, tissues, the general condition of the subject to be treated, the degree of transformation / modification sought, route of administration, mode of administration, the type of transformation / modification sought, etc.
[0560] In one embodiment, administering further comprises administering the CRISPR-Cas composition to the subject or to cells ex vivo of the subject.
[0561] Detection method
[0562] On the other hand, the present disclosure provides a method for detecting the presence of a target nucleic acid molecule in a sample, characterized in that the method comprises contacting the sample with a Cas protein of the present disclosure, a fusion protein of the present disclosure, or a complex of the present disclosure, a CRISPR-Cas system of the present disclosure, a CRISPR-Cas composition of the present disclosure, or a system of the present disclosure, a kit of the present disclosure, or a delivery composition of the present disclosure, or an enzyme preparation of the present disclosure, and detecting a detectable signal generated by the cutting of the non-target sequence, thereby detecting the target nucleic acid molecule, wherein the non-target sequence does not hybridize with the guide RNA. In some embodiments, the modification generates a detectable signal, such as a fluorescent signal. In some embodiments, a reporter nucleic acid is used to detect target DNA, and the reporter nucleic acid refers to a molecule that can be cut or otherwise inactivated by an activated CRISPR system protein as described herein. The reporter nucleic acid comprises a nucleic acid element that can be cut by a CRISPR protein (e.g., using a single-stranded non-target nucleic acid molecule, each end of which includes different reporter groups or labeling molecules). The cutting of the nucleic acid element produces a detectable signal. Before cutting, or when the reporter nucleic acid is in an "active" state, the reporter nucleic acid prevents the generation or detection of a positive detectable signal. It will be understood that in certain example embodiments, a minimal background signal may be generated in the presence of an active reporter nucleic acid. A positive detectable signal may be any signal that can be detected using optical, fluorescent, chemiluminescent, electrochemical, or other detection methods known in the art. For example, in certain embodiments, when a reporter nucleic acid is present, a first signal (i.e., a negative detectable signal) may be detected, which is then converted to a second signal (e.g., a positive detectable signal) after detection of the target molecule and cutting or inactivation by the activated CRISPR protein. The reporter nucleic acid may be a single-stranded DNA molecule, a single-stranded RNA molecule, or a single-stranded DNA-RNA hybrid. The detection method of the present invention may be used for quantitative detection of a target nucleic acid to be detected. The quantitative detection index may be quantified according to the signal strength of the reporter group, such as according to the luminescence intensity of the fluorescent group, or according to the width of the color-developing band, etc.
[0563] use
[0564] In one aspect, the use of the Cas protein of the present disclosure, the fusion protein of the present disclosure, the polynucleotide of the present disclosure, the vector of the present disclosure, the complex of the present disclosure, the CRISPR-Cas system of the present disclosure, the CRISPR-Cas composition of the present disclosure, or the system of the present disclosure, or the kit of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the drug kit of the present disclosure is for the preparation of a medicament or formulation for nucleic acid editing (e.g., gene or genome editing).
[0565] In another aspect, the use of the Cas protein of the present disclosure, the fusion protein of the present disclosure, the polynucleotide of the present disclosure, the vector of the present disclosure, the complex of the present disclosure, the CRISPR-Cas system of the present disclosure, the CRISPR-Cas composition of the present disclosure, or the system of the present disclosure, or the kit of the present disclosure, or the delivery composition of the present disclosure, or the enzyme preparation of the present disclosure, or the kit of the present disclosure, is for preparing a medicament or preparation for one or more selected from the group consisting of:
[0566] (i) ex vivo gene or genome editing;
[0567] (ii) detection of single-stranded DNA in vitro;
[0568] (iii) editing a target sequence in a target locus to modify an organism or non-human organism;
[0569] (iv) treating a disorder caused by a defect in the target sequence in the target locus;
[0570] (v) treating a condition or disease in a subject in need thereof.
[0571] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0572] Unless otherwise specified, the reagents and materials in the examples of the present invention are all commercially available products.
[0573] Example 1. Acquisition of Cas protein
[0574] By analyzing the uncultured metagenome, a new Cas protein was identified through deredundancy removal and protein clustering. Blast analysis showed that the Cas protein had low sequence identity with previously reported Cas proteins. This Cas protein was named CasY7.
[0575] The amino acid sequence of the above-mentioned CasY7 protein is shown in SEQ ID NO.1, and its nucleotide coding sequence after human codon optimization is shown in SEQ ID NO.2.
[0576] By annotating the CRISPR locus and analyzing the direct repeat (DR) sequence of the guide RNA corresponding to the above-mentioned CasY7 protein, the results showed that:
[0577] The DNA sequence encoding the direct repeat (DR) sequence of the guide RNA corresponding to the CasY7 protein is:
[0578] CAAGTTGAATCCGTCTATAACTGACGG (SEQ ID NO: 5).
[0579] The RNA secondary structure of the DR sequence in the pre-crRNA was further analyzed using RNAfold. The analysis results are shown in Figure 2. Any "T" in the sequence in the figure represents a "U" when referring to the DR sequence.
[0580] By PAM library depletion experiment (the experiment was performed according to any embodiment of Karvelis et al. Methods. 2017 May 15; 121-122: 3-8 (the entire contents of which are incorporated herein by reference) to identify the PAM sequence specificity of CasY7), it was found that the PAM corresponding to CasY7 was 5'-TTN, and N was A / T / C / G. The sgRNA (also known as crRNA) sequence of the CasY7 protein consists of a spacer sequence and a direct repeat (DR) sequence. After identification, the CasY7 of the present invention belongs to the Cas12 protein family.
[0581] Example 2. Verification of Cas protein cleavage activity
[0582] 1. Plasmid construction
[0583] (1) The TTR gene was used as the target, and a spacer sequence (Target-TTR-spacer1) was designed based on the target sequence of the target gene TTR gene: GCATCTCCCCATTCCATGAG (SEQ ID NO. 6).
[0584] According to the DR sequences of CasY7 protein and LbCpf1 protein, sgRNA sequences targeting TTR target gene were designed. See the table below for details:
[0585] According to the needs of vector expression, T7 promoter and rrnB T2 terminator were added to the 5' and 3' ends of the sgRNA sequences of CasY7 and LbCpf1 respectively to obtain the CasY7-sgRNA1 expression fragment sequence: The single underlined sequence is the CasY7DR sequence, the double underlined sequence is the spacer sequence, the italicized sequence is the T7 promoter, the wavy underlined sequence is the rrnB T2 terminator sequence, the linker sequence is between the spacer sequence and the rrnB T2 terminator sequence, the dotted sequence is the MfeI restriction site, the bold sequence is the MluI restriction site, and CACCG is the linker.
[0586] In the same way, the LbCpf1-sgRNA1 expression fragment sequence was synthesized: The single underlined sequence is the LbCpf1DR sequence, the double underlined sequence is the spacer sequence, the italicized sequence is the T7 promoter, the wavy underlined sequence is the rrnB T2 terminator sequence, the linker sequence is between the spacer sequence and the rrnB T2 terminator sequence, the dotted sequence is the MfeI restriction site, the bold sequence is the MluI restriction site, and CACCG is the linker.
[0587] To protect sequence integrity, AGC was introduced at the 5' end and ATA was introduced at the 3' end as protective bases when synthesizing the CasY7-sgRNA1 expression fragment sequence and the LbCpfl-sgRNA1 expression fragment sequence.
[0588] (2) The CasY7 protein encoding nucleotide sequence (as shown in SEQ ID NO. 2) fragment was synthesized by Suzhou Hongxun Biotechnology Co., Ltd., and the synthesized CasY7 protein encoding nucleotide sequence fragment was constructed into the ABE8e plasmid (Addgene, Plasmid #138489) 466-5160 position to construct a CasY7 recombinant expression plasmid (see Figure 1A of Figure 1 for the plasmid map).
[0589] The optimized coding nucleotide sequence (SEQ ID NO. 20) of LbCpf1 (amino acid sequence such as SEQ ID NO. 19) synthesized by Suzhou Hongxun Biotechnology Co., Ltd. was constructed in the same manner to obtain the LbCpf1 recombinant expression plasmid (see FIG1B for the plasmid map).
[0590] (3) Suzhou Hongxun Biotechnology Co., Ltd. synthesized the sgRNA expression sequence fragments (CasY7-sgRNA1 expression fragment sequence and LbCpf1-sgRNA1 expression fragment sequence) as described in step (1), and the sgRNA expression fragment sequence was double-enzyme digested (MfeI / MluI) and inserted into the CasY7 recombinant expression plasmid vector that was also double-enzyme digested (MfeI / MluI) to obtain the recombinant expression plasmid CasY7+sgRNA1 expression plasmid expressing CasY7 and sgRNA; the LbCpf1+sgRNA1 expression plasmid was constructed in the same way.
[0591] (4) Construct a target plasmid with a targeting sequence. The construction process is as follows:
[0592] The araC-pBAD-CCDB fragment (SEQ ID NO. 18) carrying the TTR target sequence (SEQ ID NO. 6) was synthesized by Suzhou Hongxun Biotechnology Co., Ltd. and inserted into the pKESK22 (Addgene, Plasmid #64857) plasmid at sites 1284-1300 to generate the target plasmid. The sequence of the target plasmid is shown in SEQ ID NO. 4, and the plasmid map is shown in Figure 3.
[0593] 2. Preparation and transformation of E. coli competent cells
[0594] The Target plasmid was transferred into DH5a competent cells and streaked with an inoculation loop onto LB solid medium containing 50 μg / ml kanamycin sulfate. Cultured overnight at 37°C in a biochemical incubator, a single colony was picked from the plate the next day and inoculated into a tube of LB liquid medium containing 4 ml of 50 μg / ml kanamycin sulfate (Sangon Biotech, A100408-0100), and cultured overnight at 37°C and 200 rpm with shaking. The next day, 4 ml of the bacterial solution was inoculated into a 2L shake flask containing 400 ml of LB liquid medium containing 50 μg / ml kanamycin sulfate, and cultured at 37°C and 200 rpm with shaking for 2-3 hours. When the OD600nm value of the bacterial solution reached 0.3-0.5, the shake flask was removed and placed on ice for 10-15 minutes. Aseptically transfer the bacterial suspension into a pre-chilled 500ml centrifuge bottle and centrifuge at 3000rpm at 4°C for 8 minutes. Discard the supernatant and add approximately 200ml of pre-chilled CaCl2 solution. Mix by pipetting to suspend the cells and place on ice for 30 minutes. Centrifuge the suspension at 3000rpm at 4°C for 8 minutes. Discard the supernatant and add approximately 8ml of pre-chilled CaCl2 solution to resuspend the cells. Aliquot 110μl of the resuspended cells into 1.5ml EP tubes and store in a -80°C freezer until needed.
[0595] 3. Determination of editing efficiency in E. coli
[0596] Transfer the CasY7+sgRNA1 expression plasmid and the LbCpf1+sgRNA1 expression plasmid into the competent cells prepared in step 2. The specific process is as follows:
[0597] (1) Take the competent cells out of -80℃ and quickly insert them into ice. After about 5 minutes, the bacterial mass melts, add the CasY7+sgRNA expression plasmid, and then gently mix it by hand at the bottom of the centrifuge tube. Let it stand in ice for 25 minutes. Heat shock it in a 42℃ water bath for 45 seconds, quickly return it to ice and let it stand for 2 minutes. Add 900μl of sterile LB medium without antibiotics to the centrifuge tube, mix it and recover it at 37℃ and 220rpm for 60min. Take 100μl of bacterial solution and spread it on LB agar plates containing 30μg / ml carbenicillin resistance (Sangon Biotechnology, A100358-0001) (referred to as C-LB medium) and LB agar plates containing 30μg / ml carbenicillin resistance and 10mM L-arabinose (Sangon Biotechnology, A610071-0100) (referred to as CL-LB medium). Two LB agar plates were placed upside down in an incubator and cultured overnight at 37°C.
[0598] (2) Detection of editing efficiency in Escherichia coli
[0599] As shown in Figure 3, the Target plasmid carries a PBAD promoter that can be induced by L-arabinose and a CCDB gene whose expression is regulated by the PBAD promoter. The CCDB gene can express the CCDB toxic protein. The CCDB toxic protein acts as a DNA gyrase inhibitor and can lock the complex of DNA gyrase and broken double-stranded DNA, making the DNA gyrase unable to function and ultimately leading to cell death.
[0600] Based on this, the applicant designed a method to detect the editing efficiency of E. coli in vivo:
[0601] In the presence of L-arabinose in the culture medium, if the CasY7 protein or LbCpf1 protein, under the guidance of sgRNA, can specifically target the target sequence (SEQ ID NO. 6) of the TTR gene on the Target plasmid and exert a cutting effect, the regulatory expression pathway of the CCDB toxic protein by the PBAD promoter is cut off, and the host cell survives because it does not produce ccdB toxic protein; conversely, if the CasY7 protein or LbCpf1 protein cannot specifically target the TTR target sequence on the Target plasmid, the host cell Escherichia coli will die because the L-arabinose-induced PBAD promoter regulates the CCDB gene to express the CCDB toxic protein.
[0602] Therefore, the editing efficiency of the CasY7 protein in targeting and cutting the TTR target gene in Escherichia coli can be calculated based on the ratio of the number of bacterial clones on the CL-LB medium to the number of bacterial clones on the C-LB medium in step (2).
[0603] The results are shown in Figure 4. After counting the number of E. coli clones and calculating the ratio, it was found that the editing efficiency of CasY7 protein was 45.5%. In addition, the editing efficiency of LbCpf1 protein was 11.1%. The editing efficiency of CasY7 protein was significantly higher than that of LbCpf1 protein.
[0604] Example 3. Editing efficiency detection in HEK293T cells
[0605] 1. Construction of TTR-sgRNA expression plasmid
[0606] (1) Design the TTR-sgRNA sequence based on the target sequence of the TTR gene (Target-TTR-spacer2) tagaagggatatacaaagtg (SEQ ID NO.11), and synthesize oligonucleotides (oligos): CasY7-TTR-sgRNA2 sequence:
[0607] CAAGTTGAATCCGTCTATAACTGACGGtagaagggatatacaaagtg (SEQ ID NO. 12), the underlined sequence is the DR sequence, and the rest of the sequence is the spacer sequence.
[0608] LbCpf1-TTR-sgRNA2 sequence:
[0609] TAATTTCTACTAAGTGTAGATtagaagggatatacaaagtg (SEQ ID NO. 13), the underlined sequence is the DR sequence, and the rest of the sequence is the spacer sequence.
[0610] (2) Add a CACC sequence to the 5' end of the upstream sequence of TTR-sgRNA and an AAAA sequence to the 5' end of the downstream sequence, and synthesize oligos. The specific sequences are as follows:
[0611] After the synthesis of the aforementioned TTR-sgRNA upstream and downstream primers, they were annealed using a preset program (95°C, 5 min; 95°C-85°C at -2°C / s; 85°C-25°C at -0.1°C / s; maintained at 4°C). The annealed product was then ligated into the PHK09T vector linearized with BsmBI (NEB, #R0580L). The sequence of the PHK09T vector is shown in SEQ ID NO. 3, and the plasmid map is shown in Figure 5.
[0612] The linearization of the PHK09T vector and its ligation with the TTR-sgRNA annealed product are as follows:
[0613] First, linearize the PHK09T vector. The linearization system is as follows:
[0614] 3 μg of PHK09T vector; 6 μL of buffer (NEB: R0539L); 2 μL of BsmBI; make up to 60 μL with ddH2O, and digest at 50°C overnight.
[0615] TTR-gRNA annealing product and linearized vector connection system:
[0616] 1 μL of T4 ligase buffer (NEB, #M0202L), 20 ng of linearized vector, 5 μL of annealed oligo fragment, 0.5 μL of T4 ligase (NEB, #M0202L), ddH2O was added to make up to 10 μL, and ligated at 16°C overnight to obtain CasY7-TTR-sgRNA2 expression plasmids and LbCpf1-TTR-sgRNA2 expression plasmids.
[0617] (3) The CasY7-TTR-sgRNA2 expression plasmid and the LbCpf1-TTR-sgRNA2 expression plasmid obtained in step (2) were respectively transferred into Escherichia coli DH5a competent cells (Weidi Biotechnology, DL1001). The specific steps are as follows:
[0618] Remove the DH5α competent cells from the -80°C freezer and quickly place them on ice. After 5 minutes, allow the bacterial mass to thaw. Add the ligation product and gently mix by hand by flicking the bottom of the centrifuge tube. Let it rest on ice for 25 minutes. Heat shock the tube in a 42°C water bath for 45 seconds, quickly return it to ice, and let it rest for 2 minutes. Add 700 μl of sterile LB medium without antibiotics to the centrifuge tube, mix thoroughly, and then recover at 37°C, 200 rpm for 60 minutes. Centrifuge at 3000 rpm for one minute, then harvest the cells. Retain approximately 100 μl of the supernatant, gently pipette to resuspend the bacterial mass, and spread it onto LB medium supplemented with Amp antibiotics. Incubate the plate upside down at 37°C in a 37°C incubator overnight. Pick individual colonies, confirm with sequencing, and shake the positive clones for plasmid extraction (using the Endotoxin-Free Plasmid Extraction Kit, TIANGEN: DP120-01). After measuring the concentration, store in a -20°C freezer until needed.
[0619] 2. Cell-level editing efficiency detection
[0620] (1) HEK293T cell culture
[0621] HEK293T cells (purchased from ATCC) were seeded in DMEM medium (Gibco, 11965092) supplemented with 10% FBS (v / v) and 1% Penicillin Streptomycin (v / v) (Gibco, 15140122) and cultured in a 37°C cell culture incubator with 5% CO2. Cells for transfection were seeded in 24-well cell culture plates the day before and cultured. The cells were observed the next day and transfected when the cells reached a cell density of approximately 80%.
[0622] (2) The CasY7 recombinant expression plasmid (see Figure 1A of Figure 1 for the plasmid map), the CasY7-TTR-sgRNA2 expression plasmid, the LbCpf1 recombinant expression plasmid (see Figure 1B of Figure 1 for the plasmid map), and the LbCpf1-TTR-sgRNA2 expression plasmid were transfected into HEK293T cells with the EGFP-C1 (Addgene, Plasmid, #54759) plasmid, respectively.
[0623] The plasmid dosages for each well of a 24-well plate transfection were 0.3 μg of nuclease expression plasmid (CasY7 recombinant expression plasmid or LbCpf1 recombinant expression plasmid), 0.3 μg of sgRNA expression plasmid (CasY7-TTR-sgRNA2 expression plasmid or LbCpf1-TTR-sgRNA2 expression plasmid), and 0.3 μg of EGFP-C1 plasmid. The specific transfection procedures are as follows:
[0624] CasY7 expression plasmid, CasY7-TTR-sgRNA2 expression plasmid and EGFP-C1 plasmid were mixed and washed with 25 μl of Dilute the transfection-specific reduced serum medium (Source Bio, L530KJ) and add 2 μl of Lipofectamine 3000 (Invitrogen, L3000015) reagent, pipette and mix well as reagent A, and let it stand for 5 minutes. At the same time, 2 μl of Lipofectamine 3000 transfection reagent (Invitrogen, L3000015) was added with 25 μl of Dilute and mix the transfection-specific reduced serum medium (Source Biotechnology, L530KJ) as reagent B and let it stand for 5 minutes.
[0625] Mix Reagent A and Reagent B, pipette well, and let stand for 20 minutes. After the stand, add the mixture dropwise to the cells to be transfected in the 24-well plate. Return the plate to a 37°C, 5% CO2 incubator and incubate. Six hours after transfection, replace the culture medium with DMEM supplemented with 10% FBS.
[0626] In the same way, LbCpf1 recombinant expression plasmid, LbCpf1-TTR-sgRNA2 expression plasmid, and EGFP-C1 plasmid were transfected into HEK293T cells.
[0627] (3) Editing efficiency detection
[0628] 48 hours after transfection, EGFP fluorescent protein expression indicated that the cells were successfully transfected. Cells positive for EGFP expression were sorted for editing efficiency testing. The cells were subjected to genomic extraction (using a genomic DNA extraction kit, TIANGEN, DP304-03). Identification primers were designed according to experimental requirements. The identification primer sequences used are shown in the following table:
[0629] Using the genome as a template, the primers in the table above were used to perform PCR amplification on the sequence near the target site. The PCR amplification system is as follows:
[0630] 2×Taq Master Mix (Vazyme, P112-03) 25 μL; Primer-F (TTR-F) (10 pmol / μL) 1 μL; Primer-R (TTR-R) (10 pmol / μL) 1 μL; Template 1 μL; ddH2O to make up to 50 μL.
[0631] The amplified PCR products were used for high-throughput deep sequencing (Qingke Biotechnology Co., Ltd.) or Sanger sequencing (Boshang Biotechnology (Shanghai) Co., Ltd.) to identify the editing efficiency.
[0632] The editing efficiency of CasY7 and LbCpf1 was detected and identified. The results are shown in Figure 6. In 293T cells, the editing efficiency of CasY7 at the TTR gene was 33%, while the editing efficiency of LbCpf1 at the TTR gene was only 22%. The editing efficiency of CasY7 was much higher than that of LbCpf1.
[0633] Example 4. Application of CasY7 in base editing
[0634] 1. Acquisition of catalytically inactive CasY7
[0635] To obtain catalytically inactive (i.e., cleavage-inactive) dCasY7, the inventors constructed CasY7 mutants with single point mutations of D592A, D643A, E820A, and D992A, respectively: D592A-dCasY7, D643-dCasY7, E820A-dCasY7, and D992A-dCasY7. The amino acid sequences of the mutants are shown in SEQ ID NOs. 47-50, respectively. The specific construction method is as follows:
[0636] The CasY7+sgRNA1 expression plasmid obtained in step 1 (3) of Example 2 was subjected to point mutation, and the amino acid modifications at four sites of CasY7 were performed, namely, aspartic acid (Asp, D) at position 592, aspartic acid (Asp, D) at position 643, glutamic acid (Glu, E) at position 820, and aspartic acid (Asp, D) at position 992 of SEQ ID No. 1, and the amino acids at the above sites were mutated to alanine (Ala, A). The codons before and after the mutation of the above amino acids are shown in the following table:
[0637] Forward and reverse primers were designed and synthesized for the amino acids and their codons in the table above, and PCR amplification was performed using the CasY7+sgRNA1 expression plasmid as a template. After amplification, the amplified product was recovered and purified using a universal DNA purification and recovery kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP214). The purified product was transformed into Escherichia coli Dh5a competent cells (Weidi Biotechnology, DL1001) and cultured at 37°C overnight. The next day, a single clone was picked and sent for sequencing. After sequencing confirmation, the positive clone was shaken and the plasmid was extracted (TIANGEN, DP120-01) and the concentration was measured. The cells were stored in a -20°C refrigerator for later use.
[0638] The obtained recombinant plasmids with point mutations were named: D592A-dCasY7+sgRNA expression plasmid, D643A-dCasY7+sgRNA expression plasmid, E820A-dCasY7+sgRNA expression plasmid, and D992A-dCasY7+sgRNA expression plasmid.
[0639] Afterwards, the constructed D592A-dCasY7 + sgRNA expression plasmid, D643A-dCasY7 + sgRNA expression plasmid, E820A-dCasY7 + sgRNA expression plasmid, and D992A-dCasY7 + sgRNA expression plasmid were respectively subjected to Escherichia coli in vivo editing efficiency detection. The detection method and calculation method were the same as steps 2 and 3 of Example 2. The experimental results are shown in Figure 7. By counting the number of Escherichia coli clones and calculating the ratio, it is believed that D592A-dCasY7, D643A-dCasY7, E820A-dCasY7, and D992A-dCasY7 lose catalytic activity (cleavage activity), that is, the point mutations of D592A, D643A, E820A, and D992A cause the CasY7 protein to lose its cleavage activity.
[0640] 2. Cell-level base editing efficiency detection
[0641] (1) Construction of CasY7-TTR-sgRNA3 and CasY7-TTR-sgRNA4 plasmids
[0642] Design sgRNAs according to the target sequence of the TTR gene: CasY7-TTR-sgRNA3, CasY7-TTR-sgRNA4 sequences, and synthesize oligonucleotides (oligos):
[0643] CasY7-TTR-sgRNA3:
[0644] CAAGTTGAATCCGTCTATAACTGACGGtatatcccttctacaaattc (SEQ ID NO. 23);
[0645] CasY7-TTR-sgRNA4:
[0646] CAAGTTGAATCCGTCTATAACTGACGGgtgtctatttccactttgta (SEQ ID NO. 24), wherein the underlined sequence is the DR sequence, and the rest of the sequence is the spacer sequence.
[0647] (2) Add a CACC sequence to the 5' end of the upstream sequence of each sgRNA, and add an AAAA sequence to the 5' end of the downstream sequence. The specific format is as follows:
[0648] According to the method of step 1 of Example 3, the upstream and downstream sequences of CasY7-TTR-sgRNA3 and CasY7-TTR-sgRNA4 were annealed and connected to the PHK09T vector to obtain the CasY7-TTR-sgRNA3 expression plasmid (named CasY7-TTR-sgRNA' expression plasmid) and the CasY7-TTR-sgRNA4 expression plasmid (named CasY7-TTR-sgRNA" expression plasmid), and were transformed into Escherichia coli DH5a competent cells for plasmid amplification and culture. After correct sequencing and concentration determination, they were stored for future use.
[0649] (3) Construction of base editor plasmid (using deaminase 005V1-10-3 as an example)
[0650] The selected adenosine deaminase catalytic domain was selected from the mutant of the amino acid sequence shown in SEQ ID NO: 31 (designated 005V1-10-3): Q148G+Q149M+P150R. The amino acid sequence of this mutant is shown in SEQ ID NO. 32, and the nucleotide sequence encoding deaminase 005V1-10-3 is shown in SEQ ID NO. 33. A base editor fusion protein consisting of deaminase 005V10-3 and CasY7 protein was constructed by homologous recombination. The specific operation is as follows:
[0651] First, Suzhou Hongxun Biotechnology Co., Ltd. synthesized the 005V1-10-3 nucleotide fragment with homology arm sequence and linker:
[0652] The bold part is the 005V1-10-3 nucleotide sequence, the italic part is the left and right homology arm regions, and the wavy line part is the linker sequence.
[0653] The D992A-dCasY7+sgRNA expression plasmid obtained in step 1 was linearized by PCR amplification to obtain a linearized expression vector. The primers used are shown in the following table:
[0654] Homologous recombination was performed between the 005V1-10-3 nucleotide fragment (SEQ ID NO: 34) containing the homology arm sequence and linker and the linearized D992A-dCasY7+sgRNA expression vector using Gibson Assembly Master Mix (NEB, E2611S). The ligation product was then transformed into Escherichia coli DH5a competent cells (Weidi Biotechnology, DL1001). The specific process is as follows:
[0655] After removing the DH5α competent cells from the -80°C freezer, quickly place them on ice. After 5 minutes, allow the bacterial mass to thaw. Add the ligation product and gently mix by flicking the bottom of the centrifuge tube. Let it rest on ice for 25 minutes. Heat shock the tube in a 42°C water bath for 45 seconds, quickly return it to ice, and let it rest for 2 minutes. Add 700 μl of sterile LB medium to the centrifuge tube, mix thoroughly, and then recover by incubating at 37°C, 200 rpm, for 60 minutes. Centrifuge at 5000 rpm for one minute to harvest the cells. Collect approximately 100 μl of the supernatant, gently pipette to resuspend the bacterial mass, and spread it onto a plate of LB medium supplemented with Amp antibiotics. Incubate the plate upside down in a 37°C incubator overnight. Single colonies were picked, and after sequencing confirmation, the positive clones were shaken and the base editor plasmid was extracted using an endotoxin-free plasmid extraction kit (TIANGEN: DP120-01). The concentration was then measured and stored in a -20°C refrigerator for later use. The nucleotide sequence encoding the base editor fusion protein 005V1-10-3-D992A-dCasY7 is shown in SEQ ID NO: 37, and the amino acid sequence is shown in SEQ ID NO: 46.
[0656] (4) According to the method of step 2 of Example 3, the base editor plasmid and EGFP-C1 (Addgene, Plasmid #54759) plasmid were co-transfected with the CasY7-TTR-sgRNA' expression plasmid and the CasY7-TTR-sgRNA" expression plasmid into 293T cells respectively.
[0657] 48 hours after transfection, EGFP fluorescent protein expression indicated that the cells were successfully transfected, and cells positive for EGFP expression were sorted for editing efficiency detection. The 293T cell genome was extracted using a kit (TIANGEN, DP304-03).
[0658] (5) Perform base editing efficiency detection according to the method of step (3) of Example 3.
[0659] Primers were designed according to experimental requirements. The identification primer sequences used are shown in the following table:
[0660] The results are shown in Figures 8A and 8B in Figure 8 . The base editor composed of D992A-dCasY7 can achieve effective editing at multiple sites. As can be seen from Figure 8A , under the guidance of CasY7-TTR-sgRNA', effective editing occurs at sites +4, +13, +15, +16, and +17, and the editing efficiency at sites +13, +15, +16, and +17 reaches close to 5% to close to 30%.
[0661] As can be seen from Figure 8B, under the guidance of "CasY7-TTR-sgRNA", effective editing occurs at the +7, +13, and +20 sites. The editing efficiency at the +7 site reaches nearly 10%, the base editing efficiency at the +13 site reaches nearly 20%, and the editing efficiency at the +20 site reaches more than 20%.
[0662] Example 5. Screening of CasY7 mutants
[0663] To screen out CasY7 mutants with high cleavage activity, the 7-684 region of the CasY7 protein (SEQ ID NO.1) was engineered for mutation, and 31 mutants were constructed.
[0664] The mutants were obtained by using the CasY7 recombinant expression plasmid in Example 2 (see Figure 1A of Figure 1 for the plasmid map) as a template, designing PCR primers centered on the mutation site, introducing the mutated nucleotide sequence onto the PCR primers, and then obtaining each CasY7 mutant plasmid by site-directed mutagenesis using PCR.
[0665] The mutation modes of each mutant are shown in the following table:
[0666] According to the target sequences of TTR gene, PD-1 gene, and Trac gene, gRNA targeting sequences were designed, and expression plasmids for each targeting sgRNA were constructed by the same method as in Example 3. The CasY7 recombinant expression plasmid or its mutant recombinant expression plasmid was co-transfected with the TTR-sgRNA2 expression plasmid into HEK293 cells by PEI transfection. A negative control group (using other targeting sgRNAs, the NT-sgRNA targeting sequence is shown in SEQ ID NO. 52, marked as "NT") and a blank control group were also double-transfected, and primers were designed and identified according to the targeting of each gRNA.
[0667] After 48 h of cell culture, genomic DNA was extracted and PCR amplified using identification primers. The amplified PCR products were used for high-throughput deep sequencing (Qingke Biotechnology Co., Ltd.) to identify the editing efficiency.
[0668] The cleavage efficiency of CasY7 wild type (WT) and each mutant for TTR-1 target, PD-1 target, Trac-1 target, Trac-2 target, Trac-3 target, and Trac-4 target are shown in Figures 9-14, respectively. Through analysis, it can be seen that relative to wild-type CasY7, the editing efficiency of each mutant of CasY7 in each target gene is close to or much higher than CasY7. For example, at the TTR gene site, except for the C06354 variant, relative to the wild type (WT), other variants all showed higher cleavage activity, especially C04346, which had a cleavage activity of about 3 times that of the parent protein; similarly, at the PD-1 gene and Trac gene sites, relative to the wild type (WT), multiple variants showed higher cleavage activity. The negative control (NT) group and blank control group set for each target did not have or had only background level cleavage activity.
[0669] Example 6 Effect of Direct Repeat (DR) Sequence on CasY7 Cleavage Activity To test the effects of different DR sequences on CasY7 activity, deletions and mismatches were designed at different positions of the DR sequence, and a new DR variant was designed: DR-1 (SEQ ID NO.71). The secondary structure of DR-1 (Figure 15, any "T" in the sequence in the figure represents "U" when referring to the DR sequence) is basically the same as the secondary structure of the wild-type DR sequence (SEQ ID NO.5) (Figure 2). The stem sequences of DR-1 and wild-type DR are the same, both consisting of 5'-CCGTC-3' and its complementary chain, while in other regions, the sequences have certain differences.
[0670] The hTTR gene was used as the target, and a spacer sequence targeting the target sequence of the TTR gene (Target-TTR-spacer2, SEQ ID NO. 11) was designed, along with a DR-1 sequence DR-1-TTR-sgRNA (SEQ ID NO. 72). The synthesized DR-1-TTR-sgRNA (SEQ ID NO. 72) sequence fragment was constructed into the PHK09T vector using the method of Example 3 to obtain the DR-1-CasY7-TTR-sgRNA expression plasmid.
[0671] Then, the DR-1-CasY7-TTR-sgRNA expression plasmid and the CasY7 expression plasmid were transfected into cells according to steps (2) and (3) of Example 3, and the editing efficiency was detected using the upstream and downstream primers TTR-F (SEQ ID NO.21) and TTR-R (SEQ ID NO.22). After analysis, it was found that the DR-1 sequence can mediate higher editing activity of CasY7 (Figure 16). This also shows that CasY7 has adaptability to DR sequences with different structures.
[0672] Example 7. Screening of highly active CasY7 mutants
[0673] 1. In order to screen out CasY7 mutants with high cleavage activity, the CasY7 protein (SEQ ID NO.1) was subjected to targeted mutagenesis and screening to construct 17 mutants.
[0674] The mutants were obtained by using the CasY7 recombinant expression plasmid in Example 2 (see Figure 1A of Figure 1 for the plasmid map) as a template, designing PCR primers centered on the mutation site, introducing the mutated nucleotide sequence onto the PCR primers, and then obtaining each CasY7 mutant plasmid by site-directed mutagenesis using PCR.
[0675] To efficiently and sensitively detect the cleavage activity of each mutant, a dual-fluorescence reporter system vector was constructed ( FIG17B ). It contains the Fluc luciferase coding sequence and the LUxUC coding sequence ( FIG17A ). The LU and UC sequences in LUxUC are the 119 bp sequence at the 5' end and the 469 bp sequence at the 3' end encoding NanoLuc luciferase (NanoLuc), respectively. The two sequences have a 60 bp overlap. An insertion sequence was designed in the middle of the LUxUC sequence. The insertion sequence contains the target sequence for cleavage activity detection. Target sequences were designed based on TTR and PD-1 targets, and insertion sequences containing the target sequences were designed separately. In this example, the insertion sequence, target sequence, and corresponding LUxUC sequence used are shown in the following table:
[0676] In this example, a dual fluorescence reporter system vector for detecting each variant targeting the cleavage of the TTR target was constructed. The nucleotide sequence of this vector is shown in SEQ ID NO.97, wherein positions 6759-7380 are the TTR-LUxUC sequence, and the TTR-LUxUC sequence is shown in SEQ ID NO.73. The TTR-LUxUC sequence contains a TTR-insertion sequence (SEQ ID NO.76), and a target sequence (SEQ ID NO.11) is designed in the middle of the TTR-insertion sequence. Similarly, a dual fluorescence reporter system vector for detecting each variant targeting the cleavage of the PD-1' target was also constructed (positions 6759-7380 of the reporter system plasmid shown in SEQ ID NO.97 were replaced with the PD-1'-LUxUC sequence), and the PD-1'-LUxUC sequence, PD-1' target sequence, and PD-1' insertion sequence are shown in the table above.
[0677] The target sequence contains a premature TAG stop codon. When this codon is cleaved, LUxUC utilizes recombination to generate the correct NanoLuc coding frame, expressing NanoLuc luciferase, which then catalyzes the substrate to emit fluorescence, the intensity of which indicates cleavage activity. Fluc luciferase serves as an internal control, and its fluorescence indicates whether the reporter vector has been successfully transfected into the host cell.
[0678] The same method as in Example 1 was used to construct recombinant expression plasmids for each mutant. SgRNA expression plasmids targeting TTR and PD-1' were constructed using the same method as in Example 3. The recombinant expression plasmids for CasY7 and each mutant were co-transfected with the corresponding dual fluorescence reporter system vector and sgRNA expression plasmid into the HEK293 cell line using the transfection method in Example 3. After 24 h of culture, the expression intensity of Fluc and NanoLuc was detected on a microplate reader using a dual luciferase reporter gene assay kit (Beyotime, RG028).
[0679] In addition, a negative control group was set up for CasY7 and each mutant. The negative control group used an sgRNA expression plasmid with a non-target sequence (SEQ ID NO.78). Analysis found that the cleavage activity of CasY7 and each mutant is shown in the table below, while no cleavage activity was detected in the negative control group. The cleavage activity of each mutant was much higher than that of CasY7.
[0680] 2. Using the same method as step 1 of this example, expression plasmids expressing 39 mutants (as shown in the table below) were constructed.
[0681] According to the method of Example 3, expression plasmids expressing sgRNA targeting TTR gene and Hao1 gene were synthesized respectively. The sgRNA sequences and targeting sequences are shown in the following table:
[0682] The cleavage activities of the above variants were detected by targeting TTR and hHao1. A dual fluorescent reporter system vector (a reporter system vector for detecting the cleavage activity of the target TTR is shown in SEQ ID NO. 97; positions 6759-7380 are replaced with the hHao1-LUxUC sequence to obtain a reporter system vector for detecting the cleavage activity of the target hHao1) was used to detect the cleavage activity. The target sequence, insert sequence, and LUxUC sequence are shown in the following table:
[0683] The analysis found that the cleavage activity of CasY7 and its mutants is shown in the table below, while no cleavage activity was detected in the negative control (NT) group.
[0684] Analysis showed that the variants exhibited higher cleavage activity at the TTR and hHao1 gene targets compared to the wild-type CasY7 protein. At the TTR gene, the variants showed at least 16 times the cleavage activity compared to the wild-type CasY7 protein, with a maximum of approximately 23 times. At the hHao1 gene, the variants showed at least 8.5 times the cleavage activity compared to the wild-type CasY7 protein, with a maximum of approximately 22 times.
[0685] Example 8. Fusion with T5 exonuclease to enhance cleavage activity
[0686] To improve the cleavage activity of the CRISPR-Cas system, the CasY7 variant C05440 (the mutation method is shown in Example 6, its amino acid sequence is shown in SEQ ID NO.82, and its nucleotide coding sequence is shown in SEQ ID NO.83) is fused with T5 nuclease (its amino acid sequence is shown in SEQ ID NO.81, and its nucleotide coding sequence is shown in SEQ ID NO.100). The T5 nuclease can be linked to the C-terminus or N-terminus of C05440:
[0687] In this example, the amino acid sequences and nucleotide coding sequences of the fusion proteins C05440-T5 and T5-C05440 are shown below:
[0688] C05440-T5 mRNA transcription template (SEQ ID NO.88) and T5-C05440 mRNA transcription template (SEQ ID NO.89) were synthesized by Nanjing GenScript Biotechnology Co., Ltd. The mRNA was transcribed in vitro using the T7 High Yield RNA Synthesis Kit (NEB, E2040S) to obtain C05440-T5 mRNA and T5-C05440 mRNA.
[0689] The hHAO1 gene was selected as the editing target, and the spacer sequence was designed based on the target sequence. The hHAO1-crRNA was synthesized by Nanjing GenScript Biotechnology. The crRNA sequence is as follows:
[0690] AGAAATCCGTCCAAAGCTGACGGggacagagggtcagcatgcc (SEQ ID NO. 90), wherein the underlined sequence is the DR-1 sequence, and the other sequences are spacer sequences.
[0691] Adopt four-component LNP lipid (purchased from Aiweituo (Shanghai) Pharmaceutical Technology Co., Ltd.) delivery, specifically, Yoltech Lipid1 (compound 10), DSPC, cholesterol, PEG-DMG are dissolved in anhydrous ethanol with a molar ratio of 50: 10: 38.5: 1.5. C05440-T5 mRNA, T5-C05440 mRNA are respectively dissolved in 100mM pH 4 enzyme-free citric acid buffer (RNA concentration is 0.2mg / mL) with hHAO-crRNA (mass ratio is 1: 1) targeting hHAO1 gene. The ethanol solution of lipid carrier is mixed with the buffer of mRNA with 1: 3 (volume / volume) (wherein the mass ratio of total lipid and mRNA is 40: 1), and nucleic acid lipid nanoparticles are obtained by microfluidic nanomedicine manufacturing system (NanoAssemblr Ignite, Canada) at a flow rate of 12ml / min. The nucleic acid lipid nanoparticles obtained are immediately diluted into 1×DPBS buffer with 40 times of volume.
[0692] HepG2 cells (purchased from ATCC) were seeded in DMEM medium (Gibco, 11965092) supplemented with 10% FBS (v / v) and 1% Penicillin Streptomycin (v / v) (Gibco, 15140122) and cultured in a 37°C cell culture incubator with 5% CO2. Cells for transfection were seeded in 96-well cell culture plates the day before and cultured. The cells were observed the next day and LNP transfection was performed when the cells reached a cell density of approximately 80%. LNP@mRNA (transfection doses of 5 ng / well, 10 ng / well, 20 ng / well, and 40 ng / well, respectively) was added to HepG2 cells. The cells were collected 48 hours after transfection and subjected to genomic extraction (TIANGEN, DP304-03) for detection of cleavage activity ( FIG18 ). The identification primer sequences used were hHAO1-F (SEQ ID NO: 91) and hHAO1-R (SEQ ID NO: 92).
[0693] Analysis showed that the cleavage activity of C05440-T5 was much higher than that of T5-C0544 and C05440 at all doses, while the cleavage activity of T5-C0544 was the lowest at all doses, indicating that the connection position of T5 nuclease is related to its cleavage activity.
[0694] Among them, Yoltech Lipid1 (Compound 10) is synthesized as follows:
[0695] 7-Butyl-21-(10-butyl-3,9-dioxyidene-2,8-dioxahexadecan-1-yl)-19-[3-(diethylamino)propyl]-8-oxyidene-19-aza-9-oxadocosan-22-yl 5-[(2-butyl-1-oxyoctylene)oxy]pentanoate
[0696] Step 1: Synthesis of compound 1-2
[0697] To a 500 mL round-bottom flask, cyclohexyl ester (25.00 g, 249.70 mmol, 1.0 eq), distilled water (20 mL), ethanol (200 mL), and sodium hydroxide (10.99 g, 274.67 mmol, 1.1 eq) were added. After reacting at 70°C for 3 hours, the solvent was removed by concentration under reduced pressure. 200 mL of acetone, tetrabutylammonium iodide (4.61 g, 12.48 mmol, 0.05 eq), and benzyl bromide (51.25 g, 299.64 mmol, 1.2 eq) were then slowly added to the flask. The reaction was then allowed to react at 70°C overnight. The reaction was quenched by the addition of 500 mL of water and extracted twice with 500 mL of ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to yield 5-hydroxyvalerate benzyl ester (37.00 g, 71.2% yield).
[0698] Step 2: Synthesis of Compounds 1-4
[0699] A 500 ml round-bottom flask was charged with benzyl 5-hydroxyvalerate (37.00 g, 177.67 mmol, 1.0 eq), 2-butyloctanoic acid (35.59 g, 177.67 mmol, 1.0 eq), 250 ml of dichloromethane, and 4-dimethylaminopyridine (21.70 g, 177.67 mmol, 1.0 eq). Finally, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (51.09 g, 266.50 mmol, 1.5 eq) was added. The mixture was reacted at room temperature for 4 hours, diluted with 500 ml of water, and extracted twice with 500 ml of dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 5-(benzyloxy)-5-oxypentyl 2-butyloctanoate (64.00 g, 92.2% yield).
[0700] Step 3: Synthesis of Compounds 1-5
[0701] A 250 mL round-bottom flask was charged with 5-(benzyloxy)-5-oxyidenepentyl 2-butyloctanoate (64.00 g, 163.87 mmol, 1.0 eq), methanol (75 mL), and tetrahydrofuran (75 mL). Finally, Pd / C (3.49 g, 32.78 mmol, 0.2 eq, 10% purity) was added. The mixture was reacted at room temperature under an atmospheric pressure of hydrogen for 16 hours. The mixture was filtered and concentrated to yield 5-[(2-butyl-1-oxyoctylene)oxy]pentanoic acid (45.00 g, 91.4% yield).
[0702] Step 4: Synthesis of Compounds 1-7
[0703] At room temperature, 5-[(2-butyl-1-oxyoctyl)oxy]pentanoic acid (10.00 g, 33.29 mmol, 1.0 eq), 2-hydroxymethylpropane-1,3-diol (3.53 g, 33.29 mmol, 1.0 eq), 4-dimethylaminopyridine (0.81 g, 6.66 mmol, 0.2 eq), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (9.57 g, 49.94 mmol, 1.5 eq) and N,N-diisopropylethylamine (8.60 g, 66.58 mmol, 2.0 eq) were added to a round-bottom flask containing 100 ml of dichloromethane and stirred at room temperature for 4 hours. The reaction solution was quenched by adding 200 ml of water, extracted twice with 200 ml of dichloromethane, and the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give 2-butyloctanoic acid-18-butyl-8-(hydroxymethyl)-5,11,17-trioxy-6,10,16-trioxatetracosane-1-yl ester (7.80 g, yield 69.9%).
[0704] Step 5: Synthesis of Compound 1-8
[0705] At room temperature, the compound 2-butyloctanoate-18-butyl-8-(hydroxymethyl)-5,11,17-trioxydeca-6,10,16-trioxa-tetracosane-1-yl ester (3.90 g, 5.81 mmol, 1.0 eq) and triethylamine (1.76 g, 17.43 mmol, 3.0 eq) were added to 30 ml of dichloromethane, and methylsulfonic anhydride (2.02 g, 11.62 mmol, 2.0 eq) was slowly added at zero degrees Celsius. The temperature was slowly restored to room temperature and the reaction was allowed to react for 4 hours. The reaction solution was quenched by adding 30 ml of water, extracted twice with 50 ml of dichloromethane respectively, the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give methanesulfonic acid-12-butyl-2-(10-butyl-3,9-dioxy-2,8-dioxahexadecan-1-yl)-5,11-dioxy-4,10-dioxahexadecan-1-yl ester (3.85 g, yield 88.4%).
[0706] Step 6: Synthesis of Compound 1-10
[0707] At room temperature, compound 1-8 (600.0 mg, 0.80 mmol, 1.0 eq), 3-amino-1-propanol (300.0 mg, 3.99 mmol, 5.0 eq), potassium carbonate (280.0 mg, 2.00 mmol, 2.5 eq), and potassium iodide (130.0 mg, 0.80 mmol, 1.0 eq) were added to 10 ml of acetonitrile, protected by nitrogen, heated to 90 degrees Celsius, and reacted for 16 hours. The reaction mixture was concentrated, diluted with water, and extracted three times with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain the compound 5-[(2-butyl-1-oxyoctyl)oxy]pentanoic acid-12-butyl-2-{[(3-hydroxypropyl)amino]methyl}-5,11-dioxyidene-4,10-dioxaoctadec-1-yl ester (210.0 mg, 36.11%). MS: m / z [M+H] + =728.6.
[0708] Step 7: Synthesis of compound 10
[0709] At room temperature, the compound 2-butyloctanoic acid-8-(10-butyl-3,9-dioxyidene-2,8-dioxahexadecan-1-yl)-14-ethyl-5-oxyidene-10,14-diaza-6-oxahexadecan-1-yl ester (500.0 mg, 0.64 mmol, 1.0 eq), 2-butyloctanoic acid-9-bromononyl ester (390.0 mg, 0.96 mmol, 1.5 eq), potassium carbonate (270.0 mg, 1.92 mmol, 3.0 eq), potassium iodide (110.0 mg, 0.64 mmol, 1.0 eq) were added to 20 ml of acetonitrile, protected by nitrogen, heated to 90 degrees Celsius, and reacted overnight. The reaction mixture was concentrated, diluted with water, and extracted three times with dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 7-butyl-21-(10-butyl-3,9-dioxyidene-2,8-dioxahexadecan-1-yl)-19-[3-(diethylamino)propyl]-8-oxyidene-19-aza-9-oxadocosan-22-yl 5-[(2-butyl-1-oxyoctyl)oxy]pentanoate (132.8 mg, 18.8% yield). MS: m / z [M+H] + =1107.9. 1 H NMR(300MHz, CDCl3)δ4.15-4.01(m,10H),3.44-3.20(m,4H),2.71-2.50(m,6H), 2.39-2.23(m,12H),2.02-1.40(m,28H),1.38-1.22(m,48H),0.92-0.75(m,18H).
[0710] Example 9 Verification of CasY7 off-target activity at the Trac gene
[0711] To evaluate the application of CasY7 in human cells, a spacer sequence targeting the Trac gene target, Target-Trac-spacer3 (SEQ ID NO. 59), was designed based on the PAM sequence of CasY7. 29 gene sites and off-target prototype spacer sequences that may cause off-target cleavage were predicted, as shown in the following table:
[0712] The DR-1 sequence used in this embodiment is used as a direct repeat sequence, and the DR-1-Trac sequence is as follows: AGAAATCCGTCCAAAGCTGACGGttgctccaggccacagcact (SEQ ID NO.93). The gRNA expression plasmid was constructed in the manner of Example 3, and the CasY7 recombinant expression plasmid and the above-mentioned gRNA expression plasmid were co-transfected into HEK293 cells using PEI transfection. On-target activity and off-target activity were detected by deep sequencing. Analysis showed that CasY7 showed substantially no off-target cleavage activity at the predicted site (Figure 19, On Target represents on-target cleavage activity, and OT1-29 represents predicted off-target gene sites). The CRISPR-Cas system disclosed herein has a wide range of applications, has high cleavage activity and low incidental activity, and can be used for drug screening, disease diagnosis and prognosis, and treatment of various genetic diseases.
[0713] Example 10 Cleavage activity of CasY7 in plant cells
[0714] To evaluate the targeted cleavage of CasY7 in plant cells, the applicant selected the rice endogenous gene OsBEL as the target gene. Based on the PAM of CasY7 (5'-TTN-3'), the OsBEL-crRNA was designed, and the DR sequence used was DR-1. The OsBEL-crRNA sequence is shown below:
[0715] AGAAATCCGTCCAAAGCTGACGGATCTCCTTCTAGAAGCACAA(SEQ ID NO.94)
[0716] The purified CasY7 protein (60 μg) was combined with OsBEL-crRNA (120 μg) to form RNPs at 37°C. The RNPs were then transferred into rice protoplasts using PEG4000. After 24 hours of culture, the editing activity was detected and analysis revealed that CasY7 had approximately 75% cleavage activity at the target site. This suggests that the CRIPSR-CasY7 system can be used in the plant field and has potential application value.
[0717] Sequence information:
[0718] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A Cas protein, characterized in that The protein is selected from the group consisting of: (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1; (b) a polypeptide having at least about 60% (e.g., 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%) identity to the amino acid sequence of SEQ ID NO:1; (c) a polypeptide formed by substituting, deleting or adding one or more (optionally, about 1-50, 1-10, about 1-40, about 1-30, about 2 to 25, preferably 2-20) amino acid residues of any of the amino acid sequences shown in SEQ ID NO:
1.
2. The Cas protein according to claim 1, characterized in that The Cas protein comprises a mutation at one or more sites relative to the polypeptide of the amino acid sequence shown in SEQ ID NO: 1, so that the cleavage activity or preference is changed (for example, the double-stranded cleavage activity is increased or decreased, the single-stranded cleavage activity is increased or decreased, or there is no cleavage activity).
3. The Cas protein according to claim 1 or 2, characterized in that It comprises any amino acid substitution at one or more of the following positions corresponding to SEQ ID NO: 1: V7, R8, T11, S12, S110, I149, N150, H151, N152, L153, Q160, E161, Y162, N163, C164, Y165, S166, S167, F168, K195, S196, K197, S198, A199, C215, T216, A217, K219, S225, L227, L229, M231, D234, S240, S 241, Q242, E243, I244, S250, F251, E252, K253, V254, K260, T261, E263, N276, Y282, D283, A285, N292, S303, I304, L307, Y308, S309, R315, E316, T317, I318, I319, V348, I349, E350, P351, L354, S355, N356, L357, K358, I373, G416 , I417, E418, F419, D420, I455, R456, V458, H486, N487, S488, L501, R509, P510, V511, L512, G513, N514, R515, V51 6. L525, I526, N527, K528, K529, C633, T634, T635, K636, N637, D638, R639, G640, E641, F642, E648, L650, A651, Y6 52. A661, T681, N682, E683, S684, G727, K728, N729, E730, S743, E748, G749, S751, K752, K781, L782, G783, E784, C 785, S787, K865, P866, Y867, N868, I872, D896, N936, M957, F958, Q960, W961, P1018, S1019, R1020, N1021, S1022; Optionally, the Cas protein comprises the following mutations relative to SEQ ID NO: 1: (a) M231+D234; Preferably, selected from M231K+D234V; (b) S240+S241+Q242+E243; Preferably, selected from S240A+S241R+Q242P+E243L, S240L+S241A+Q242S+E243H+I244L+L307R+Y308F+S309A; (c) L227+L229; Preferably, selected from L227I+L229R, S225P+L227A+L229R; (d) L307+Y308+S309; Preferably, it is selected from S240L+S241A+Q242S+E243H+I244L+L307R+Y308F+S309A, D283S+A285P+L307R+Y308F+S309A, L307R+Y308F+S309A+E648R+L650I+A651P+Y652F, D283S+A285P+L307R+Y308F+S309A 7R+Y308F+S309A+I373V+E748G+S751G+K752R+S787F, S303T+I304M+L307R+Y308A+S 309I, S196N+K197F+S198N+A199T+I304A+L307R+Y308A+S309A, L307R+Y308F+S309A; (e)S250+F251+E252+K253+V254; Preferably, selected from S250W+F251A+E252A+K253R+V254R; (f) K260+T261+E263; Preferably, selected from K260R+T261P+E263H; (g)R315+E316+T317+I318+I319; Preferably, selected from R315L+E316R+T317R+I318V+I319A, Y282F+D283Q+A285T+R315A+E316Q+T317R+I318L+I319Q, Y282F+D283Q+A285T+R315S+E316R+T317K+I318K+I319W+E648S+A651L; (h)L354+S355+N356+L357+K358; Preferably, selected from L354F+S355G+N356D+L357I+K358R; (i) E648+A651; Preferably, selected from E648S+A651L, E648S+A651T+Y652W, Y282F+D283Q+A285T+E648T+A651S+Y652F, Y282F+D283Q+A285T+E648L+A651G, N276S+D283N+E648S+A651L, Y282F+D283Q+A285T+R315S+E316R+T317K+I318K+I319W+E648S+A651L; (j) T681+N682+E683; Preferably, selected from T681V+N682G+E683R+S684G, T681P+N682T+E683G+S684R, T681S+N682P+E683R+S684G, T681A+N682H+E683Y+S684R, Y282F+D283Q+A285T+T681P+N682P+E683Q+S684C, Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+T681N+N682P+ E683G+S684A, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+T681D+N682A+E683R+S684D, Y165W+S166R+S198N+G416R+I41 7V+E418Q+F419V+D420T+T681S+N682R+E683R, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509N+P510G+V511G+L512S+ T681S+N682R+E683R, G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R+G727V+K728C+N729G+E730G, Y282F+D283Q+A28 5T+G416A+I417R+E418V+F419C+D420Q+R509V+P510R+V511L+L512A+T681S+N682R+E683R, Y165W+S166R+G416R+I417V+E418Q+ F419V+D420T+R509Q+P510A+V511A+L512R+T681S+N682R+E683R+A661V, S110G+Y165W+S166R+G416R+I417V+E418Q+F419V+D42 0T+R509A+P510A+V511R+L512Q+T681S+N682R+E683R, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509L+P510V+V511S+ L512F+T681S+N682R+E683R, Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509G+P510K+L512C+T681S+N682R+ E683R, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+T634V+T635Y+K636S+N637R+T681S+N682R+E683R; (k) Y165+S166; Preferably, it is selected from Y165W+S166R, Y165W+S166V+S167I+F168I, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T, Y165W+S166R+G416R+I417E+E418Q+F419V+D420A, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+T681D+N682A+E683R+S684D, Y165W+S166R+S198N+G416R+I417V+E418Q+F41 9V+D420T+T681S+N682R+E683R, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+N682G+E683A+D896N, Y165W+S166R+G416R+I417V+E418 Q+F419V+D420T+R509N+P510G+V511G+L512S+T681S+N682R+E683R, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513L+N514A+R515V+ V516M+N682G+E683A+S684R+D896N, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+N682G+E683A+S684R+D896N, Y 165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+N487N+S488W +N682G+E683A+S684R+D896N、Y165W+S166R+G416R+I417V+E418Q+F41 9V+D420T+R509Q+P510A+V511A+L512R+T681S+N682R+E683R+A661V, S110G+Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509A+P510 A+V511R+L512Q+T681S+N682R+E683R、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+T635S+K636G+N637L+N682G+E683A+S684R+D896N、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+T634V+T635Y+K636S+N637R+T681S+N682R+E683R、Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+K781T+G783S+E784F+C785L+D896N、Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+D638F+R639P+G640N+E641Y+F642L、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+N682G+E683A+S684R+P1018L+S1019R+R1020P+N1021R+S1022V;、 (l)Q160+E161+Y162+N163+C164; Preferably, selected from Q160V+E161I+Y162T+N163S+C164V, Q160S+E161S+Y162L+N163C+C164V, Q160P+E161V+Y162H+N163S+C164T, Q160L+E161S+Y162F+N163S+C164A; (m)V7+T11+S12; Preferably, selected from V7H+T11R+S12M, V7F+R8L+T11R+S12V, V7I+T11V+S12M+Y282F+D283Q+A285T; (n)I149+N150+H151+N152+L153; Preferably, selected from I149M+N150S+H151C+N152T+L153Y; (o)K195+K197+S198+A199; Preferably, selected from K195R+K197A+S198A+A199G; (p)T216+A217+K219; Preferably, selected from T216L+A217T+K219R, C215V+T216S+A217S+K219R; (q) D283+A285; Preferably, it is selected from Y282F+D283Q+A285T, D283I+A285R+N292L, Y282F+D283Q+A285T+K865S+P866S+Y867H+N868F+I872L, Y282F+D283Q+A285T+M957V+F958L+Q960V+W961V, Y282F+D283Q+A285T+V348I+I349V+E350L+P351T, Y282F+D283Q+A285T+T681P+N682P+E683Q+S684C, Y282F+D283Q+A28 5T+E748A+G749S+S751G, Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V, Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420 A. Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q, Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+N936S, Y282F+ D283Q+A285T+G416S+I417H+E418Q+F419T+D420V+L501P+T681N+N682P+E683G+S684A, Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D 420Q、Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A+I455G +R456E+V458E、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D42 0Q+R509C+P510S+L512F+L525R+I526V+N527D+K528P+K529G+N682G+E683A+S684R+D896N, Y282F+D283Q+A285T+G416A+I417R+E418V+F419 C+D420Q+R509V+P510R+V511L+L512A+T681S+N682R+E683R, Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V,Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509G+P510K+L512C+T681S+N682R+E683R、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+G727E+K728H+N729Q+E730R、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+S743T、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+K781H+L782I+G783F+E784R+C785S、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+D638P+E641M+F642V、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+、 L512V+P1018S+S1019R+R1020V+N1021M+S1022P, Y282F+D283Q+A285T+G416A+ I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633N+T634E+T635E+K636G +N637L+N682G+E683A+S684R+S743T、Y282F+D283Q+A285T+G416A+I417R+E418 V+F419C+D420Q+R509C+P510S+L512F+C633F+T634P+T635F+K636P+N637C+N68 2G+E683A+S684R+S743T, Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D4 20Q+R509C+P510S+L512F+C633S+T634C+T635G+K636H+N637F+N682G+E683A+S 684R+S743T, Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+ P510S+L512F+C633R+T634Y+T635L+K636V+N637D+N682G+E683A+S684R+S743T; (r)G416+I417+E418+F419+D420; Preferably, selected from G416R+I417W+E418T+F419R+D420V, Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D420V, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T, Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A, Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q, Y165W+S166R+G416R+I417V+E418Q+F419V+D420 E418Q+F419V+D420A, Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D 420V+L501P+N936S, Y282F+D283Q+A285T+G416S+I417H+E418Q+F419T+D42 0V+L501P+T681N+N682P+E683G+S684A, Y165W+S166R+G416R+I417V+E418 Q+F419V+D420T+T681D+N682A+E683R+S684D, Y165W+S166R+S198N+G416R+ I417V+E418Q+F419V+D420T+T681S+N682R+E683R, Y165W+S166R+G416R+I 417V+E418Q+F419V+D420T+N682G+E683A+D896N, Y282F+D283Q+A285T+G41 6A+I417R+E418V+F419C+D420Q, R509C+P510S+L512F+G416R+I417V+E418 Q+F419V+D420T+H486A+S488W+N682G+E683A+S684R+D896N, Y165W+S166R+ G416R+I417V+E418Q+F419V+D420T+R509N+P510G+V511G+L512S+T681S+N 682R+E683R, Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513L+N51 4A+R515V+V516M+N682G+E683A+S684R+D896N, Y165W+S166R+G416R+I417 V+E418Q+F419V+D420T+G513C+R515Y+V516M+N682G+E683A+S684R+D896N,G416R+I417V+E418Q+F419V+D420T+T681S+N682R+E683R+G727V+K728C+N729G+E730G、Y282F+D283Q+A285T+G416L+I417Q+E418M+F419R+D420A+I455G+R456E+V458E、Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+N487N+S488W+N682G+E683A+S684R+D896N、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+L525R+I526V+N527D+K528P+K529G+N682G+E683A+S684R+D896N、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509V+P510R+、 V511L+L512A+T681S+N682R+E683R、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509Q+P510A+V511A+L512R+T681S+N682R+E683R+A661V、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V、S110G+Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509A+P510A+V511R+L512Q+T681S+N682R+E683R、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+R509L+P510V+V511S+L512F+T681S+N682R+E683R、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509G+P510K+L512C+T681S+N682R+E683R、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+G727E+K728H+N729Q+E730R、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+G513C+R515Y+V516M+T635S+K636G+N637L+N682G+E683A+S684R+D896N、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+T634V+T635Y+K636S+N637R+T681S+N682R+E683R、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+N682G+E683A+S684R+S743T、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+K781H+L782I+G783F+E784R+C785S、Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+K781T+G783S+E784F+C785L+D896N、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+D638P+E641M+F642V、Y165W+S166R+G416A+I417R+E418V+F419C+D420Q+H486S+S488W+D638F+R639P+G640N+E641Y+F642L、Y165W+S166R+G416R+I417V+E418Q+F419V+D420T+H486A+S488W+N682G+E683A+S684R+P1018L+S1019R+R1020P+N1021R+S1022V、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+P510D+V511H+L512V+P1018S+S1019R+R1020V+N1021M+S1022P、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633N+T634E+T635E+K636G+N637L+N682G+E683A+S684R+S743T、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633F+T634P+T635F+K636P+N637C+N682G+E683A+S684R+S743T、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633S+T634C+T635G+K636H+N637F+N682G+E683A+S684R+S743T、Y282F+D283Q+A285T+G416A+I417R+E418V+F419C+D420Q+R509C+P510S+L512F+C633R+T634Y+T635L+K636V+N637D+N682G+E683A+S684R+S743T;、 (2) comprising amino acid substitutions at one or more of the following positions corresponding to SEQ ID NO: 1: D592, D643, E820, D992; Optionally, the Cas protein comprises D592A, D643A, E820A and / or D992A relative to SEQ ID NO: 1; Preferably, the Cas protein comprises the amino acid sequence shown in any one of SEQ ID NOs: 47-50, or an amino acid sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%) sequence identity to the amino acid sequence shown in any one of SEQ ID NOs: 47-50.
4. A fusion protein, characterized in that Comprising the Cas protein according to any one of claims 1 to 3; and one or more functional domains; Optionally, the functional domain is selected from a nuclear localization signal (NLS), a nuclear export signal (NES), a reporter protein (e.g., a fluorescent protein), a Cas protein targeting portion, a DNA binding domain (e.g., Lex A DBD, Gal4DBD, Sp1 DBD), an epitope tag (e.g., His, myc, V5, FLAG, HA, VSV-G, etc.), a transcription activation domain (e.g., VP64, VPR, p65, Rta), a transcription repression domain (e.g., a KRAB domain, a SID domain, a NuE domain, an NcoR domain, or a SID4X domain), a nuclease, a deaminase (e.g., adenosine deaminase or cytidine deaminase), a methylase (e.g., a DNA methylase DNMT), a demethylase, a transcription release factor, an HDAC, a cleavage-active polypeptide, a ligase, an integrase, a transposase, a recombinase, a polymerase, an exonuclease (e.g., T5E), and a base excision repair inhibitor (e.g., a uracil-DNA glycosylase inhibitor (UGI)). Optionally, the functional domain comprises one or more of the following enzymatic activities on the target sequence: methylase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity, glycosylation activity (e.g., from O-GlcNAc transferase) and deglycosylation activity; Optionally, the functional domain is selected from an adenosine deaminase catalytic domain or a cytidine deaminase catalytic domain; Optionally, the adenosine deaminase catalytic domain or the cytidine deaminase catalytic domain comprises one or more of ADAR1, ADAR2, APOBEC, AID or TAD; Optionally, the adenosine deaminase catalytic domain comprises an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 31 (selected from 005V1 deaminase in CN114634923A, in which the amino acid sequence is SEQ ID NO: 2) or SEQ ID NO: 70 (selected from 004V1 deaminase in CN114634923A, in which the amino acid sequence is SEQ ID NO: 1), and it retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 31; Optionally, the amino acid sequence of the adenosine deaminase catalytic domain has amino acid additions, insertions, deletions and substitutions relative to the amino acid sequence shown in SEQ ID NO: 31 or 70; Optionally, the adenosine deaminase catalytic domain comprises a mutant of the amino acid sequence shown in SEQ ID NO: 31 or 70; Optionally, the functional domain is the full length or functional fragment of TadA8e; Optionally, the localization signal comprises a nuclear localization signal (NLS) and / or a nuclear export signal (NES); Optionally, the sequence of the nuclear localization signal is shown in any one of SEQ ID NOs: 38-45; Optionally, the sequence of the nuclear localization signal is located at, near or close to the end (e.g., N-terminus or C-terminus) of the Cas protein of claim 1; Optionally, the nuclear export signal comprises protein tyrosine kinase 2 (such as human protein tyrosine kinase 2); Optionally, the reporter protein includes glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, autofluorescent protein; Optionally, the autofluorescent protein includes green fluorescent protein (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, CopGFP, AceGFP, etc.), HcRed, DsRed, cyan fluorescent protein (e.g., eCFP, Cerulean, CyPet, AmCyanl, etc.), yellow fluorescent protein (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, etc.), blue fluorescent protein (e.g., eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire); Optionally, the DNA binding domain includes methylation binding protein, LexADBD, Gal4DBD; Optionally, the epitope tag includes a histidine tag, a V5 tag, a FLAG tag, an influenza virus hemagglutinin tag, a Myc tag, a VSV-G tag, a thioredoxin tag, a streptavidin tag; Optionally, the transcriptional activation domain comprises VP64 and / or VPR; Optionally, the transcriptional repression domain comprises KRAB and / or SID; Optionally, the nuclease comprises FokI; Optionally, the cleavage active polypeptide includes a polypeptide having single-stranded RNA cleavage activity, a polypeptide having double-stranded RNA cleavage activity, a polypeptide having single-stranded DNA cleavage activity or a polypeptide having double-stranded DNA cleavage activity; Optionally, the ligase comprises DNA ligase and / or RNA ligase; Optionally, the exonuclease is selected from TREX2 protein, TREX1 protein, APE1 protein, Artemis protein, CtIP protein, Exo1 protein, Mre11 protein, RAD1 protein, RAD9 protein, Tp53 protein, WRN protein, exonuclease V, T5 exonuclease or T7 exonuclease or variants thereof; Optionally, the exonuclease is selected from T5 exonuclease, and optionally, the T5 exonuclease comprises the amino acid sequence shown in SEQ ID NO.81; Optionally, the functional domain is connected to the N-terminus and / or C-terminus of the Cas protein variant; Optionally, the functional domain is inserted between the N-terminus and the C-terminus of the Cas protein variant; Optionally, the one or more functional domains are optionally connected to the N-terminus and / or C-terminus of the Cas protein variant via a linker; Optionally, the fusion protein comprises the amino acid sequence shown in any one of SEQ ID NOs. 46, 84, and 86.
5. An isolated polynucleotide, characterized in that The polynucleotide encodes the Cas protein according to any one of claims 1 to 3 or the fusion protein according to claim 4; preferably, the polynucleotide has been codon-optimized for expression in eukaryotic cells; Alternatively, the polynucleotide comprises a nucleotide sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%) sequence identity to the nucleotide sequence shown in any one of SEQ ID NO. 2, 37, 83, 85, 87; Optionally, the polynucleotide comprises a nucleotide sequence shown in any one of SEQ ID NO.2, 37, 83, 85, and 87.
6. A guide RNA (gRNA), characterized in that It contains (1) a direct repeat (DR) sequence, which is capable of forming a complex with the Cas protein according to any one of claims 1 to 3, or the fusion protein according to claim 4; Preferably, the direct repeat (DR) sequence comprises the nucleotide sequence shown in any one of SEQ ID NO.5 and 71, or a nucleotide sequence having at least about 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with the nucleotide sequence shown in any one of SEQ ID NO.5 and 71; more preferably, the DR sequence comprises a stem-loop structure near the 3' end of the DR sequence, and the stem-loop structure comprises 5'-X1X2X3X4X5NNNNNNNX6X7X8X9X 10 -3';X1,X2,X3,X4,X5,X6,X7,X8,X9,X 10 is any base including A, T, C or G, N is any base including A, T, C or G; wherein X1, X2, X3, X4, X5 and X6, X7, X8, X9, X 10 can hybridize with each other to form a stem and make NNNNNNN form a loop; more preferably, the DR sequence comprises any of the following stem-loop structures near the 3' end of the DR sequence: 5'-CCGTCNNNNNNNGACGG-3' (SEQ ID NO.80); wherein, wherein N is any base comprising A, T, C or G; (2) a spacer sequence that is capable of hybridizing with a target sequence of a target DNA, thereby guiding the complex to the target DNA; Optionally, the spacer sequence is at least 15 nt in length, for example, the spacer sequence is 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 nt in length; Optionally, the spacer sequence is 15-50 nt in length; Optionally, the spacer sequence is 18-41 nt in length; Optionally, the spacer sequence is 18-27 nt in length; Optionally, the spacer sequence is 18-24 nt in length; Optionally, the spacer sequence is 18-22 nt in length; Optionally, the 5' end of the direct repeat sequence is connected to the spacer sequence; Optionally, the spacer sequence comprises at least 15 consecutive nucleotides in the nucleotide sequence of any one of SEQ ID NO.6, 11, 53, 55, 57, 59, 61, and 101.
7. An isolated nucleic acid molecule, characterized in that It comprises a sequence selected from the following, or consists of a sequence selected from the following: (i) the sequence shown in SEQ ID NO: 5 or 71; (ii) a sequence having one or more base substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 base substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 5 or 71; (iii) a sequence having at least 20% (25%, 30%, 35%, at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%) sequence identity to the sequence set forth in SEQ ID NO: 5 or 71; (iv) a sequence that hybridizes to the sequence described in any one of (i) to (iii) under stringent conditions; (v) the complement of the sequence described in any one of (i) to (iii); or (vi) a nucleotide sequence encoding the sequence described in any one of (i) to (v); Furthermore, the sequence described in any one of (ii) to (vi) substantially retains the biological function of the sequence from which it is derived; For example, the isolated nucleic acid molecule is RNA; For example, the isolated nucleic acid molecule comprises a direct repeat (DR) sequence in the CRISPR / Cas system.
8. A carrier, characterized in that Comprising the polynucleotide of claim 5, and / or the nucleotide encoding the guide RNA of claim 6; Optionally, the vector comprises a plasmid or a viral vector; Optionally, the viral vector is selected from the group consisting of adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, herpes virus, SV40, poxvirus, or a combination thereof; Optionally, the vector includes a cloning vector, a transformation vector, an expression vector, a shuttle vector, an integration vector, a multifunctional vector; Optionally, the vector comprises: (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the Cas protein of any one of claims 1 to 3 or a nucleotide sequence encoding the fusion protein of claim 4; and (2) a second regulatory element, the second regulatory element being operably linked to a nucleotide sequence encoding a guide RNA, the guide RNA comprising: (a) a direct repeat (DR) sequence, which is capable of forming a complex with the Cas protein or fusion protein, and (b) a spacer sequence capable of hybridizing with a target sequence of a target DNA, thereby guiding the complex to the target DNA; Optionally, the first regulatory element and the second regulatory element are located on the same or different vectors; In certain embodiments, the first regulatory element and / or the second regulatory element is a promoter, such as an inducible promoter; In certain embodiments, the vector comprises one or more promoters operably linked to the nucleic acid sequence, enhancer, transcription termination signal, polyadenylation sequence, origin of replication, selectable marker, nucleic acid restriction site, and / or homologous recombination site.
9. A composite, characterized in that Include: (i) a protein component selected from the group consisting of the Cas protein of any one of claims 1 to 3, the fusion protein of claim 4, or a combination thereof; and (ii) The guide RNA according to claim 6.
10. A CRISPR-Cas system, characterized in that Include: (i) the Cas protein of any one of claims 1 to 3 or the fusion protein of claim 4, or a nucleotide encoding the Cas protein or the fusion protein; and (ii) the guide RNA of claim 6, or a nucleotide of the guide RNA; The guide RNA comprises: (a) a direct repeat (DR) sequence, which is capable of forming a complex with the Cas protein or fusion protein, and (b) a spacer sequence capable of hybridizing to a target sequence of a target DNA, thereby directing the complex to the target DNA.
11. A CRISPR-Cas composition, characterized in that Include: (i) a first component selected from the group consisting of the Cas protein of any one of claims 1 to 3, the fusion protein of claim 4, a nucleotide sequence encoding the Cas protein of any one of claims 1 to 3 or the fusion protein of claim 4, and any combination thereof; and (ii) a second component, wherein the second component comprises one or more guide RNAs according to claim 6, or a nucleotide sequence encoding the one or more guide RNAs according to claim 6; The guide RNA comprises: (a) a direct repeat (DR) sequence, which is capable of forming a complex with the Cas protein or fusion protein, and (b) a spacer sequence capable of hybridizing to a target sequence of a target DNA, thereby directing the complex to the target DNA.
12. A CRISPR-Cas system, characterized in that Comprising one or more vectors, the one or more vectors comprising: (i) a first nucleic acid, which is a nucleotide sequence encoding the Cas protein of any one of claims 1 to 3 or the fusion protein of claim 4; optionally, the first nucleic acid is operably linked to a first regulatory element; as well as (ii) a second nucleic acid encoding a nucleotide sequence comprising the guide RNA of claim 6; optionally, the second nucleic acid is operably linked to a second regulatory element; in: The first nucleic acid and the second nucleic acid are present on the same or different vectors; The guide RNA comprises: (a) a direct repeat (DR) sequence, which is capable of forming a complex with the Cas protein or fusion protein, and (b) a spacer sequence capable of hybridizing to a target sequence of a target DNA, thereby directing the complex to the target DNA.
13. A kit, characterized in that: Comprising one or more components selected from the following: the Cas protein of any one of claims 1 to 3, the fusion protein of claim 4, the polynucleotide of claim 5, the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the CRISPR-Cas system of claim 12.
14. A delivery composition, characterized in that Comprising a delivery vehicle, and one or more selected from the following: the Cas protein of any one of claims 1-3, the fusion protein of claim 4, the polynucleotide of claim 5, the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12.
15. A host cell, characterized in that Comprising the Cas protein of any one of claims 1-3, the fusion protein of claim 4, the polynucleotide of claim 5, the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, the system of claim 12 or the delivery composition of claim 14.
16. An enzyme preparation, characterized in that The enzyme preparation comprises the Cas protein of any one of claims 1-3, the fusion protein of claim 4, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, or the delivery composition of claim 14.
17. A medicine box, characterized in that: include: A first container, and the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, or a drug containing the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12 located in the first container.
18. A medicine box, characterized in that: include: (a1) a first container, and the Cas protein according to any one of claims 1 to 3, or the fusion protein according to claim 4, or a gene encoding it or an expression vector thereof, or a drug containing the Cas protein variant according to any one of claims 1 to 3, or the fusion protein according to claim 4, or a gene encoding it or an expression vector thereof, located in the first container; (b1) an optional second container, and the guide RNA or its expression vector according to claim 6, or a drug containing the guide RNA or its expression vector according to claim 6, located in the second container.
19. A method for targeting and editing a target gene or cleaving a target gene, characterized in that: include: The Cas protein of any one of claims 1 to 3, or the fusion protein of claim 4, or the complex of claim 9, or the CRISPR-Cas system of claim 10, the composition of claim 11, or the system of claim 12, or the delivery composition of claim 14, or the enzyme preparation of claim 16, or the kit of claim 17 or 18 is contacted with the target gene, or delivered to a cell containing the target gene, and the target sequence is present in the target gene.
20. A method for inducing a change in cell state, characterized in that: The method comprises contacting the Cas protein of any one of claims 1 to 3, or the fusion protein of claim 4, or the complex of claim 9, or the CRISPR-Cas system of claim 10, the composition of claim 11, or the system of claim 12, or the delivery composition of claim 14, or the enzyme preparation of claim 16, or the drug kit of claim 17 or 18 with a target gene in a cell.
21. A method for altering the expression of a gene product, characterized in that include: The Cas protein of any one of claims 1 to 3, or the fusion protein of claim 4, or the complex of claim 9, or the CRISPR-Cas system of claim 10, the composition of claim 11, or the system of claim 12, or the delivery composition of claim 14, or the enzyme preparation of claim 16, or the kit of claim 17 or 18 is contacted with a nucleic acid molecule encoding the gene product, or delivered to a cell comprising the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.
22. Use of the Cas protein of any one of claims 1 to 3, the fusion protein of claim 4, the polynucleotide of claim 5, the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, or the kit of claim 13, or the delivery composition of claim 14, or the enzyme preparation of claim 16, or the kit of claim 17 or 18, characterized in that: For use in the preparation of a medicament or formulation for nucleic acid editing (e.g., gene or genome editing).
23. Use of the Cas protein of any one of claims 1 to 3, the fusion protein of claim 4, the polynucleotide of claim 5, the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, or the kit of claim 13, or the delivery composition of claim 14, or the enzyme preparation of claim 16, or the kit of claim 17 or 18, characterized in that: For use in the preparation of a drug or preparation, the drug or preparation is used for one or more selected from the following groups: (i) ex vivo gene or genome editing; (ii) Detection of single-stranded DNA in vitro; (iii) editing a target sequence in a target locus to modify an organism or non-human organism; (iv) treating a disorder caused by a defect in the target sequence in the target locus; (v) treating a condition or disease in a subject in need thereof.
24. A method for detecting whether a target nucleic acid molecule exists in a sample, characterized in that: The method comprises contacting a sample with the Cas protein of any one of claims 1 to 3, the fusion protein of claim 4, or the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, the kit of claim 13, or the delivery composition of claim 14, or the enzyme preparation of claim 16, and a non-target sequence, and detecting a detectable signal generated by cleavage of the non-target sequence, thereby detecting the target nucleic acid molecule, wherein the non-target sequence does not hybridize with the guide RNA.
25. A method for diagnosing, preventing or treating a disease in a subject in need thereof, the method comprising administering to the subject the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, or the kit of claim 13, or the delivery composition of claim 14, or the enzyme preparation of claim 16, or the kit of claim 17 or 18, wherein the disease is associated with a target DNA, wherein a spacer sequence is capable of hybridizing with a target sequence of the target DNA, and the target DNA is modified, thereby diagnosing, preventing or treating the disease.
26. A pharmaceutical composition, characterized in that Comprising the vector of claim 8, the complex of claim 9, the CRISPR-Cas system of claim 10, the CRISPR-Cas composition of claim 11, or the system of claim 12, or the kit of claim 13, or the delivery composition of claim 14, or the host cell of claim 15, or the enzyme preparation of claim 16, and a pharmaceutically acceptable carrier or excipient.
Citation Information
Patent Citations
Novel crispr DNA targeting enzymes and systems
CN112041444A
Novel CRISPR-Cas12i system
CN114015674A
CRISPR-Cas effector protein as well as gene editing system and application thereof
CN114921439A
Crispr / cas effector protein and system
WO2019201331A1
Engineered cas12i nuclease, effector protein and use thereof
WO2022247873A1
